

NZLSOS

NZ Lawyers Speaking Out with Science

22 April 2022

A Coster
The Police Commissioner

By email: andrew.coster@police.govt.nz

Dear Andrew

THIRD OPEN LETTER TO THE POLICE COMMISSIONER AND AN OFFICIAL INFORMATION ACT REQUEST FOR INFORMATION (“OIA”)

1. We refer to our previous correspondence (copies of which are set out in **Schedule A**) (“**NZLSOS’s Correspondence**”) and your responses dated 12 April 2022 and 30 March 2022 (copies of which are annexed to **Schedule B**).
2. Once again, we note that we are writing to you as members of the NZLSOS lobby group, and we are not acting in our professional capacities but as concerned citizens of New Zealand.
3. It is clear from the responses from the New Zealand Police (“**police**”) that there is no intention:
 - (a) to investigate the contents of the Comirnaty vaccine (“**the vaccine**”) despite various scientists and doctors in NZ and around the world, along with an Australian politician and a former Pfizer employee raising concerns about what appears to be microscopically visible artificial technology (“**microtechnology**”) in the vaccine;
 - (b) to confirm that there is no microtechnology in the vaccine and provide us with a copy of your investigatory report;
 - (c) to meet with us and doctors and scientists to discuss our concerns.

4. Accordingly, we will be writing to the admiralty of the Royal New Zealand Navy and the Governor-General to raise our concerns.
5. It would appear from the police's response that either the police are *'just following orders'* from above (reminiscent of another time in history) or the police do not understand the concerns being raised.
6. If the latter is true, then the police have a duty to investigate to ensure the maintenance of public safety, national security and crime prevention under the Policing Act 2008 ("**the Policing Act**"). Only the Executive branch of Government can confirm that there is no microtechnology in the vaccine as they control the stock of vaccines. Once the vaccines leave this branch of Government, there are arguments around the chain of custody.
7. A barrister has provide us with a copy of an OIA response dated 15 March 2022 which states that the Government refuses to release a copy of the Pfizer contract due to "*commercial sensitivity*". However, the Ministry of Health confirmed in the OIA response that there is no clause prohibiting testing of the vaccine batches or vial.
8. Why does the Government refuse to investigate? Why do the police refuse to investigate?
9. The Government has signed a multi-million dollar contract, perhaps billions given the boosters, with Big Pharma. As the Government refuses to disclose the contract, we can only speculate if any onerous terms and conditions are being hidden.
10. Wion TV¹ reports that Pfizer is holding governments to ransom, interfering with national legislation, and even demanding military bases as a guarantee. What security has the Government provided under the contract? Our military bases or perhaps our water? Is Big Pharma demanding the mandates under the contract?
11. The vaccines are big business, and power, greed, and money often lead to corruption. CNN² reported that Pfizer's earnings and sales doubled in the past quarter (as of November 2021) due to its Covid-19 vaccine, with adjusted earnings of \$7.7 billion, up 133% from a year earlier. Revenue soared to \$24.1 billion, up 134%. The sky is the limit, with four monthly boosters possible since protection (if any) wanes quickly.

¹ <https://www.youtube.com/watch?v=2zoSSHx9QtA>

² <https://edition.cnn.com/2021/11/02/business/pfizer-earnings/index.html>

12. Why is the Government trusting Pfizer with an experimental vaccine when the company has incurred \$10,193,896,333³ in fines since 2000? Would you travel on an aeroplane manufactured by a company with a similar record concerning false claims and safety violations? Why are we asking healthy children with a very small risk of death or hospitalisation to participate in a vaccine trial for an experimental vaccine? If we vaccinate children entering puberty, what is the impact on fertility? We will not know the answer to that question for years to come. We assume you are aware that Pfizer settled for \$75,000,000.00 for the experiments that it ran on children in Nigeria⁴.
13. New Zealanders are dying and being seriously injured from the vaccine. The Government appears to be turning a blind eye as it does not require mandatory reporting of adverse reactions or actively investigate incidents.
14. **The police have a duty to protect public safety and to protect life. It is therefore incumbent on the police that take action to halt the roll out of the vaccine immediately until they are satisfied with the own investigation of vaccine.**
15. We know from an OIA response from MedSafe dated 11 March 2022 that the Government relies on Pfizer's Certificates of Analysis. However, the Government refused to release the Acceptance Criteria Chris James confirmed in his letter to Sue Gray that:

"[t]he Ministry relies on Pfizer, as the sponsor, for certain assurances and information, which the importer is required to have. For example, this may be Certificates of Analysis (CoA) which detail the test criteria the vaccine needs to meet and the test results for that particular batch of vaccines. The CoA for every batch received in New Zealand is checked by the Logistics Quality Representative to ensure it meets all test specifications."
16. Alternatively, the police may be refusing to investigate on the basis that they are 'just following orders' from politicians and/or the like. In that case, we have a grave issue that needs to be addressed – is New Zealand currently a democracy or a police state?

³ <https://violationtracker.goodjobsfirst.org/parent/pfizer>

⁴ <https://www.business-humanrights.org/en/latest-news/pfizer-settles-drug-testing-case-with-nigerian-state-for-75-million/>

17. Please could you advise which of our presumptions is correct or offer us an alternative explanation. Are the police *'just following orders'* from above or the police do not understand the concerns being raised.
18. As the police are unwilling to meet with us, which would seem like a irrational action to take when independent professionals raise concerns, we request the information set out below under the Official Information Act 1982 ("**the Act**"). Please provide us with:
- (a) the instructions from the Police Commissioner, Andrew Coster ("**the Police Commissioner**"), to the management assistant who responded to our letter dated 12 April 2022;
 - (b) confirmation that the reference to Commissioner in the police email dated 12 April 2022 is a reference to the Police Commissioner;
 - (c) all internal police correspondence, information and data (including all correspondence, information and data to and from the Police Commissioner) concerning NZLSOS's correspondence to the police;
 - (d) all external correspondence, information and data (including all correspondence, information and data to and from the Police Commissioner) concerning NZLSOS's correspondence to the police;
 - (e) all external and internal correspondence, information and data held by the police, including the Police Commissioner, which raises any concern(s) concerning the vaccine (excluding the concerns raised by NZLSOS);
 - (f) all external and internal correspondence, information and data held by the police, including the Police Commissioner, which raises any concern(s) concerning microtechnology and/or other substances in the vaccine;
 - (g) all external and internal correspondence, information and data held by the police, including the Police Commissioner, in regards to ALC-0159 and ALC-0315 ingredients in the vaccine;

- (h) all external and internal correspondence, information and data held by the police, including the Police Commissioner, concerning Agenda 2030 and/or the Fourth Industrial Revolution;
 - (i) all external and internal correspondence, information and data held by the police, including the Police Commissioner, which raises any concern(s) concerning the `adverse reactions` and `incidents` connected with the vaccine (temporal or otherwise); and
 - (j) all external and internal correspondence, information and data held by the police, including the Police Commissioner, to and from the Coroner's office in regard to the `adverse reactions`, `deaths` and `incidents` connected with the vaccine (temporal or otherwise).
19. Given that the police have been quick to respond to NZLSOS Correspondence, we trust that the police will not claim that our request is too broad and needs to be refocused. If the police make any such claim in regards to the microtechnology and/or other substances in the vaccine and/or `adverse reactions`, `deaths` and `incidents` connected with the vaccine (temporal or otherwise), then surely the police need to conduct an urgent investigation.
20. We look forward to receiving this information as soon as possible and within the statutory timeframe.

Yours Sincerely

Kirsten Murfitt
Kirsten Murfitt
Member of NZLSOS
E nzlsos@protonmail.com

Sue Grey
Sue Grey
Member of NZLSOS
E nzlsos@protonmail.com

Darrin Cassidy
Darrin Cassidy
Member of NZLSOS
E nzlsos@protonmail.com

Alison Pavlovich
Alison Pavlovich
Member of NZLSOS
E nzlsos@protonmail.com

Endorsed by other members of NZLSOS

Schedule A

Copies of our previous correspondence to the police.

NZLSOS

NZ Lawyers Speaking Out with Science

11 April 2022

A Coster
The Police Commissioner

By email: andrew.coster@police.govt.nz

Dear Andrew

SECOND OPEN LETTER TO THE POLICE COMMISSIONER AND A REQUEST FOR A MEETING

21. We refer to our letter dated 17 March 2022 (a copy is annexed at **Schedule 1**), and your response dated 30 March 2022 (a copy is annexed at **Schedule 2**). Once again, we write to you as members of the NZLSOS lobby group, and we are not acting in our professional capacities but as concerned citizens of New Zealand.

22. In our previous letter, we raised the failure of:

- (a) the Government to take action to investigate the contents of the Comirnaty vaccine ("**the vaccine**") after Dr Matthew Shelton ("**Dr Shelton**") from New Zealand Doctors Speaking Out with Science ("**NZDSOS**") raised concerns about what appears to be microscopically visible artificial technology ("**microtechnology**") in the vaccine; and
- (b) the New Zealand Police ("**police**") to investigate after being presented with images of the alleged microtechnology at Orewa Police Station (File Number: 220217/0669).

23. We requested that the police:

- (a) confirm that there is no microtechnology in the vaccine and provide us with a copy of your investigatory report;
 - (b) provide a reason if the police refused to investigate the contents of the vaccine; and
 - (c) meet with us, along with doctors and scientists, to discuss our concerns.
24. The police have failed to:
- (a) confirm that there is no microtechnology in the vaccine;
 - (b) state the reasons for refusing to investigate the contents of the vaccine; and
 - (c) accept our invitation to meet with them.
25. The police's response merely states that the police cannot comment on the concerns that we have raised. We are not asking for the police to comment on the Covid-19 Response as you state; we are asking the police to investigate the vaccine's contents as more doctors and scientists are voicing their concerns about the undisclosed ingredients, along with evidence of graphene oxide and possible microtechnology.
26. It is a fact, not a conspiracy theory, that there are two unknown but declared "*proprietary additives*" in the vaccine.
27. Medsafe⁵ lists the ingredients of the vaccine as BNT162b2 [mRNA] 0.5 mg/mL equivalent to 30 µg/0.3mL dose, 1,2-Distearoyl-sn-glycero-3-phosphocholine, ALC-0159, ALC-0315, Cholesterol, Dibasic sodium phosphate dihydrate, Monobasic potassium phosphate, Potassium chloride, Sodium chloride, Sucrose and Water. ALC-0159 and ALC-0315 are two patented ingredients that are manufactured by a Chinese pharmaceutical and medical company. Medsafe has responded to an OIA email request on 11 November 2021 and confirmed in writing that "[w]e do not hold the MDSS [Material Safety Data Sheet] for these [ALC-0159 and ALC-0315]". A material safety data sheet explains how a substance should be safely used, stored, transported and disposal.

⁵ Medsafe Product Detail, Medsafe (Revised 21 May 2019) New Zealand Medicines and Medical Devices Safety Authority <https://medsafe.govt.nz/regulatory/ProductDetail.asp?ID=21938>

28. The substances are manufactured by a company in China called Sinopeg. Sinopeg's website does not have any MDSS information either. However, the website states that these substances are for "research use only"⁶ ⁷.
29. Since writing to you only three weeks ago, we have become aware that the following scientists and one politician have now come forward to raise concerns about the potential microtechnology:
- (a) A new team (team three) of experienced NZ clinical microscopists have presented new and concerning images (refer to the link set out in paragraph 11);
 - (b) Dr Robin Wakeling (team four), a senior NZ microbiologist and nano-emulsion technology expert, has released his analysis and images⁸;
 - (c) A team of Australian scientists contacted Zeee Media to provide evidence of their findings⁹;
 - (d) Australian Senator, Malcolm Roberts, has called for a Royal Commission into the harm being caused by the vaccine¹⁰ and the potential microtechnology in the vaccine¹¹;
30. The above teams are in addition to the Spanish science group La Quinta Columna (www.laquintacolumna.net), the English translation site <http://www.orwell.city>¹², Dr Campra¹³, the group of German pathologists and other specialists¹⁴, retired viral immunologist Dr Sukharit Bhakdi on Dr Burkhardt's follow-up work¹⁵, the Unit Report from the UK¹⁶, and the two New Zealand team (<https://lifeoftheblood.com/> and <https://nzdsos.com/>) as set out in our earlier letter. We have also become aware that Dr Jane Ruby, a US health professional and a pharmaceutical drug development expert with over 20 years of experience in regulatory

⁶ https://www.sinopeg.com/2-polyethylene-glycol-2000-n-n-ditetradecylacetamide-alc-0159-cas-1849616-42-7_p477.html

⁷ https://www.sinopeg.com/4-hydroxybutyl-azanedivyl-bis-hexane-6-1-divyl-bis-2-hexyldecanoate-alc-0315-cas-2036272-55-4_p476.html

⁸ <https://drsambailey.com/videos/nz-scientist-examines-pfizer-jab-under-the-microscope/>

⁹ <https://zeemedia.com/interview/exclusive-australian-whistleblower-scientists-provide-evidence/>

¹⁰ <https://www.malcolmrobertsqld.com.au/malcolm-roberts-drops-bombshells-in-senate-after-covid-under-question-inquiry/>

¹¹ <https://zeemedia.com/interview/maria-zeee-uncensored-australian-senator-exposes-nanotech-and-declares-this-is-genocide/>

¹² [Vaccines - Self-assembling Nanotech Pfizer \(odysee.com\)](https://www.vaccines-self-assembling-nanotech-pfizer-odysee.com)

¹³ [NEW - DR CAMPRA PROVES GRAPHENE OXIDE IN COVID VACCINES \(notonthebeeb.co.uk\) and DR CAMPRA PROVES G.O. IN VIALS - YouTube](https://www.youtube.com/watch?v=...) and [C0r0n@2Inspect – Revisión y análisis de los artículos científicos relativos a las técnicas y métodos experimentales empleados en las vacunas contra el c0r0n@v|rus, evidencias, daños, hipótesis, opiniones y retos. \(Corona2Inspect\)](https://www.corona2inspect.com/)

¹⁴ <https://rivercitymalone.com/health/pathologists-investigate-deaths-after-covid-vaccination/>

¹⁵ <https://dailyexpose.uk/2022/01/04/93-percent-of-covid-vaccination-deaths-are-caused-by-the-jabs/>

¹⁶ [UK LAB FINDS GRAPHENE IN C19 VACCINES \(notonthebeeb.co.uk\)](https://www.notonthebeeb.co.uk/) and [Covid-19 Injection Contents: Dr. Robert Verkerk Summarizes EbMCsquared CiC Study Preliminary Finding \(bitcute.com\)](https://www.bitcute.com/)

processes for drug approval with the FDA and the EMA, has also been speaking out about the presence of microtechnology and the microtechnology patents¹⁷, along with a former Pfizer employee of ten years who claims that she has the documentation to prove that microtechnology exists in the vaccine¹⁸. There will be others speaking out.

31. NZDSOS has updated their slides showing the images of the potential microtechnology. You may access the slides by clicking on the link below:

<https://nzdsos.com/2022/04/03/presentation-on-micro-tech-in-comirnaty/>

32. As set out in full in our last email, all passive reporting systems worldwide are flagging extremely high death and injury rates and insurance companies are voicing concerns – to near silence from regulators.

33. In November 2021, the FDA released the first batch of Pfizer’s clinical trial documents under a Freedom of Information court order. The FDA did not want to release the documents and asked the Court to grant them 50 plus years to release the documents. The post-marketing Pfizer documents¹⁹ list nine pages of “adverse reactions of special interest” (each reaction separated by a semicolon and no paragraphs – we have reproduced the nine pages at **Schedule 3**) and showed huge death and injury early on.

34. We know that the Government knew about the risk of myocarditis as early as 11 May 2021 and did not issue a warning until 15 December 2021 after a young man, Rory Narin, died suddenly following the vaccine (the full information is set out in the Open Letter to Parliament dated 22 January 2022 at **Schedule 4**). There have been many sudden deaths and people suffering from myocarditis and pericarditis following the vaccine, and many are being ignored, as you are no doubt aware. We have a member of NZLSOS who has had pericarditis following taking the vaccine and is still having to return to the hospital for heart issues which doctors have confirmed are from the vaccine.

35. We understand that it is hard to fathom that microtechnology has been placed in the vaccine. However, the science exists, and microtechnology is being developed for various purposes. For

¹⁷ <https://rumble.com/vsu57w-dr.-jane-ruby-whats-inside-the-covid-19-vaccines.html> and [Ask Dr. Jane: Metaverse, self assembling nanotechnology through vaccinations \(rumble.com\)](#)

¹⁸ <https://www.sgtreport.com/2022/03/pfizer-nano-beast-whistle-blower-melissa-mcatee/>

¹⁹ <https://phmpt.org/pfizers-documents/>

example (and we are happy to provide further examples), Northwestern University in the US has developed the “*smallest-ever human-made flying structures*”, the size of a grain of sand, to “*sense the environment for contamination monitoring, population surveillance or disease tracking*”²⁰. In addition, Harvard University has been working on microtechnology²¹ for years, and nanomaterial delivered through vaccines is not novel²². Harvard’s research work has been sponsored by the Defense Advanced Research Projects Agency (DARPA) (a research and development agency of the United States Department of Defense responsible for the development of emerging technologies for use by the military), the National Institute of Health (NIH), the US Office of Naval Research, the UA Air Force Office of Scientific Research and Mitre (a nanosystems Group has been performing broadly based research and development in nanotechnology, with a focus on systems engineering that starts at the molecular scale).

36. We are standing at a crucial juncture in history that may have devastating consequences.
37. As set out in full in our previous letter, the World Economic Forum (“**WEF**”) (the most powerful economic organisation in the world) can speak freely about the fourth industrial revolution, which will result in human augmentation via the ability to “*hack human beings*.”²³
38. Klaus Schwab (“**Schwab**”), the founder and executive chairman of the WEF, is the champion of the Fourth Industrial Revolution (also referred to as the Great Reset and Agenda 2030), and he would not have spent hundreds of hours researching and writing ‘*The Fourth Industrial Revolution*’ and ‘*Covid-19- The Great Reset*’ to fuel a conspiracy theory. Likewise, the WEF would not have spent thousands of hours planning and creating a detailed and interactive website²⁴ that sets out how global governance, corporate governance, blockchain, a new digital economy and society, a new financial and monetary system and many more schemes connect to everything in the Fourth Industrial Revolution.

²⁰ [Scientists build the 'smallest-ever human-made flying structure' - CNET](#) and [Winged microchip is smallest-ever human-made flying structure - Northwestern Now](#) and [Winged Microchip Is Smallest-Ever Human-Made Flying Structure – The Size of a Grain of Sand \(scitechdaily.com\)](#)

²¹ [The Lieber group is focused broadly on science and technology at the nanoscale - Lieber Research Group \(harvard.edu\)](#)

²² [Nanovaccines: recent developments in vaccination | SpringerLink](#)

²³

<https://www.bing.com/videos/search?q=%22yuval+noah+harari%22+coronavirus&&view=detail&mid=95D5BC940834A6A87F0595D5BC940834A6A87F05&&FORM=VRDGAR&ru=%2Fvideos%2Fsearch%3Fq%3D%2522yuval%2Bnoah%2Bharari%2522%2Bcoronavirus%26qs%3Dn%26form%3DQBVR%26sp%3D-1%26pq%3D%2522yuval%2Bnoah%2Bharari%2522%2Bcoronavirus%26sc%3D2-31%26sk%3D%26cvid%3D1C452F516A3745E1806E8C796A4A79D0>

²⁴ <https://www.weforum.org/great-reset>

39. Schwab gloated in 2017 at the Malcolm H. Wiener Lecture on International Political Economy titled *'Strengthening Collaboration in a Fractured World'* at the Harvard Kennedy School²⁵ that he was "very proud" that the WEF "penetrate the cabinets" of Justin Trudeau and then President of Argentina, Mauricio Macri. Schwab explained that at a "reception" for Trudeau, he noted that "even more than half of his cabinet are actually Young Global Leaders of the World Economic Forum." David Gergen and Klaus Schwab also pointed out that Young Global Leaders have "penetrated" the cabinets in Argentina. The President of France, Emmanuel Macron, is also a former young Global Leader. The comments can be found around 1.08 of the video on Harvard Kennedy School's website²⁶.
40. It would seem that Schwab's claim was true, as illustrated by one brief example below.
41. The United Kingdom's Government has committed to the implementation of the Fourth Industrial Revolution, and its website contains various white papers and speeches highlighting the importance of artificial intelligence and 5G²⁷. The WEF began pushing the Fourth Industrial Revolution idea in 2017, and Matt Hancock's speeches²⁸ welcoming the idea and the importance of "5G" and "AI, nano and biotechnologies, and additive manufacturing, to name a few. Our Industrial Strategy outlines what we're doing to ensure the UK is a leader overall" can be found on the Government's website. The UK's Department for Business, Energy & Industrial Strategy ("DBEIS") 2019 'Regulations for the Fourth Industrial Revolution – White Paper'²⁹ state that:
- "[t]he Fourth Industrial Revolution is of a scale, speed and complexity that is unprecedented. It is characterised by a fusion of technologies – such as artificial intelligence, gene editing and advanced robotics – that is blurring the lines between the physical, digital and biological worlds. It will disrupt nearly every industry in every country, creating new opportunities and challenges for people, places and businesses to which we must respond."*
42. We note that WEF has posted the "Reimagining Regulation for the Age of AI: New Zealand Pilot Project – White Paper – June 2020" on the WEF's website³⁰.

²⁵ <https://www.hks.harvard.edu/more/alumni/alumni-stories/collaboration-fractured-world-klaus-schwab-mcempa-speaks-harvard-kennedy>

²⁶ <https://www.hks.harvard.edu/more/alumni/alumni-stories/collaboration-fractured-world-klaus-schwab-mcempa-speaks-harvard-kennedy>

²⁷ <https://www.gov.uk/search/all?keywords=%22fourth+industrial+revolution%22&order=relevance>

²⁸ <https://www.gov.uk/government/speeches/the-4th-industrial-revolution>

²⁹ [Regulation for the Fourth Industrial Revolution: white paper \(print-ready PDF\) \(publishing.service.gov.uk\)](#)

³⁰ https://www3.weforum.org/docs/WEF_Reimagining_Regulation_Age_AI_2020.pdf

43. On 3 October 2019, the UK Parliament debated the 'Internet of Things' and Hansard and Jon Cruddas discussed transhumanism:

"My hon. Friend did not mention those who come at the issues from a transhumanist approach. Modern transhumanism asserts that technological change creates the opportunity to transcend the human condition and become transhuman, and that that is to be celebrated, while resistance is deemed nostalgic or parochial. Politicians now and in the future will have to defend a discernible human condition in these debates, which will be a huge challenge.

For example, what happens when transhumanist thinking informs the technologists? Nick Bostrom is the director both of Humanity+, an international transhumanist organisation, and the Future of Humanity Institute at Oxford University, which regularly produces policy recommendations for Government. The point is that politicians and policy makers need to avoid being captivated by the promise of technological progress without an appreciation of the philosophical assumptions that inform the thinking behind the policies being advocated by those with agendas. Consequently, philosophers such as Jürgen Habermas have argued that politicians and policy makers should maintain a "species ethic" when navigating this terrain. These are deep waters, yet such questions are not really addressed in modern political debate.

On a slightly more practical level, the potential risks of mismanaging artificial intelligence are phenomenal. The most obvious example is mass unemployment. It is not possible to pick up a newspaper without reading about the march of the robots and the end of work. Estimates of the proportion of jobs in the UK that could, over the next two decades, be replaced by artificial intelligence and related technologies range from some 22% to between 40% and 45%. There are a wide range of estimates—some of them quite dodgy—of future structural unemployment, and they point to a range of conflicting policy options, such as universal basic income versus full employment. That suggests a wider range of policy remedies, but we are not spending enough time scrutinising the assumptions and empirical data that underscore those policy debates. Maybe we should.

To give a further example, we have already seen data analytics being used malignly in targeted political campaigns, and that practice will become ever more sophisticated, at the expense of our democratic process. As has been mentioned, in the corporate world facial recognition software is now being trialled for the purpose of marketing, to detect the efficacy of an advert on the viewer by judging their facial expressions. Businesses now have the potential to reach into people's lives in the way Orwell's "1984" imagined for totalitarian regimes. Toggle showing location of Column 411WH

Similarly, we have seen the social media filter bubble effect on civic and social life. It feeds us information that aligns with our preconceived notions of the world, closing us off from any contradictory information. Perhaps in the future our children will ask why we as parents allowed them to be so unprotected against such technological power. Left unchallenged, future public debate will suffer from the ease with which fake news could be produced on an industrial scale, given that AI makes the processing and manipulating of all forms of digital data substantially easier and cheaper.

Our very knowledge of the world around us and notions of truth are at stake. That may seem melodramatic, but I do not think it is. The greatest threat to the established political

“System and methods for anonymously selecting subjects for treatment against an infectious disease caused by a pathogen. The system comprises a plurality of electronic devices comprising instructions to generate an ID and, when in proximity of another such electronic device, one or both electronic devices transmit/receive the ID to/from the other electronic device. Then, a score is generated based on a plurality of such received IDs. Additionally, based on information received from a server, relevant treatment instructions are displayed to the subjects based on the received information and the score. The server comprises instructions for sending to the plurality of electronic devices the information to be displayed with the relevant treatment instructions, additionally the server and/or the electronic devices comprise instructions to generate a prediction of likelihood of a subject transmitting the pathogen, based on the score of the subject.”

47. We know that Ms Ardern, as a graduate of the WEF’s Global Leaders Programme, has committed New Zealand to the Great Reset as set out in our previous letter, and maybe it was a ‘coincidence’ that Schwab sent her copies of his book as confirmed by an Official Information Act response³⁵. Maybe it is another ‘coincidence’ that Auckland City Council has adopted the WEF’s agenda for the Fourth Industrial Revolution and states in its Auckland Plan 2050³⁶. It is no secret that the Global Shapers is part of the WEF and that it has hubs in Auckland, Wellington and Christchurch, which lists the names of its young and influential members³⁷.
48. While these powerful organisations and people can openly speak about such matters, the doctors, scientists, politicians, lawyers and journalists that speak out with concerns are portrayed as conspiracy theorists - even when quoting them verbatim.
49. Given that *“treatments involving novel vaccination processes and gene and cell therapies are examples of human augmentation already in the pipeline the technology exists³⁸”*, the Fourth Industry Revolution’s *“technologies will not stop at becoming part of the physical world around us—they will become part of us³⁹”* and the desire of the WEF to *“hack human beings⁴⁰”* are facts, rather than conspiracy theories, we have the right to know what the structures are in the vaccine.
50. When doctors and scientists raise serious concerns, risking their careers, and the Government of the day blatantly ignores them, the police are obliged to step up and investigate evidence of

³⁵ <https://fyi.org.nz/request/16378/response/62394/attach/3/03.09.2021%20Letter%20to%20Benseman%20PMO%202021%20180.pdf>

³⁶ <https://www.aucklandcouncil.govt.nz/plans-projects-policies-reports-bylaws/our-plans-strategies/auckland-plan/opportunities-prosperity/Pages/fourth-industrial-revolution.aspx>

³⁷ <https://www.globalshapers.org/hubs/auckland-hub>

³⁸ https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/986301/Human_Augmentation_SIP_access2.pdf

³⁹ Chapter 2 of The Fourth Industrial Revolution

⁴⁰

<https://www.bing.com/videos/search?q=%22yuval+noah+harari%22+coronavirus&&view=detail&mid=95D5BC940834A6A87F0595D5BC940834A6A87F05&&FORM=VRDGAR&ru=%2Fvideos%2Fsearch%3Fq%3D%2522yuval%2Bnoah%2Bharari%2522%2Bcoronavirus%26qs%3Dn%26form%3DQBV%26sp%3D-1%26pg%3D%2522yuval%2Bnoah%2Bharari%2522%2Bcoronavirus%26sc%3D2-31%26sk%3D%26cvid%3D1C452F516A3745E1806E8C796A4A79D0>

harm. If police are forced to follow orders from politicians in fear of losing their jobs, then the third branch of Government has failed.

51. We hope that the doctors and scientists are wrong and the Fourth Industry Revolution is benign, as that would be the best possible outcome. However, consider the consequences to your loved ones, children and grandchildren if the doctors and scientists are right that there is something unexplainable in the vaccine. What if the structures in the vaccine are connected to the Fourth Industrial Revolution and augmented humans?
52. If microtechnology is present in the vaccine, then the police should be seriously concerned for public safety unless the Government provides a satisfactory explanation for the purpose of the microtechnology.
53. With due respect, we remind you of section 9 of the Policing Act 2008 ("**the Policing Act**"), which states that the functions of police include maintaining public safety, national security and crime prevention.
54. Failure to investigate a potential crime based on growing evidence is a serious matter, is it not?
55. The common law, which is preserved by section 5 of the Imperial Laws Act, places a duty on the police to protect life and property in a dangerous situation⁴¹, prevent crime⁴² and investigate suspected offences and enforce the criminal law⁴³.
56. We once again request that you investigate the contents of the vaccine. If microtechnology is found in the vaccine following the police investigation, there are potential crimes under the Crimes Act 1961 and other legislation. In such a case, the police may wish to consider sections 145 (Criminal Nuisance), 160 (Culpable Homicide), 166 (Causing Injury the Treatment of which causes Death), 189 (Injury with Intent), 190 (Injury by Unlawful Act) and 200 (Poisoning with Intent) of the Crimes Act 1961.
57. In addition, there is potential crime of serious misconduct in public office. Serious misconduct in public office is defined as a public officer acting as such; wilfully neglects to perform his or her duty, and/or wilfully misconducts him or herself; to such a degree as to amount to an abuse

⁴¹ R v Ngan [2007] NZSC 105, [2008] 2 NZLR 48, (2007) 23 CRNZ 754; Police v Amos [1977] 2 NZLR 564 (SC) at 569; Haynes v Harwood [1935] 1 KB 146(CA).

⁴² Rice v Connolly [1966] 2 QB 414 at 419, [1966] 2 All ER 649 at 651; Police v Amos [1977] 2 NZLR 564 (SC) at 569

⁴³ Hill v Chief Constable of West Yorkshire [1989] AC 53, [1988] 2 All ER 238 (HL) at 240-241.

of the public's trust in the office holder; without reasonable excuse or justification. Another potential crime of gross negligence is the conscious and voluntary disregard of the need to use reasonable care, which is likely to cause foreseeable grave injury or harm to persons, property, or both.

58. We also request a meeting with you as a matter of urgency as this matter is a concern to many New Zealanders.
59. We trust that you will reflect on your obligations under the Policing Act and consider the potential risks should there be microtechnology in the vaccine, as scientists and doctors are reporting. We understand that you may be under political pressure, and we will support you.

Yours Sincerely

Kirsten Murfitt

Kirsten Murfitt
Member of NZLSOS
E nzlsos@protonmail.com

Sue Grey

Sue Grey
Member of NZLSOS
E nzlsos@protonmail.com

Darrin Cassidy

Darrin Cassidy
Member of NZLSOS
E nzlsos@protonmail.com

Alison Pavlovich

Alison Pavlovich
Member of NZLSOS
E nzlsos@protonmail.com

Endorsed by other members of NZLSOS

Schedule A

Our letter dated 17 March 2022.

NZLSOS

NZ Lawyers Speaking Out with Science

16 March 2022

A Coster
The Police Commissioner

By email: andrew.coster@police.govt.nz

Dear Andrew

OPEN LETTER TO THE POLICE COMMISSIONER AND A REQUEST FOR A MEETING


60. We are writing to you as members of a newly formed lobby group of law students, legally trained individuals and current and retired lawyers and barristers. We are not acting in our professional capacities but as concerned citizens of New Zealand.
61. We raise the failure of the:
- (c) Government to take action to investigate the contents of the Comirnaty vaccine ("**the vaccine**") after Dr Matthew Shelton ("**Dr Shelton**") from New Zealand Doctors Speaking Out with Science ("**NZDSOS**") raised concerns about what appears to be microtechnology in the vaccine; and
 - (d) New Zealand Police to investigate after being presented with images of the alleged microtechnology at Orewa Police Station (File Number: 220217/0669).
62. We request an urgent meeting with you on either Tuesday, 22 March or Wednesday, 23 March 2022. Please advise which date you would prefer by **5 pm on Tuesday, 22 March 2022**.

63. Our concerns are not intended to be frivolous or disruptive but stem from a genuine concern as to what is represented by the images and the Government's subsequent stonewalling of any discussion without explanation. We are happy to consider any explanation that the Government may have regarding the images, as there may be a reasonable explanation that satisfies the doctors and scientists. Free and robust debate is at the heart of science. Accordingly, preventing such debate and refusing to have a "conversation" with professionals that have raised concerns leads to distrust.
64. We request that you review this matter given section 9 of the Policing Act 2008 ("**the Policing Act**") states that the functions of police include maintaining public safety and crime prevention.
65. According to the media, the vaccine has been administered to a large percentage of the population. If microtechnology is present in the vaccine, then the police should be seriously concerned for public safety unless the Government provides a satisfactory explanation as to the purpose of the microtechnology. If the structures in the vaccine are not microtechnology, then the Government must explain what the unusual structures are after undertaking an independent investigation.
66. The rollout of the "*boosters*", along with Pfizer's recent admission that a 4th dose will be needed⁴⁴, is a concern, and any potential risk will be amplified if microtechnology is in the vaccine. If microtechnology is in the vaccine and is not investigated, this may result in serious harm to New Zealanders. If this transpires over time, it will be viewed as a failure to prevent a crime, given that the matter has been raised with the police and ignored.
67. It appears certain that New Zealanders are dying and being seriously injured from the vaccine. The true impact of the vaccines' deaths and injuries are not being captured as mandatory reporting of adverse reactions is not required, and the Government is not actively investigating incidents.
68. A recent analysis of weekly vaccination totals and all-cause mortality for the 60 plus age cohort showed an extra 2000 deaths⁴⁵. This analysis was possible due to our unique situation in New

⁴⁴ <https://www.msn.com/en-us/health/medical/a-4th-dose-of-covid-19-vaccine-will-be-needed-pfizers-ceo-says-but-the-company-is-working-on-a-shot-to-handle-all-variants/ar-AAV0rSm?ocid=uxbndlbing>

⁴⁵ <https://www.bitchute.com/video/dASUoQ92PTbD/>

Zealand. We are protected at our borders, have had a low incidence of Covid up until recently, and therefore the short-term impact of vaccination on health can be reviewed in isolation from the confounding factors of Covid infections and deaths. Grant Dixon obtained figures from Medsafe through an OIA request and graphed the temporal association between all cause deaths and vaccination for the 60+ age cohort during the rollout of the mRNA vaccine in New Zealand between the beginning of March 2021 to the end of October 2021.



69. Likewise, the Citizens Database, which gathers as much information as possible, has verified that at least 399 deaths (mostly sudden and/or unexpected) have followed vaccination. They would like all these suspicious deaths fully investigated.

70. It should not be up to the citizens of New Zealand to investigate deaths temporal to the vaccine. Mandatory reporting of adverse reactions and temporal deaths should be required for a novel vaccine. Since the Government refuses to investigate the potential microtechnology in the vaccine, the police should act independently and impartially under the principles that underpin the Policing Act.

71. The death rate in the United States for those aged 18-64 has risen an astonishing 40% over pre-pandemic levels. According to the CEO of Indianapolis-based insurance company OneAmerica, "*We are seeing, right now, the highest death rates we have seen in the history of this business – not just at OneAmerica*⁴⁶". OneAmerica is a \$100 billion insurance company that's been in operation since 1877 and has approximately 2,400 employees.

⁴⁶ [Life Insurance CEO Says Deaths Up 40% Among Those Aged 18-64 | ZeroHedge](#)

72. Similarly, one of Germany's largest health insurance companies released data suggesting German health authorities are significantly underreporting vaccine injuries⁴⁷. The company, BKK ProVita, said its analysis revealed a "*significant alarm signal*" and that "*a risk to human life cannot be ruled out*."⁴⁸ The German Health Agency claimed that there were 244,576 suspected cases of vaccine side effects reported in 2021, but BKK said its analysis revealed more than 400,000 cases.
73. German pathologists have been researching whether the spike protein that forms in the body as a result of the vaccine could be responsible for the pathologically observed inflammations and lesions of vessels. The pathologists have succeeded in reliably detecting the vaccine spike protein in the vessels of a person who died four months after "vaccination" and who had vascular lesions and vaccine-induced myocarditis.

Background

74. On 25 January 2022, Dr Shelton contacted us and requested an affidavit to be drafted and then sworn by him (a copy is **attached** as Annexure "A"). Dr Shelton was concerned after he had spent time with two qualified scientists who had shown him real-time and digital microscopic images of what he believed to be a sample of the contents of a vial of the vaccine.
75. On 27 January 2022, we emailed Ian Town, Chief Science Adviser at the Ministry of Health ("**MOH**"), Chris James, Group Manager at Medsafe, Morag McDowell, the Health and Disability Commissioner. We invited them to meet with Dr Shelton; Sue Grey ("**Ms Grey**"), lawyer and trained scientist; Donna Pokere-Phillips, trained lawyer and politician; and a human rights lawyer.
76. On 28 January 2022, Crown Law advised us that none of the invitees from the Crown would attend the meeting. Subsequently, Dr Shelton and Ms Grey managed to secure a spot to present to the Health Select Committee, which was listening to submissions that afternoon.
77. On 30 January 2022, Lisa Hansen, Barrister, wrote to the Minister of Health, the Minister of Covid-19 Response, Chris James, and the Chief Legal Adviser requesting an urgent meeting to discuss the photographic evidence (a copy is **attached** as Annexure "B"). A selection of photographic images were included, and the invitation to view video recordings. The

⁴⁷ <https://www.berliner-zeitung.de/news/impffolgen-krankenkasse-bkk-schreibt-brief-an-paul-ehrlich-institut-li.213676?fbclid=IwAR3ZSdDytlj5BXN3pB3myb6dNavvbTlFUpbr8On2M1o8K6uz17trCIES7js>

⁴⁸ <https://childrenshealthdefense.org/defender/covid-vaccine-injuries-german-health-insurer/>

Government once again declined the meeting, which was frustrating given such a meeting could have resolved matters quickly. More concerning, it was revealed that Medsafe stated internally that the images submitted to them were line drawings.

78. Dr Shelton has sent a presentation to the Health Select Committee (a copy is **attached** as Annexure "C") ("**Health Select Committee Presentation**").

The Images

79. The images set out in the Health Select Committee Presentation are highly magnified (up to 4000 x magnification). Microtechnology is visible at this resolution; a micrometer is a thousandth of a millimetre. For instance, a red blood cell is just under 8 micrometers in diameter. Of course, the processes involved, like all biochemistry, are active in the nanoscale, a thousand times smaller again. Here, scanning electron microscopy is needed, but everything of immediate concern is quite visible with a good light microscope, as the scientists demonstrate.
80. We understand that it is difficult to believe the images are real, and you may experience cognitive dissonance (i.e., the mind rejects new information that would force it to change an internal belief about one's world) when you first view the images. However, Dr Shelton has sworn an affidavit that the images are real.
81. Two teams in New Zealand have personally seen the images down a microscope and published their work on www.lifeoftheblood.com. Dr Shelton is the only person prepared to publicly speak out; the others are scared for their own safety. Since drafting this letter, we have been advised that a further two independent teams in New Zealand have come forward with similar findings. NZDSOS members, including Dr Shelton, have seen this new work.
82. Overseas scientists are raising similar concerns. One such group is the Spanish science group La Quinta Columna (www.laquintacolumna.net and the English translation site <http://www.orwell.city>). This group has a chain of custody proof obviating any fraud. German pathologists and other specialists released their findings in September 2021⁴⁹. Like Dr Campra from La Quinta Columna, the United Kingdom's UNIT science group has publicised proof of graphene-based structures in the vaccines.

⁴⁹ [https://odysee.com/@en:a5/PK_Tot-durch-Impfung_english:a_Why_are_people_dying_after_getting_the_Covid_vaccine?Pathologists_now_have_answers.\(rivercitymalone.com\)](https://odysee.com/@en:a5/PK_Tot-durch-Impfung_english:a_Why_are_people_dying_after_getting_the_Covid_vaccine?Pathologists_now_have_answers.(rivercitymalone.com))

83. We also understand that scientists in Japan and the USA have found undeclared metal-containing components in the vaccine.

Evidential Threshold

84. NZDSOS acknowledges that it does not yet have a chain of custody, even though the Spanish team do. However, an investigation by the police would be able to establish a chain of custody.
85. Regardless of the chain of custody matter, it is NZDSOS' view that the evidential threshold has been met to compel the police to investigate the contents of the vaccine for the following reasons:
- (a) a precautionary approach is required given the potentially serious and harmful risk to the public if the microtechnology is present in the vaccine;
 - (b) CARM has recorded many adverse events and deaths following the administration of the vaccine and concedes on its website that recorded reports likely only represent about 5% of actual numbers of adverse events;
 - (c) CARM does not appear to be concerned about these numbers and proposes to "continue to monitor" rather than act and has not made clear at what point it would act;
 - (d) The possibility of foreign material in the vaccines provides a mechanism for the adverse events that are being recorded;
 - (e) the risk of harm is increased with the "boosters";
 - (f) the Government refuses to discuss the issue, which is likely to do with the confidentiality clause in the Pfizer contract, which is being withheld under the Official Information Act ("OIA");
 - (g) the Government refuses to investigate;
 - (h) Medsafe has confirmed by way of a letter to Ms Grey, dated 11 March 2022, that the MOH relies on Pfizer's Certificate of Analysis rather than its own analysis;
 - (i) the vaccine has not been subject to a stringent approval process:

- (i) The vaccine is still under provisional approval, not full approval; and
- (ii) Medsafe has confirmed in writing, in response to an OIA request, that it does not hold Material Safety Data Sheets ("MSDS") for ALC-0159 and ALC-0315 (two of the ingredients in the vaccine). The vaccine helpline is unable to provide the MSDS either.

Microtechnology

- 86. To assist you with background information which puts the possibility of this technology in a scientific and political context, we have set out some brief information below on microtechnology, microtechnology in vaccines and the political appetite to use microtechnology for human augmentation.
- 87. Microtechnology has been around for many years despite the public not being familiar with such technology. A 2015 article in the National Library of Medicine⁵⁰ reports that between 2005 and 2015 nanotechnological research budget that was spent in environmental, health and defence industry fields in the United States was US\$575 billion dollars.
- 88. Microtechnology vaccines that deliver forms of nanospheres, nanobeads or nanoprojections are not a novel idea either. We have found published journal articles from the early 2000s⁵¹.
- 89. Many of those who have worked on microtechnology were no doubt trying to improve health outcomes. However, if microtechnology is in the vaccine, it needs to be disclosed. If disclosure or investigation is not forthcoming, then people will naturally question and be less trusting.
- 90. The Lieber Research Group⁵² at Harvard University focuses on science and technology at the nanoscale, harnessing the unique physical properties of novel nanomaterials to push scientific boundaries in biology and medicine. The Lieber Research Group's publications confirm that microtechnology is being delivered via syringe, and brain-machine interfaces (BMIs) can serve as bidirectional connections that output electrical signals of brain activity or input electrical stimuli to modulate brain activity in concert with external machines, including computer processors and prosthetics, for "*human enhancement*"⁵³.

⁵⁰ <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5393069/>

⁵¹ <https://link.springer.com/article/10.1007/s12038-009-0114-3>

⁵² <http://cml.harvard.edu/>

⁵³ <http://cml.harvard.edu/assets/Nanowire-probes-could-drive-high-resolution-brain-machine-interfaces.pdf>

91. Likewise, Stanford University has been developing 'hairpin'-like nanoscale devices that have the potential to lead to advanced brain-machine interfaces⁵⁴.

Political Background

92. We agree that it would be easy to disregard our concerns regarding the alleged microtechnology in the vaccine as a 'conspiracy theory'. However, we are experienced professionals that have invested time and money into our careers, paid our taxes, collected GST and paid it to the Government as good citizens to fund public services, and we have not questioned or taken such a political stand before.
93. The summary below of the political agenda is not intended to be comprehensive. Merely, to notify you of the potential politics.
94. To begin, the UK Ministry of Defence Report, 'Human Augmentation – The Dawn of a New Paradigm', a strategic implications project dated May 2021,⁵⁵ states:

*"We cannot wait for the ethics of human augmentation to be decided for us, we must be part of the conversation now. The ethical implications are significant but not insurmountable; early and regular engagement will be essential to remain at the forefront of this field. Ethical perspectives on human augmentation will change and this could happen quickly. There may be a moral obligation to augment people, particularly in cases where it promotes well-being or protects us from novel threats. **It could be argued that treatments involving novel vaccination processes and gene and cell therapies are examples of human augmentation already in the pipeline** (p 13).*

Currently pharmaceuticals have only limited use in human augmentation but developments in biotechnology, microtechnology and bioinformatics could allow new pharmaceuticals to be designed that have more powerful and precise effects (p 34)...

Nanotechnological systems have significant potential for human augmentation technologies (p 37)... Nano-systems have the potential to reduce the size of many human augmentation-related components. Longer terms possibilities include replacing organs with functionality equivalent or better systems, as well as adding new capacities, such as 'nano-blood' (p 38) "

95. The World Economic Forum ("WEF") has been involved in the strategic management of the coronavirus pandemic, with a major emphasis on using the pandemic as a catalyst for digital transformation and the global introduction of digital identity systems. Klaus Schwab

⁵⁴ <https://engineeringcommunity.nature.com/posts/50599-an-array-of-nano-hairpins-probes-the-interior-of-cells>

⁵⁵

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/986301/Human Augmentation SIP_access2.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/986301/Human_Augmentation_SIP_access2.pdf)

("Schwab"), the founder and executive chairman of the WEF, is the champion of the Fourth Industrial Revolution (also referred to as the Great Reset and Agenda 2030). Schwab states:

*"The Fourth Industrial Revolution, as I wrote in the book four years ago when I coined the expression, many of those technologies just look at facial recognition, just look at the technologies which you need for tracking people. What we are seeing now with some of the **companies engaged into research for vaccines using completely new methods based on synthetic biology**. A tremendous challenge we have in creating this Great Reset".*

96. Dr Yuval Noah Harari ("Harari") is an advisor to Schwab and a member of the WEF. Dr Harari stated on an interview on the BBC⁵⁶

*"...people could look back in a hundred years and identify the coronavirus epidemic as the moment when a new regime of surveillance took over, **especially surveillance under the skin** which I think is the most important development of the 21st century, is this ability to **hack human beings** ..."*

97. Interestingly, Dr Harari the WEF Annual Conference in 2018 and stated:

"Data might enable human elites to do something even more radical than just build digital dictatorships by hacking organisms, elites may gain the power to re-engineer the future of life itself. Because once you can hack something, you can also usually engineer it. ... now, in the past, many tyrants and Governments wanted to do it, but no one understood biology well enough, and nobody had enough computing power and data to hack millions of people. Neither the Gestapo nor the KGB could do it. But soon, at least some corporations and Governments will be able to systematically hack all the people ... and if indeed we succeed in hacking and engineering life, this will be not just the greatest revolution in the history of humanity. This will be the greatest revolution in biology since the very beginning of life, 4 billion years ago. Four billion years, nothing from the mental changed. Science is replacing evolution by natural selection with evolution by intelligent design. Not the intelligent design of some God up above the clouds but our intelligent design and the intelligent design of our clouds. The IBM clouds, the Microsoft clouds. These are the new driving forces of evolution."

98. Gillian R. Tett, Managing Editor, US, Financial Times, USA, introduced Harari introduced in his speech *Will the Future be Human* on the WEF's Youtube channel back in 2018. Harari is quoted amongst many other concerning comments and ethical issues as stating⁵⁷:

"Some things are definitely going to happen. For example, computers and robots replacing more and more humans. But what will the consequence of that be? Will this create an extremely unequal society in which an elite control all of the economy and make all the profits, whereas most humans become part of some kind of useless class? This is not inevitable, this is up to us."

⁵⁶

<https://www.bing.com/videos/search?q=%22yuval+noah+harari%22+coronavirus&&view=detail&mid=95D5BC940834A6A87F0595D5BC940834A6A87F05&&FORM=VRD&ru=%2Fvideos%2Fsearch%3Fq%3D%2522yuval%2Bnoah%2Bharari%2522%2Bcoronavirus%26qs%3Dn%26form%3DQBVR%26sp%3D-1%26pq%3D%2522yuval%2Bnoah%2Bharari%2522%2Bcoronavirus%26sc%3D2-31%26sk%3D%26cvid%3D1C452F516A3745E1806E8C796A4A79D0>

⁵⁷ <https://www.youtube.com/watch?v=Jguf2RK8e7w>

99. By way of background, Schwab established a parallel institution to the WEF in 1992, the Global Leaders for Tomorrow school, which was re-established as the Young Global Leaders in 2004. Members of the school's very first class in 1992 already included many who went on to become important political figures, such as Angela Merkel, Nicolas Sarkozy, and Tony Blair (who Ms Ardern worked for in the U.K.⁵⁸). Ms Ardern is on the alumni list, and in 2014 she was picked as one of 200 Young Global Leaders by the WEF.

100. Ms Ardern is committed to creating the Great Reset. She told the audience at an event arranged by Goalkeepers in 2019, an organisation set up by the Gates Foundation, that:

"...my Government is doing something not many other countries have tried. We have incorporated the principles of the 2030 Agenda into our domestic policy-making in a way that we hope will drive system-level actions... I believe that the change in approach that we have adopted in New Zealand is needed at a global scale."⁵⁹

101. Ms Ardern is also a member of the WEF⁶⁰ and has attended meetings at Davos. On 23 November 2020, the Office for the Prime Minister received a copy of the book "*Covid-19 – The Great Reset*" from Schwab himself (he is also one of the authors), and on 3 February 2021, the Office of the Prime Minister received a copy of the book "*Stakeholder Capitalism*" also from Schwab⁶¹.

102. Schwab made the following statements in *Shaping the Fourth Industrial Revolution*.

Section 1 *The Fourth Industrial Revolution* – Chapter 2

*"Fourth Industrial Revolution **technologies will not stop at becoming part of the physical world around us—they will become part of us.** Indeed, some of us already feel that our smartphones have become an extension of ourselves. Today's external devices—from wearable computers to virtual reality headsets—**will almost certainly become implantable in our bodies and brains.** Exoskeletons and prosthetics will increase our physical power, while advances in neurotechnology enhance our cognitive abilities. We will become better able to manipulate our own genes, and those of our children. These developments raise profound questions: Where do we draw "the line between human and machine? What does it mean to be human?"*

⁵⁸ <https://www.youtube.com/watch?v=3kcWHiTehF8>

⁵⁹ <https://youtu.be/1XsUV7pwSRg>

⁶⁰ <https://www.weforum.org/people/jacinda-ardern>

⁶¹

<https://fyi.org.nz/request/16378/response/62394/attach/3/03.09.2021%20Letter%20to%20Benseman%20PMO%202021%20180.pdf>

Section 2.3 Altering the Human Beings – Chapter 11

The future will challenge our understanding of what it means to be human, from both a biological and a social standpoint. Emerging biotechnology agendas promise to improve and augment human lifespans and to enhance physical and mental health. The opportunity for the integration of digital technologies with biological tissues is also growing, and what that portends for the next decades is inspiring a range of emotions, from hope to wonder to fear."

*These technologies will operate within our own biology and change how we interface with the world. They are capable of crossing the boundaries of body and mind, enhancing our physical abilities, and even having a lasting impact on life itself. They are more than mere tools and demand special **"consideration for their ability to augment or intrude upon human beings, human behaviors and human rights."***

Chapter 5 – New Computing Technologies

*"External wearable devices, such as smart watches, intelligent earbuds and augmented reality glasses, are giving way to active implantable nanochips that break the skin barrier of our bodies, creating intriguing possibilities that range from integrated treatment systems to opportunities for human enhancement...**Biological computing could soon allow us to replace specialised nanochips with custom-designed organisms, a key aspect of a new cultural form of expression and consumption called "biohacking."***

103. The Auckland City Council has adopted the WEF's agenda for the Fourth Industrial Revolution and states in its Auckland Plan 2050⁶² the following (we have screenshot the information for ease of reading).

⁶² <https://www.aucklandcouncil.govt.nz/plans-projects-policies-reports-bylaws/our-plans-strategies/auckland-plan/opportunities-prosperity/Pages/fourth-industrial-revolution.aspx>

AUCKLAND PLAN 2050

Search the Auckland Plan 2050

Menu

[The Auckland Plan 2050](#) > [Outcome: Opportunity and Prosperity](#) > [The Fourth Industrial Revolution](#)

The Fourth Industrial Revolution

Technology disruption is predicted to be of a scale so great that it is described as the fourth industrial revolution. An important part of long term planning is to account for a variety of possible futures.

We use the term "fourth industrial revolution" as an acknowledgement of the disruption the world, and Auckland, will continue to face as technology advances.

Technology advancement can present both problems and opportunities for economies.

We want to create the conditions for a resilient economy. We also want to develop skills and talent for the changing nature of work.

See [Opportunity and Prosperity - evidence report \(PDF 6MB\)](#) for more information on the impact of advanced technology, increasing automation and digitisation.

The following is taken from World Economic Forum, [The Global Competitiveness Report, 2016-2017 \(PDF 11.9MB\)](#), Geneva, 2016. It was adapted from Klaus Schwab's 2016 book titled [The Fourth Industrial Revolution](#). Find out more on the [World Economic Forum website](#).

"We are at the beginning of a global transformation that is characterized by the convergence of digital, physical, and biological technologies in ways that are changing both the world around us and our very idea of what it means to be human. The changes are historic in terms of their size, speed, and scope.

This transformation – the Fourth Industrial Revolution – is not defined by any particular set of emerging technologies themselves, but rather by the transition to new systems that are built on the infrastructure of the digital revolution. As these individual technologies become ubiquitous, they will fundamentally alter the way we produce, consume, communicate, move, generate energy, and interact with one another.

And given the new powers in genetic engineering and neurotechnologies, they may directly impact who we are and how we think and behave. The fundamental and global nature of the revolution also poses new threats related to the disruptions it may cause – affecting labour markets and geopolitical security as well as social value systems and ethical frameworks."

[Share this page](#)

104. Klaus Schwab has also stated:

"People assume that we are just going back to the good old world which we had and everything will be normal again. This is, let's say, fiction. It will not happen. The cut which we have now is much too strong in order not to leave traces. We know that the world will look different. There will be a lot of anger. We have to prepare for a more angry world. Social revolution. Anger on the streets. We are at a rapture point .. terminating of humankind."

105. Schwab also states on the WEF website that:

"[w]e must address, individually and collectively, moral and ethical issues raised by cutting-edge research in artificial intelligence and biotechnology, which will enable significant life extension, designer babies, and memory extraction."⁶³

⁶³ <https://www.weforum.org/agenda/2016/01/how-can-we-embrace-the-opportunities-of-the-fourth-industrial-revolution>

106. The above statements reflect a small sample of Schwab and Harari's comments. We agree that they are entitled to an opinion, but it is concerning when Schwab claims on numerous occasions that the WEF has infiltrated multiple Governments around the world⁶⁴. What is also notable in their speeches and writing is the steady, monotonous delivery of truly earth-shaking threats and promises, with no warmth or attempts to relate to their audiences' potential surprise, disbelief, fear or non-consent. They appear not to notice or care, both of which can alert to the amoral sociopath, historically capable of atrocities, and often in the name of the greater good. Note Soviet dictator Josef Stalin's famous rationalisation for genocide: "*A hundred deaths is a tragedy; a million is just a statistic.*"

Conclusion

107. The principles established in the Policing Act confirm that a wide measure of public support, confidence, ethics and integrity is required in New Zealand.

108. We acknowledge that this is a strange time in history that few of us have experienced. However, when doctors and scientists raise serious concerns, risking their careers and livelihoods when it would be more convenient for them and their families to be quiet, and the Government of the day blatantly ignores them, the police are obliged to step up and investigate if we are truly in a democracy.

109. If the police are burdened with politics and unable to investigate and be part of the third branch of Government, which is meant to ensure safeguards, transparency and faith in a democracy, then we have a serious problem. If microtechnology is found in the vaccine following the police investigation, there are potential crimes under the Crimes Act 1961 and other legislation.

110. In addition, there is all the potential crime of serious misconduct in public office. Serious misconduct in public office is defined as a public officer acting as such; wilfully neglects to perform his or her duty and/or wilfully misconducts him or herself; to such a degree as to amount to an abuse of the public's trust in the office holder; without reasonable excuse or justification. Another potential crime of gross negligence is the conscious and voluntary

disregard of the need to use reasonable care, which is likely to cause foreseeable grave injury or harm to persons, property, or both.

111. We trust that you will reflect on your obligations under the Policing Act and consider the potential risks should there be microtechnology in the vaccine, as scientists and doctors are reporting. If there are no concerns, please confirm in writing that there is no microtechnology in the vaccine and provide us with copies of your investigatory report. If the police are unable to provide us with such an assurance, given that the Government refuses or is contractually unable to address the matter due to the terms of the Pfizer contract, then please provide us on what basis the police refuse to investigate?
112. An increasing number of medics, scientists and lawyers here and overseas see that the accumulation of emerging evidence of significant harm and potential wrongdoing is becoming unstoppable. We require a brave and courageous Police force to step up to assure public protection.
113. We look forward to your best attempts at a speedy resolution of this matter, and assure you of our cooperation and full support for an urgent investigation by New Zealand Police.

Yours Sincerely

Kirsten Murfitt
Kirsten Murfitt
Member of NZLSOS
E nzlsos@protonmail.com

Sue Grey
Sue Grey
Member of NZLSOS
E nzlsos@protonmail.com

Annexure A

Dr Shelton's Affidavit

Affidavit of Matthew Henty Shelton

Dated: 26 January 2022

I, Matthew Henty Shelton, of Wellington, Medical Doctor, swear:

1. I graduated from the University of Sheffield in the United Kingdom. I have been a registered medical doctor since 1985 and registered in New Zealand since 1994.
2. I have been suspended from practising in New Zealand by the New Zealand Medical Council for giving my medical professional opinion to patients.
3. In the last 24 hours, I have spent time with two qualified NZ scientists who have shown me real-time and digital microscopic images of what I believe to be a sample of the genuine vial of the Pfizer Comirnaty Vaccine. I believe the lot number can be made available.
4. Both from my own eyes and my assessment of the trustworthiness and the credibility of the scientists, the scientists told me, and I believe the following to be true:
 - (a) The Pfizer vaccine currently being used clinically contains man-made microscopic technology that appears to be self-assembling and electronic in nature. I have viewed hundreds of images and tens of video clips containing images that appear to be circuit board wires and electronic chips in varying degrees of self-assembly;
 - (b) These findings have been obtained over approximately one month of detailed and painstaking investigation by these scientists, both experienced in vaccines and their technology. The scientists have researched and crossed checked with other experts in dark field microscopy. Our unanimous consensus is that these findings are unprecedented, obviously alarming and represent a grave to the health of the recipient.
 - (c) Several different vials have been examined, and work to examine other vials and control samples is ongoing. In addition, has been demonstrated apparent organic life forms. Most of this work has used dark field microscopy with a high-end professional microscope and knowledgeable operators.
 - (d) Last Wednesday, on 19th January 2022, another science colleague and myself viewed similarly concerning images that we could not explain using a conventional light microscope. This was provoked by reading of groups reporting these abnormal findings.
 - (e) As a result of NZDSOS discussing our plan to arrange the purchase of a microscope to view the NZ vaccine, I was put in touch with the two scientists.

KH . Q

- (f) I have some limited experience of whole blood analysis using dark field microscopy but no formal qualifications, having worked alongside practitioners that use them. The scientists and I are confident that many of the bizarre and unusual structures and appearances were never seen in patients using dark field microscopy before the Covid-19 vaccine rollout around the world. I have listened to interviews, seen videos and read scientific reports from other groups internationally with similar findings of apparent technology in the vaccine, but there has been nothing as detailed and frankly horrifying in its implications as has been found here in New Zealand.

- (g) Although I also saw slides and videos of live blood analysis from vaccinated patients with definite abnormalities, clear images of "nanotech" were only seen in the vaccine alone and when mixed with blood on the slide. One can only suppose what is happening in the bodies of the vaccine recipients.

Sworn by Matthew Henry Shelton) *Matthew Henry Shelton*
 on _____ 26/1/2022
 at _____, Wairarapa.

Before me: *Katherine Marie Henry*
Barrister
Oamaru.
 (a solicitor of the High Court of New Zealand/Registrar/Deputy Registrar)

Katherine Henry
 Barrister
 100 Thames Street, Oamaru
 027 303 5203

Annexure B
Barrister's Letter

Barristers.Comm • Level 7 • Legal House • 101 Lambton Quay
PO Box 6140 • Wellington 6145 • New Zealand • T +64 4 914 1052 • F +64 4 473 3179
M 021 0241 3822 • E l.hansen@bcomm.nz • W www.bcomm.nz

LISA

BA(Hons)LLB(Hons) Otago **HANSEN**

BARRISTER

30 January 2022

To: Minister of Health, Andrew Little, a.little@ministers.govt.nz

To: Minister of Covid-19 Response, Chris Hipkins, c.hipkins@ministers.govt.nz

To: Chris James, Medsafe, chris.james@health.govt.nz

CC: Phil Knipe, Chief Legal Adviser, Ministry of Health, phil.knipe@health.govt.nz

Dear Ministers and Mr James

URGENT REQUEST TO IMMEDIATELY SUSPEND THE VACCINATION PROGRAMME DUE TO DISCOVERY OF POSSIBLE EXISTENCE OF NANO-SCALE ADVANCED TECHNOLOGY IN THE COVID-19 VACCINE BEING DISTRIBUTED IN NEW ZEALAND

Summary

The purpose of this letter is to bring to your attention evidence of the possible existence of nano-technology in vaccines in New Zealand.

If this technology is present the risks are unknown but potentially serious and harmful.

A precautionary approach requires the immediate cessation of the vaccination programme while investigations are carried out.

Failure to do so may cause serious harm to New Zealanders.

An urgent meeting is requested so that the full import of the material provided can be properly explained.

Introduction

I have been engaged by New Zealand Doctors Speaking Out with Science (NZDSOS) to formally bring to the immediate and urgent attention of key Ministers and government officials, photographic evidence that suggests Pfizer Comirnaty vials in New Zealand may contain nano-scale advanced technology.

A selection of photographic images are **enclosed**. My client is also in possession of videos which cannot be easily sent by email that need to be separately provided to you.

The exact source of the New Zealand investigations must remain confidential. However, Dr Matthew Shelton, who was contacted by the scientists involved, has given the **enclosed** sworn affidavit as to his first-hand assessment of the veracity and provenance of the images and how they were obtained, and the quality and experience of the scientists.

This evidence is consistent with evidence emerging overseas

Similar findings of nano-technology being detected in vaccines have already been raised and published internationally with high quality technical reports being released.

For example, graphene oxide has been detected in Covid-19 vaccines by micro-raman spectroscopy – refer document **enclosed**. As you will be aware graphene oxide is highly toxic and has no legitimate reason to be in the Covid-19 vaccines.

In another report by Dr Young (**enclosed**), spectroscopic analyses confirms that non-organic chemical elements are present in Covid-19, e.g. aluminium. While Dr Young's report does not meet publication level standard, it still contains some important data.

In addition, I understand regulators and relevant ministers have previously received letters of concern from NZDSOS from the beginning of the Government's pandemic strategy. A particular concern raised was that the vials of the vaccine may be contaminated with graphene oxide. This document is also **enclosed**.

Unknown implications of such technology justifies immediate cessation of the vaccine

The potential presence of such technology in vaccines being used in New Zealand is of grave concern. It would mean that vaccines being distributed in New Zealand may contain ingredients that do not occur in nature, have not been disclosed in any official data safety sheets, have not been tested in any clinical trials, and that therefore the actual risk to recipients from these substances is unknown.

Whether or not these structures have any effects in the human body, harmful or otherwise, their potential presence demands an immediate precautionary response from the government and regulators.

Taken together with mounting evidence of death and injuries associated temporally with the injections, NZDSOS believes that the evidence supplied should be prima facie presumed to be a true reflection of the vaccine contents unless and until proven otherwise and interpreted as presenting a possible serious threat to the health of New Zealanders.

They say that an immediate halt to the vaccination campaign whilst regulators investigate is not only fully justified but is the only available and responsible response.

Interpreting the images

What has been provided are highly magnified images of incredibly small structures (i.e. shown up to 4000 x magnification). In the time allowed between being shown and then carrying out a preliminary assessment of the information, and recognizing the urgent public health imperative of official regulators being informed, NZDSOS have not been able to do a detailed scientific study themselves, nor provide any certainty as to the purpose of this technology.

However, the additional material provided with this letter provides an obvious framework for assessing the images that have been obtained in NZ. These should be used in order to best interpret the NZ images.

Action required

You may find the images shocking and disturbing. A degree of cognitive dissonance may be an expected reaction. However, NZDSOS reiterate that given the public health implications, the images should be regarded as a true reflection of the vaccine contents, until proven otherwise.

Please urgently confirm receipt of this information and confirm that immediate action will be taken to meaningfully engage with this material and take the necessary steps to protect the public from further potential serious harm.

Additionally, NZDSOS seek an urgent meeting with appropriate senior Ministers and/or regulators and officials in the week of **31 January 2022** so that the full import of this information can be properly explained, and to assist them take the necessary appropriate next steps. The videos referred to above would also be provided.

Yours sincerely



Lisa Hansen

Encl

Annexure C

Dr Shelton's presentation to the Health Select Committee

Please click on the link below to access the presentation. We have linked the presentation due to its size. Please note that the link may take a few seconds to open.

<https://docdro.id/BGuPfc6>

Schedule 3

“adverse reactions of special interest” from Pfizer’s Documents

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST

1p36 deletion syndrome;2-Hydroxyglutaric aciduria;5'nucleotidase increased;Acoustic neuritis;Acquired C1 inhibitor deficiency;Acquired epidermolysis bullosa;Acquired epileptic aphasia;Acute cutaneous lupus erythematosus;Acute disseminated encephalomyelitis;Acute encephalitis with refractory, repetitive partial seizures;Acute febrile neutrophilic dermatosis;Acute flaccid myelitis;Acute haemorrhagic leukoencephalitis;Acute haemorrhagic oedema of infancy;Acute kidney injury;Acute macular outer retinopathy;Acute motor axonal neuropathy;Acute motor-sensory axonal neuropathy;Acute myocardial infarction;Acute respiratory distress syndrome;Acute respiratory failure;Addison's disease;Administration site thrombosis;Administration site vasculitis;Adrenal thrombosis;Adverse event following immunisation;Ageusia;Agranulocytosis;Air embolism;Alanine aminotransferase abnormal;Alanine aminotransferase increased;Alcoholic seizure;Allergic bronchopulmonary mycosis;Allergic oedema;Alloimmune hepatitis;Alopecia areata;Alpers disease;Alveolar proteinosis;Ammonia abnormal;Ammonia increased;Amniotic cavity infection;Amygdalohippocampectomy;Amyloid arthropathy;Amyloidosis;Amyloidosis senile;Anaphylactic reaction;Anaphylactic shock;Anaphylactic transfusion reaction;Anaphylactoid reaction;Anaphylactoid shock;Anaphylactoid syndrome of pregnancy;Angioedema;Angiopathic neuropathy;Ankylosing spondylitis;Anosmia;Anti-acetylcholine receptor antibody positive;Anti-actin antibody positive;Anti-aquaporin-4 antibody positive;Anti-basal ganglia antibody positive;Anti-cyclic citrullinated peptide antibody positive;Anti-epithelial antibody positive;Anti-erythrocyte antibody positive;Anti-exosome complex antibody positive;Anti-GAD antibody negative;Anti-GAD antibody positive;Anti-ganglioside antibody positive;Antigliadin antibody positive;Anti-glomerular basement membrane antibody positive;Anti-glomerular basement membrane disease;Anti-glycyl-tRNA synthetase antibody positive;Anti-HLA antibody test positive;Anti-IA2 antibody positive;Anti-insulin antibody increased;Anti-insulin antibody positive;Anti-insulin receptor antibody increased;Anti-insulin receptor antibody positive;Anti-interferon antibody negative;Anti-interferon antibody positive;Anti-islet cell antibody positive;Antimitochondrial antibody positive;Anti-muscle specific kinase antibody positive;Anti-myelin-associated glycoprotein antibodies positive;Anti-myelin-associated glycoprotein associated polyneuropathy;Antimyocardial antibody positive;Anti-neuronal antibody positive;Antineutrophil cytoplasmic antibody increased;Antineutrophil cytoplasmic antibody positive;Anti-neutrophil cytoplasmic antibody positive vasculitis;Anti-NMDA antibody positive;Antinuclear antibody increased;Antinuclear antibody positive;Antiphospholipid antibodies positive;Antiphospholipid syndrome;Anti-platelet antibody positive;Anti-prothrombin antibody positive;Antiribosomal P antibody positive;Anti-RNA polymerase III antibody positive;Anti-saccharomyces cerevisiae antibody test positive;Anti-sperm antibody positive;Anti-SRP antibody positive;Antisynthetase syndrome;Anti-thyroid antibody positive;Anti-transglutaminase antibody increased;Anti-VGCC antibody positive;Anti-VGKC antibody positive;Anti-vimentin antibody positive;Antiviral prophylaxis;Antiviral treatment;Anti-zinc transporter 8 antibody positive;Aortic embolus;Aortic thrombosis;Aortitis;Aplasia pure red cell;Aplastic anaemia;Application site thrombosis;Application site vasculitis;Arrhythmia;Arterial bypass occlusion;Arterial bypass thrombosis;Arterial thrombosis;Arteriovenous fistula thrombosis;Arteriovenous graft site stenosis;Arteriovenous graft thrombosis;Arteritis;Arteritis

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

CONFIDENTIAL

Page 1

FDA-CBER-2021-5683-0000083

Page 30

coronary;Arthralgia;Arthritis;Arthritis enteropathic;Ascites;Aseptic cavernous sinus thrombosis;Aspartate aminotransferase abnormal;Aspartate aminotransferase increased;Aspartate-glutamate-transporter deficiency;AST to platelet ratio index increased;AST/ALT ratio abnormal;Asthma;Asymptomatic COVID-19;Ataxia;Atheroembolism;Atonic seizures;Atrial thrombosis;Atrophic thyroiditis;Atypical benign partial epilepsy;Atypical pneumonia;Aura;Autoantibody positive;Autoimmune anaemia;Autoimmune aplastic anaemia;Autoimmune arthritis;Autoimmune blistering disease;Autoimmune cholangitis;Autoimmune colitis;Autoimmune demyelinating disease;Autoimmune dermatitis;Autoimmune disorder;Autoimmune encephalopathy;Autoimmune endocrine disorder;Autoimmune enteropathy;Autoimmune eye disorder;Autoimmune haemolytic anaemia;Autoimmune heparin-induced thrombocytopenia;Autoimmune hepatitis;Autoimmune hyperlipidaemia;Autoimmune hypothyroidism;Autoimmune inner ear disease;Autoimmune lung disease;Autoimmune lymphoproliferative syndrome;Autoimmune myocarditis;Autoimmune myositis;Autoimmune nephritis;Autoimmune neuropathy;Autoimmune neutropenia;Autoimmune pancreatitis;Autoimmune pancytopenia;Autoimmune pericarditis;Autoimmune retinopathy;Autoimmune thyroid disorder;Autoimmune thyroiditis;Autoimmune uveitis;Autoinflammation with infantile enterocolitis;Autoinflammatory disease;Automatism epileptic;Autonomic nervous system imbalance;Autonomic seizure;Axial spondyloarthritis;Axillary vein thrombosis;Axonal and demyelinating polyneuropathy;Axonal neuropathy;Bacterascites;Baltic myoclonic epilepsy;Band sensation;Basedow's disease;Basilar artery thrombosis;Basophilopenia;B-cell aplasia;Behcet's syndrome;Benign ethnic neutropenia;Benign familial neonatal convulsions;Benign familial pemphigus;Benign rolandic epilepsy;Beta-2 glycoprotein antibody positive;Bickerstaff's encephalitis;Bile output abnormal;Bile output decreased;Biliary ascites;Bilirubin conjugated abnormal;Bilirubin conjugated increased;Bilirubin urine present;Biopsy liver abnormal;Biotinidase deficiency;Birdshot chorioretinopathy;Blood alkaline phosphatase abnormal;Blood alkaline phosphatase increased;Blood bilirubin abnormal;Blood bilirubin increased;Blood bilirubin unconjugated increased;Blood cholinesterase abnormal;Blood cholinesterase decreased;Blood pressure decreased;Blood pressure diastolic decreased;Blood pressure systolic decreased;Blue toe syndrome;Brachiocephalic vein thrombosis;Brain stem embolism;Brain stem thrombosis;Bromosulphthalein test abnormal;Bronchial oedema;Bronchitis;Bronchitis mycoplasmal;Bronchitis viral;Bronchopulmonary aspergillosis allergic;Bronchospasm;Budd-Chiari syndrome;Bulbar palsy;Butterfly rash;C1q nephropathy;Caesarean section;Calcium embolism;Capillaritis;Caplan's syndrome;Cardiac amyloidosis;Cardiac arrest;Cardiac failure;Cardiac failure acute;Cardiac sarcoidosis;Cardiac ventricular thrombosis;Cardiogenic shock;Cardiolipin antibody positive;Cardiopulmonary failure;Cardio-respiratory arrest;Cardio-respiratory distress;Cardiovascular insufficiency;Carotid arterial embolus;Carotid artery thrombosis;Cataplexy;Catheter site thrombosis;Catheter site vasculitis;Cavernous sinus thrombosis;CDKL5 deficiency disorder;CEC syndrome;Cement embolism;Central nervous system lupus;Central nervous system vasculitis;Cerebellar artery thrombosis;Cerebellar embolism;Cerebral amyloid angiopathy;Cerebral arteritis;Cerebral artery embolism;Cerebral artery thrombosis;Cerebral gas embolism;Cerebral microembolism;Cerebral septic infarct;Cerebral thrombosis;Cerebral venous sinus thrombosis;Cerebral venous thrombosis;Cerebrospinal thrombotic

090177 e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

CONFIDENTIAL

Page 2

FDA-CBER-2021-5683-000084

Page 3

tamponade;Cerebrovascular accident;Change in seizure presentation;Chest discomfort;Child-Pugh-Turcotte score abnormal;Child-Pugh-Turcotte score increased;Chillblains;Choking;Choking sensation;Cholangitis sclerosing;Chronic autoimmune glomerulonephritis;Chronic cutaneous lupus erythematosus;Chronic fatigue syndrome;Chronic gastritis;Chronic inflammatory demyelinating polyradiculoneuropathy;Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids;Chronic recurrent multifocal osteomyelitis;Chronic respiratory failure;Chronic spontaneous urticaria;Circulatory collapse;Circumoral oedema;Circumoral swelling;Clinically isolated syndrome;Clonic convulsion;Coeliac disease;Cogan's syndrome;Cold agglutinins positive;Cold type haemolytic anaemia;Colitis;Colitis erosive;Colitis herpes;Colitis microscopic;Colitis ulcerative;Collagen disorder;Collagen-vascular disease;Complement factor abnormal;Complement factor C1 decreased;Complement factor C2 decreased;Complement factor C3 decreased;Complement factor C4 decreased;Complement factor decreased;Computerised tomogram liver abnormal;Concentric sclerosis;Congenital anomaly;Congenital bilateral perisylvian syndrome;Congenital herpes simplex infection;Congenital myasthenic syndrome;Congenital varicella infection;Congestive hepatopathy;Convulsion in childhood;Convulsions local;Convulsive threshold lowered;Coombs positive haemolytic anaemia;Coronary artery disease;Coronary artery embolism;Coronary artery thrombosis;Coronary bypass thrombosis;Coronavirus infection;Coronavirus test;Coronavirus test negative;Coronavirus test positive;Corpus callosotomy;Cough;Cough variant asthma;COVID-19;COVID-19 immunisation;COVID-19 pneumonia;COVID-19 prophylaxis;COVID-19 treatment;Cranial nerve disorder;Cranial nerve palsies multiple;Cranial nerve paralysis;CREST syndrome;Crohn's disease;Cryofibrinogenaemia;Cryoglobulinaemia;CSF oligoclonal band present;CSWS syndrome;Cutaneous amyloidosis;Cutaneous lupus erythematosus;Cutaneous sarcoidosis;Cutaneous vasculitis;Cyanosis;Cyclic neutropenia;Cystitis interstitial;Cytokine release syndrome;Cytokine storm;De novo purine synthesis inhibitors associated acute inflammatory syndrome;Death neonatal;Deep vein thrombosis;Deep vein thrombosis postoperative;Deficiency of bile secretion;Deja vu;Demyelinating polyneuropathy;Demyelination;Dermatitis;Dermatitis bullous;Dermatitis herpetiformis;Dermatomyositis;Device embolisation;Device related thrombosis;Diabetes mellitus;Diabetic ketoacidosis;Diabetic mastopathy;Dialysis amyloidosis;Dialysis membrane reaction;Diastolic hypotension;Diffuse vasculitis;Digital pitting scar;Disseminated intravascular coagulation;Disseminated intravascular coagulation in newborn;Disseminated neonatal herpes simplex;Disseminated varicella;Disseminated varicella zoster vaccine virus infection;Disseminated varicella zoster virus infection;DNA antibody positive;Double cortex syndrome;Double stranded DNA antibody positive;Dreamy state;Dressler's syndrome;Drop attacks;Drug withdrawal convulsions;Dyspnoea;Early infantile epileptic encephalopathy with burst-suppression;Eclampsia;Eczema herpeticum;Embolia cutis medicamentosa;Embolitic cerebellar infarction;Embolitic cerebral infarction;Embolitic pneumonia;Embolitic stroke;Embolism;Embolism arterial;Embolism venous;Encephalitis;Encephalitis allergic;Encephalitis autoimmune;Encephalitis brain stem;Encephalitis haemorrhagic;Encephalitis periaxialis diffusa;Encephalitis post immunisation;Encephalomyelitis;Encephalopathy;Endocrine disorder;Endocrine ophthalmopathy;Endotracheal intubation;Enteritis;Enteritis leukopenic;Enterobacter pneumonia;Enterocolitis;Enteropathic spondylitis;Eosinopenia;Eosinophilic

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

CONFIDENTIAL

Page 3

FDA-CBER-2021-5683-0000085

Page 32

fasciitis;Eosinophilic granulomatosis with polyangiitis;Eosinophilic oesophagitis;Epidermolysis;Epilepsy;Epilepsy surgery;Epilepsy with myoclonic-atonic seizures;Epileptic aura;Epileptic psychosis;Erythema;Erythema induratum;Erythema multiforme;Erythema nodosum;Evans syndrome;Exanthema subitum;Expanded disability status scale score decreased;Expanded disability status scale score increased;Exposure to communicable disease;Exposure to SARS-CoV-2;Eye oedema;Eye pruritus;Eye swelling;Eyelid oedema;Face oedema;Facial paralysis;Facial paresis;Faciobrachial dystonic seizure;Fat embolism;Febrile convulsion;Febrile infection-related epilepsy syndrome;Febrile neutropenia;Felty's syndrome;Femoral artery embolism;Fibrillary glomerulonephritis;Fibromyalgia;Flushing;Foaming at mouth;Focal cortical resection;Focal dyscognitive seizures;Foetal distress syndrome;Foetal placental thrombosis;Foetor hepaticus;Foreign body embolism;Frontal lobe epilepsy;Fulminant type 1 diabetes mellitus;Galactose elimination capacity test abnormal;Galactose elimination capacity test decreased;Gamma-glutamyltransferase abnormal;Gamma-glutamyltransferase increased;Gastritis herpes;Gastrointestinal amyloidosis;Gelastic seizure;Generalised onset non-motor seizure;Generalised tonic-clonic seizure;Genital herpes;Genital herpes simplex;Genital herpes zoster;Giant cell arteritis;Glomerulonephritis;Glomerulonephritis membranoproliferative;Glomerulonephritis membranous;Glomerulonephritis rapidly progressive;Glossopharyngeal nerve paralysis;Glucose transporter type 1 deficiency syndrome;Glutamate dehydrogenase increased;Glycocholic acid increased;GM2 gangliosidosis;Goodpasture's syndrome;Graft thrombosis;Granulocytopenia;Granulocytopenia neonatal;Granulomatosis with polyangiitis;Granulomatous dermatitis;Grey matter heterotopia;Guanase increased;Guillain-Barre syndrome;Haemolytic anaemia;Haemophagocytic lymphohistiocytosis;Haemorrhage;Haemorrhagic ascites;Haemorrhagic disorder;Haemorrhagic pneumonia;Haemorrhagic varicella syndrome;Haemorrhagic vasculitis;Hantavirus pulmonary infection;Hashimoto's encephalopathy;Hashitoxicosis;Hemimegalencephaly;Henoch-Schonlein purpura;Henoch-Schonlein purpura nephritis;Hepaplastin abnormal;Hepaplastin decreased;Heparin-induced thrombocytopenia;Hepatic amyloidosis;Hepatic artery embolism;Hepatic artery flow decreased;Hepatic artery thrombosis;Hepatic enzyme abnormal;Hepatic enzyme decreased;Hepatic enzyme increased;Hepatic fibrosis marker abnormal;Hepatic fibrosis marker increased;Hepatic function abnormal;Hepatic hydrothorax;Hepatic hypertrophy;Hepatic hypoperfusion;Hepatic lymphocytic infiltration;Hepatic mass;Hepatic pain;Hepatic sequestration;Hepatic vascular resistance increased;Hepatic vascular thrombosis;Hepatic vein embolism;Hepatic vein thrombosis;Hepatic venous pressure gradient abnormal;Hepatic venous pressure gradient increased;Hepatitis;Hepatobiliary scan abnormal;Hepatomegaly;Hepatosplenomegaly;Hereditary angioedema with C1 esterase inhibitor deficiency;Herpes dermatitis;Herpes gestationis;Herpes oesophagitis;Herpes ophthalmic;Herpes pharyngitis;Herpes sepsis;Herpes simplex;Herpes simplex cervicitis;Herpes simplex colitis;Herpes simplex encephalitis;Herpes simplex gastritis;Herpes simplex hepatitis;Herpes simplex meningitis;Herpes simplex meningoencephalitis;Herpes simplex meningomyelitis;Herpes simplex necrotising retinopathy;Herpes simplex oesophagitis;Herpes simplex otitis externa;Herpes simplex pharyngitis;Herpes simplex pneumonia;Herpes simplex reactivation;Herpes simplex sepsis;Herpes simplex viraemia;Herpes simplex virus conjunctivitis neonatal;Herpes simplex visceral;Herpes virus

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

infection;Herpes zoster;Herpes zoster cutaneous disseminated;Herpes zoster infection neurological;Herpes zoster meningitis;Herpes zoster meningoencephalitis;Herpes zoster meningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster necrotising retinopathy;Herpes zoster oticus;Herpes zoster pharyngitis;Herpes zoster reactivation;Herpetic radiculopathy;Histone antibody positive;Hoigne's syndrome;Human herpesvirus 6 encephalitis;Human herpesvirus 6 infection;Human herpesvirus 6 infection reactivation;Human herpesvirus 7 infection;Human herpesvirus 8 infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemia benign monoclonal;Hyperglycaemic seizure;Hypersensitivity;Hypersensitivity vasculitis;Hyperthyroidism;Hypertransaminaemia;Hyperventilation;Hypoalbuminaemia;Hypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve paralysis;Hypoglossal nerve paresis;Hypoglycaemic seizure;Hyponatraemic seizure;Hypotension;Hypotensive crisis;Hypothener hammer syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4 lymphocytopenia;Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathic neutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM nephropathy;IIIrd nerve paralysis;IIIrd nerve paresis;Iliac artery embolism;Immune thrombocytopenia;Immune-mediated adverse reaction;Immune-mediated cholangitis;Immune-mediated cholestasis;Immune-mediated cytopenia;Immune-mediated encephalitis;Immune-mediated encephalopathy;Immune-mediated endocrinopathy;Immune-mediated enterocolitis;Immune-mediated gastritis;Immune-mediated hepatic disorder;Immune-mediated hepatitis;Immune-mediated hyperthyroidism;Immune-mediated hypothyroidism;Immune-mediated myocarditis;Immune-mediated myositis;Immune-mediated nephritis;Immune-mediated neuropathy;Immune-mediated pancreatitis;Immune-mediated pneumonitis;Immune-mediated renal disorder;Immune-mediated thyroiditis;Immune-mediated uveitis;Immunoglobulin G4 related disease;Immunoglobulins abnormal;Implant site thrombosis;Inclusion body myositis;Infantile genetic agranulocytosis;Infantile spasms;Infected vasculitis;Infective thrombosis;Inflammation;Inflammatory bowel disease;Infusion site thrombosis;Infusion site vasculitis;Injection site thrombosis;Injection site urticaria;Injection site vasculitis;Instillation site thrombosis;Insulin autoimmune syndrome;Interstitial granulomatous dermatitis;Interstitial lung disease;Intracardiac mass;Intracardiac thrombus;Intracranial pressure increased;Intrapericardial thrombosis;Intrinsic factor antibody abnormal;Intrinsic factor antibody positive;IPEX syndrome;Irregular breathing;IRVAN syndrome;IVth nerve paralysis;IVth nerve paresis;JC polyomavirus test positive;JC virus CSF test positive;Jeavons syndrome;Jugular vein embolism;Jugular vein thrombosis;Juvenile idiopathic arthritis;Juvenile myoclonic epilepsy;Juvenile polymyositis;Juvenile psoriatic arthritis;Juvenile spondyloarthritis;Kaposi sarcoma inflammatory cytokine syndrome;Kawasaki's disease;Kayser-Fleischer ring;Keratoderma blenorrhagica;Ketosis-prone diabetes mellitus;Kounis syndrome;Lafora's myoclonic epilepsy;Lamb's excrescences;Laryngeal dyspnoea;Laryngeal oedema;Laryngeal rheumatoid arthritis;Laryngospasm;Laryngotracheal oedema;Latent autoimmune diabetes in adults;LE cells present;Lemierre syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidase increased;Leukoencephalomyelitis;Leukoencephalopathy;Leukopenia;Leukopenia neonatal;Lewis-Sumner syndrome;Lhermitte's sign;Lichen planopilaris;Lichen planus;Lichen sclerosus;Limbic encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver function test abnormal;Liver function test decreased;Liver function test increased;Liver induration;Liver injury;Liver iron concentration abnormal;Liver iron concentration

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

CONFIDENTIAL

Page 5

FDA-CBER-2021-5683-000087

Page 3

increased;Liver opacity;Liver palpable;Liver sarcoidosis;Liver scan abnormal;Liver tenderness;Low birth weight baby;Lower respiratory tract herpes infection;Lower respiratory tract infection;Lower respiratory tract infection viral;Lung abscess;Lupoid hepatic cirrhosis;Lupus cystitis;Lupus encephalitis;Lupus endocarditis;Lupus enteritis;Lupus hepatitis;Lupus myocarditis;Lupus myositis;Lupus nephritis;Lupus pancreatitis;Lupus pleurisy;Lupus pneumonitis;Lupus vasculitis;Lupus-like syndrome;Lymphocytic hypophysitis;Lymphocytopenia neonatal;Lymphopenia;MAGIC syndrome;Magnetic resonance imaging liver abnormal;Magnetic resonance proton density fat fraction measurement;Mahler sign;Manufacturing laboratory analytical testing issue;Manufacturing materials issue;Manufacturing production issue;Marburg's variant multiple sclerosis;Marchiafava-Bignami disease;Marine Lenhart syndrome;Mastocytic enterocolitis;Maternal exposure during pregnancy;Medical device site thrombosis;Medical device site vasculitis;MELAS syndrome;Meningitis;Meningitis aseptic;Meningitis herpes;Meningoencephalitis herpes simplex neonatal;Meningoencephalitis herpetic;Meningomyelitis herpes;MERS-CoV test;MERS-CoV test negative;MERS-CoV test positive;Mesangioproliferative glomerulonephritis;Mesenteric artery embolism;Mesenteric artery thrombosis;Mesenteric vein thrombosis;Metapneumovirus infection;Metastatic cutaneous Crohn's disease;Metastatic pulmonary embolism;Microangiopathy;Microembolism;Microscopic polyangiitis;Middle East respiratory syndrome;Migraine-triggered seizure;Miliary pneumonia;Miller Fisher syndrome;Mitochondrial aspartate aminotransferase increased;Mixed connective tissue disease;Model for end stage liver disease score abnormal;Model for end stage liver disease score increased;Molar ratio of total branched-chain amino acid to tyrosine;Molybdenum cofactor deficiency;Monocytopenia;Mononeuritis;Mononeuropathy multiplex;Morphoea;Morvan syndrome;Mouth swelling;Moyamoya disease;Multifocal motor neuropathy;Multiple organ dysfunction syndrome;Multiple sclerosis;Multiple sclerosis relapse;Multiple sclerosis relapse prophylaxis;Multiple subpial transection;Multisystem inflammatory syndrome in children;Muscular sarcoidosis;Myasthenia gravis;Myasthenia gravis crisis;Myasthenia gravis neonatal;Myasthenic syndrome;Myelitis;Myelitis transverse;Myocardial infarction;Myocarditis;Myocarditis post infection;Myoclonic epilepsy;Myoclonic epilepsy and ragged-red fibres;Myokymia;Myositis;Narcolepsy;Nasal herpes;Nasal obstruction;Necrotising herpetic retinopathy;Neonatal Crohn's disease;Neonatal epileptic seizure;Neonatal lupus erythematosus;Neonatal mucocutaneous herpes simplex;Neonatal pneumonia;Neonatal seizure;Nephritis;Nephrogenic systemic fibrosis;Neuralgic amyotrophy;Neuritis;Neuritis cranial;Neuromyelitis optica pseudo relapse;Neuromyelitis optica spectrum disorder;Neuromyotonia;Neuronal neuropathy;Neuropathy peripheral;Neuropathy, ataxia, retinitis pigmentosa syndrome;Neuropsychiatric lupus;Neurosarcoidosis;Neutropenia;Neutropenia neonatal;Neutropenic colitis;Neutropenic infection;Neutropenic sepsis;Nodular rash;Nodular vasculitis;Noninfectious myelitis;Noninfective encephalitis;Noninfective encephalomyelitis;Noninfective oophoritis;Obstetrical pulmonary embolism;Occupational exposure to communicable disease;Occupational exposure to SARS-CoV-2;Ocular hyperaemia;Ocular myasthenia;Ocular pemphigoid;Ocular sarcoidosis;Ocular vasculitis;Oculofacial paralysis;Oedema;Oedema blister;Oedema due to hepatic disease;Oedema mouth;Oesophageal achalasia;Ophthalmic artery thrombosis;Ophthalmic herpes simplex;Ophthalmic herpes zoster;Ophthalmic vein thrombosis;Optic neuritis;Optic

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

neuropathy;Optic perineuritis;Oral herpes;Oral lichen planus;Oropharyngeal oedema;Oropharyngeal spasm;Oropharyngeal swelling;Osmotic demyelination syndrome;Ovarian vein thrombosis;Overlap syndrome;Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection;Paget-Schroetter syndrome;Palindromic rheumatism;Palisaded neutrophilic granulomatous dermatitis;Palmoplantar keratoderma;Palpable purpura;Pancreatitis;Panencephalitis;Papillophlebitis;Paracancerous pneumonia;Paradoxical embolism;Parainfluenzae viral laryngotracheobronchitis;Paraneoplastic dermatomyositis;Paraneoplastic pemphigus;Paraneoplastic thrombosis;Paresis cranial nerve;Parietal cell antibody positive;Paroxysmal nocturnal haemoglobinuria;Partial seizures;Partial seizures with secondary generalisation;Patient isolation;Pelvic venous thrombosis;Pemphigoid;Pemphigus;Penile vein thrombosis;Pericarditis;Pericarditis lupus;Perihepatic discomfort;Periorbital oedema;Periorbital swelling;Peripheral artery thrombosis;Peripheral embolism;Peripheral ischaemia;Peripheral vein thrombus extension;Periportal oedema;Peritoneal fluid protein abnormal;Peritoneal fluid protein decreased;Peritoneal fluid protein increased;Peritonitis lupus;Pernicious anaemia;Petit mal epilepsy;Pharyngeal oedema;Pharyngeal swelling;Pityriasis lichenoides et varioliformis acuta;Placenta praevia;Pleuroparenchymal fibroelastosis;Pneumobilia;Pneumonia;Pneumonia adenoviral;Pneumonia cytomegaloviral;Pneumonia herpes viral;Pneumonia influenza;Pneumonia measles;Pneumonia mycoplasma;Pneumonia necrotising;Pneumonia parainfluenzae viral;Pneumonia respiratory syncytial viral;Pneumonia viral;POEMS syndrome;Polyarteritis nodosa;Polyarthritis;Polychondritis;Polyglandular autoimmune syndrome type I;Polyglandular autoimmune syndrome type II;Polyglandular autoimmune syndrome type III;Polyglandular disorder;Polymicrogyria;Polymyalgia rheumatica;Polymyositis;Polyneuropathy;Polyneuropathy idiopathic progressive;Portal pyaemia;Portal vein embolism;Portal vein flow decreased;Portal vein pressure increased;Portal vein thrombosis;Portosplenomesenteric venous thrombosis;Post procedural hypotension;Post procedural pneumonia;Post procedural pulmonary embolism;Post stroke epilepsy;Post stroke seizure;Post thrombotic retinopathy;Post thrombotic syndrome;Post viral fatigue syndrome;Postictal headache;Postictal paralysis;Postictal psychosis;Postictal state;Postoperative respiratory distress;Postoperative respiratory failure;Postoperative thrombosis;Postpartum thrombosis;Postpartum venous thrombosis;Postpericardiotomy syndrome;Post-traumatic epilepsy;Postural orthostatic tachycardia syndrome;Pre-cerebral artery thrombosis;Pre-eclampsia;Preictal state;Premature labour;Premature menopause;Primary amyloidosis;Primary biliary cholangitis;Primary progressive multiple sclerosis;Procedural shock;Proctitis herpes;Proctitis ulcerative;Product availability issue;Product distribution issue;Product supply issue;Progressive facial hemiatrophy;Progressive multifocal leukoencephalopathy;Progressive multiple sclerosis;Progressive relapsing multiple sclerosis;Prosthetic cardiac valve thrombosis;Pruritus;Pruritus allergic;Pseudovasculitis;Psoriasis;Psoriatic arthropathy;Pulmonary amyloidosis;Pulmonary artery thrombosis;Pulmonary embolism;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary microemboli;Pulmonary oil microembolism;Pulmonary renal syndrome;Pulmonary sarcoidosis;Pulmonary sepsis;Pulmonary thrombosis;Pulmonary tumour thrombotic microangiopathy;Pulmonary vasculitis;Pulmonary veno-occlusive disease;Pulmonary venous thrombosis;Pyoderma gangrenosum;Pyostomatitis vegetans;Pyrexia;Quarantine;Radiation leukopenia;Radiculitis

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

CONFIDENTIAL

Page 7

FDA-CBER-2021-5683-0000089

Page 36

brachial;Radiologically isolated syndrome;Rash;Rash erythematous;Rash pruritic;Rasmussen encephalitis;Raynaud's phenomenon;Reactive capillary endothelial proliferation;Relapsing multiple sclerosis;Relapsing-remitting multiple sclerosis;Renal amyloidosis;Renal arteritis;Renal artery thrombosis;Renal embolism;Renal failure;Renal vascular thrombosis;Renal vasculitis;Renal vein embolism;Renal vein thrombosis;Respiratory arrest;Respiratory disorder;Respiratory distress;Respiratory failure;Respiratory paralysis;Respiratory syncytial virus bronchiolitis;Respiratory syncytial virus bronchitis;Retinal artery embolism;Retinal artery occlusion;Retinal artery thrombosis;Retinal vascular thrombosis;Retinal vasculitis;Retinal vein occlusion;Retinal vein thrombosis;Retinol binding protein decreased;Retinopathy;Retrograde portal vein flow;Retroperitoneal fibrosis;Reversible airways obstruction;Reynold's syndrome;Rheumatic brain disease;Rheumatic disorder;Rheumatoid arthritis;Rheumatoid factor increased;Rheumatoid factor positive;Rheumatoid factor quantitative increased;Rheumatoid lung;Rheumatoid neutrophilic dermatosis;Rheumatoid nodule;Rheumatoid nodule removal;Rheumatoid scleritis;Rheumatoid vasculitis;Saccadic eye movement;SAPHO syndrome;Sarcoidosis;SARS-CoV-1 test;SARS-CoV-1 test negative;SARS-CoV-1 test positive;SARS-CoV-2 antibody test;SARS-CoV-2 antibody test negative;SARS-CoV-2 antibody test positive;SARS-CoV-2 carrier;SARS-CoV-2 sepsis;SARS-CoV-2 test;SARS-CoV-2 test false negative;SARS-CoV-2 test false positive;SARS-CoV-2 test negative;SARS-CoV-2 test positive;SARS-CoV-2 viraemia;Satoyoshi syndrome;Schizencephaly;Scleritis;Sclerodactylia;Scleroderma;Scleroderma associated digital ulcer;Scleroderma renal crisis;Scleroderma-like reaction;Secondary amyloidosis;Secondary cerebellar degeneration;Secondary progressive multiple sclerosis;Segmented hyalinising vasculitis;Seizure;Seizure anoxic;Seizure cluster;Seizure like phenomena;Seizure prophylaxis;Sensation of foreign body;Septic embolus;Septic pulmonary embolism;Severe acute respiratory syndrome;Severe myoclonic epilepsy of infancy;Shock;Shock symptom;Shrinking lung syndrome;Shunt thrombosis;Silent thyroiditis;Simple partial seizures;Sjogren's syndrome;Skin swelling;SLE arthritis;Smooth muscle antibody positive;Sneezing;Spinal artery embolism;Spinal artery thrombosis;Splenic artery thrombosis;Splenic embolism;Splenic thrombosis;Splenic vein thrombosis;Spondylitis;Spondyloarthropathy;Spontaneous heparin-induced thrombocytopenia syndrome;Status epilepticus;Stevens-Johnson syndrome;Stiff leg syndrome;Stiff person syndrome;Stillbirth;Still's disease;Stoma site thrombosis;Stoma site vasculitis;Stress cardiomyopathy;Stridor;Subacute cutaneous lupus erythematosus;Subacute endocarditis;Subacute inflammatory demyelinating polyneuropathy;Subclavian artery embolism;Subclavian artery thrombosis;Subclavian vein thrombosis;Sudden unexplained death in epilepsy;Superior sagittal sinus thrombosis;Susac's syndrome;Suspected COVID-19;Swelling;Swelling face;Swelling of eyelid;Swollen tongue;Sympathetic ophthalmia;Systemic lupus erythematosus;Systemic lupus erythematosus disease activity index abnormal;Systemic lupus erythematosus disease activity index decreased;Systemic lupus erythematosus disease activity index increased;Systemic lupus erythematosus rash;Systemic scleroderma;Systemic sclerosis pulmonary;Tachycardia;Tachypnoea;Takayasu's arteritis;Temporal lobe epilepsy;Terminal ileitis;Testicular autoimmunity;Throat tightness;Thromboangiitis obliterans;Thrombocytopenia;Thrombocytopenic purpura;Thrombophlebitis;Thrombophlebitis migrans;Thrombophlebitis

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

CONFIDENTIAL

Page 8

FDA-CBER-2021-5683-0000090

Page 37

neonatal;Thrombophlebitis septic;Thrombophlebitis superficial;Thromboplastin antibody positive;Thrombosis;Thrombosis corpora cavernosa;Thrombosis in device;Thrombosis mesenteric vessel;Thrombotic cerebral infarction;Thrombotic microangiopathy;Thrombotic stroke;Thrombotic thrombocytopenic purpura;Thyroid disorder;Thyroid stimulating immunoglobulin increased;Thyroiditis;Tongue amyloidosis;Tongue biting;Tongue oedema;Tonic clonic movements;Tonic convulsion;Tonic posturing;Topectomy;Total bile acids increased;Toxic epidermal necrolysis;Toxic leukoencephalopathy;Toxic oil syndrome;Tracheal obstruction;Tracheal oedema;Tracheobronchitis;Tracheobronchitis mycoplasmal;Tracheobronchitis viral;Transaminases abnormal;Transaminases increased;Transfusion-related alloimmune neutropenia;Transient epileptic amnesia;Transverse sinus thrombosis;Trigeminal nerve paresis;Trigeminal neuralgia;Trigeminal palsy;Truncus coeliacus thrombosis;Tuberous sclerosis complex;Tubulointerstitial nephritis and uveitis syndrome;Tumefactive multiple sclerosis;Tumour embolism;Tumour thrombosis;Type 1 diabetes mellitus;Type I hypersensitivity;Type III immune complex mediated reaction;Uhthoff's phenomenon;Ulcerative keratitis;Ultrasound liver abnormal;Umbilical cord thrombosis;Uncinate fits;Undifferentiated connective tissue disease;Upper airway obstruction;Urine bilirubin increased;Urobilinogen urine decreased;Urobilinogen urine increased;Urticaria;Urticaria papular;Urticarial vasculitis;Uterine rupture;Uveitis;Vaccination site thrombosis;Vaccination site vasculitis;Vagus nerve paralysis;Varicella;Varicella keratitis;Varicella post vaccine;Varicella zoster gastritis;Varicella zoster oesophagitis;Varicella zoster pneumonia;Varicella zoster sepsis;Varicella zoster virus infection;Vasa praevia;Vascular graft thrombosis;Vascular pseudoaneurysm thrombosis;Vascular purpura;Vascular stent thrombosis;Vasculitic rash;Vasculitic ulcer;Vasculitis;Vasculitis gastrointestinal;Vasculitis necrotising;Vena cava embolism;Vena cava thrombosis;Venous intravasation;Venous recanalisation;Venous thrombosis;Venous thrombosis in pregnancy;Venous thrombosis limb;Venous thrombosis neonatal;Vertebral artery thrombosis;Vessel puncture site thrombosis;Visceral venous thrombosis;Vlth nerve paralysis;Vlth nerve paresis;Vitiligo;Vocal cord paralysis;Vocal cord paresis;Vogt-Koyanagi-Harada disease;Warm type haemolytic anaemia;Wheezing;White nipple sign;Xlth nerve paralysis;X-ray hepatobiliary abnormal;Young's syndrome;Zika virus associated Guillain Barre syndrome.

Schedule 4

Open Letter to Parliament dated 22 January 2022

Chief Executive
Department of the Prime Minister and Cabinet
Level 8
Executive Wing
Parliament Buildings
Wellington

Ministry of Health
133 Molesworth Street
Wellington

By email and post

information@dpmc.govt.nz

info@health.govt.nz

Members of Parliament

Dear all

THE CONTROLLED DEMOLITION OF DEMOCRACY IN NEW ZEALAND – SECOND OPEN LETTER TO THE MEMBERS OF PARLIAMENT

1. I refer to my previous letter dated 25 August 2021. Once again, I write to you in my personal capacity and as a concerned citizen of New Zealand.
2. The democratic process is being demolished by an overreaching Government. Legislation is being passed without conventional parliamentary scrutiny, designed to protect against abuse of power. The Government has changed legislation in defiance of a High Court ruling, refused to consult with the public concerning Three Waters, covertly declared its commitment to Agenda 2030, introduced vaccine mandates resulting in financial hardship for many families and mandated vaccine passports despite the paradox of segregation given the vaccine does not provide immunity (i.e., it does not stop transmission or prevent infection).
3. The above issues are political, and there has been no healthy debate - let alone transparency. We are told to trust a Government that holds up science but goes out of its way to smear doctors and scientists that speak out against the Government's narrative. The term "*misinformation*" is now a euphemism for any statement that departs from the Government's declaration that it is the sole source of truth. Free and robust debate is at the heart of science, and preventing such debate is dangerous.
4. An article in the British Medical Journal⁶⁵ highlights how "[p]oliticians and governments are suppressing science. Veteran New Zealand doctor, René de Monchy⁶⁶, stated "[a]t some point,

⁶⁵ [Covid-19: politicisation, "corruption," and suppression of science | The BMJ](#)

⁶⁶ [NZ doctor exposes 'Perverse' monetary incentives to vaccinate and 'hush money' aid to victims' families - Seemorerocks](#)

it dawned on me: this is not so much about health, but more about politics, money, power, and social manipulation.”

5. The vaccine passports are an example of politics, money, power and social manipulation. There is no evidence that vaccine passports serve any purpose in preventing transmission of SARS-CoV-2 (i.e., the virus), let alone reduce the incidents of COVID-19 (i.e., the disease that may or may not develop from SARS-CoV-2). Dr Michael Baker was recently quoted in the Guardian⁶⁷ newspaper as follows:

“the traffic light system won’t help us very much because it was never designed to dampen down transmission, it was only designed to nudge people towards vaccination,”

6. Dr Ashley Bloomfield was quoted by Radio New Zealand⁶⁸ that:

“It’s quite clear that Omicron does escape vaccinations.”

7. Omicron has swept through the U.K. and other countries and been found to be milder than the Wuhan, Alpha, Beta or Delta strains of SARS-CoV-2. Accordingly, the U.K. has recently announced that it is lifting almost all the restrictions, including the masks mandates and the vaccine passports⁶⁹.

8. The purpose of this letter is to raise concerns in regard to the following matters:

- (a) The Government is allowing Pfizer’s rights to trump those of good New Zealand citizens;
- (b) The Pfizer trial is highly questionable;
- (c) The vaccine does not stop transmission;
- (d) The vaccine is not reducing serious outcomes.
- (e) There is a lack of transparency in regards to the risks of the vaccine;
- (f) The number of Cases and Deaths are not accurate;
- (g) There are serious concerns about the ingredients in the vaccine;
- (h) Why has the definition of vaccine changed?
- (i) The Government knew in January 2021 that boosters were necessary;
- (j) The Government is ignoring concern over vaccine selection pressure;
- (k) There are effective early treatments
- (l) The Government is ignoring concerns over vaccine-associated enhanced disease;
- (m) The narrative is continually changing, the goalposts are being moved, and there are rules for some and not for others.

9. This letter is lengthy, but I want to ensure that you are aware, or at least in receipt of the information.

[Big Pharma’s Rights Trump New Zealanders’ Rights and Freedoms](#)

10. Medical interventions must be proven safe and effective before they are rolled out on a healthy population, let alone mandated under provisional consent. As you are aware, full consent has not been granted for the vaccine to date. Pharmaceutical companies have unsuccessfully attempted to bring an mRNA vaccine to market for decades, all of which have failed due to efficacy and safety concerns. Regardless, the Government has agreed for Big Pharma to vaccinate a predominately healthy population first and research later. The short-term safety

⁶⁷ [New Zealand not prepared for Omicron outbreak expected in ‘matter of weeks’, experts warn | New Zealand | The Guardian](#)

⁶⁸ <https://www.msn.com/en-nz/news/national/traffic-light-system-may-need-strengthening-or-adjusting-in-face-of-omicron-bloomfield/ar-AASct3>

⁶⁹ <https://www.newstalkzb.co.nz/news/world/covid-19-omicron-outbreak-uk-lifts-covid-restrictions-says-omicron-wave-has-peaked/>

and efficacy data changed significantly over 2021, which should have you worried, and the medium and long term effects will not be known for years.

11. The Government has signed a multi-million dollar contract, perhaps billions given the boosters, with Big Pharma. The Government refuses to disclose the contract to the public. Consequently, we can only speculate if any onerous terms and conditions are being hidden.
12. Wion TV⁷⁰ reports that Pfizer is holding governments to ransom, interfering with national legislation, and even demanding military bases as a guarantee. What security has the Government provided under the contract? Our military bases or perhaps our water? Is Big Pharma demanding the mandates under the contract?
13. Vaccines are big business, and often power, greed, and money lead to corruption. CNN⁷¹ reported that Pfizer's earnings and sales doubled in the past quarter (as of November 2021) due to its Covid-19 vaccine with adjusted earnings of \$7.7 billion, up 133% from a year earlier. Revenue soared to \$24.1 billion, up 134%. The sky is the limit, with four monthly boosters as protection (if any) wanes quickly.
14. Why is the Government trusting Pfizer with an experimental vaccine when the company has incurred \$10,193,896,333⁷² in fines since 2000? Would you travel on an aeroplane manufactured by a company with a similar record concerning false claims and safety violations? Why are we asking healthy children with a low risk of death or hospitalisation to participate in a vaccine trial for an experimental vaccine? If we are vaccinating children entering puberty, what is the impact on fertility? We will not know the answer to that question for years to come. I assume you are aware of the fact that Pfizer settled for \$75,000,000.00 for the experiments that it ran on children in Nigeria⁷³.
15. New Zealanders are dying and being seriously injured from the vaccine. The Government is turning a blind eye as it does not require mandatory reporting of adverse reactions, nor does it actively investigate incidents. If the same amount of money that is being put into identifying Covid-19 cases in healthy people (a.k.a. asymptomatic cases with a probable false-positive PCR test) was put into looking at those suffering and dying from heart attacks, strokes and other injuries following the administration of the vaccine, it would show a different picture. If you disagree, please forward an affidavit stating the Government is undertaking standard monitoring, investigation and reporting, which would be undertaken for any other new and experimental vaccine or medicine.
16. Many doctors and scientists contend that the vaccine is doing more harm than good. Over 11,400 doctors and scientists have signed the Rome Declaration⁷⁴, over 15,000 medical and public health scientists and over 46,000 medical practitioners have signed the Great Barrington Declaration⁷⁵, to name a few declarations. Various groups of doctors and scientists have been established, such as World Council for Health⁷⁶, America's Frontline Doctors⁷⁷, Canadian Covid

⁷⁰ <https://www.youtube.com/watch?v=2zoSSHx9QtA>

⁷¹ <https://edition.cnn.com/2021/11/02/business/pfizer-earnings/index.html>

⁷² <https://violationtracker.goodjobsfirst.org/parent/pfizer>

⁷³ <https://www.business-humanrights.org/en/latest-news/pfizer-settles-drug-testing-case-with-nigerian-state-for-75-million/>

⁷⁴ <https://concernedoctors.org/rome-declaration/>

⁷⁵ <https://gbdeclaration.org/>

⁷⁶ <https://worldcouncilforhealth.org/>

⁷⁷ <https://americasfrontlinedoctors.org/>

Care Alliance⁷⁸ (“CCCA”), New Zealand Doctors Speaking Out with Science⁷⁹, along with many other groups.

17. So why do we not hear about these groups and concerns in the mainstream media? In December 2020, Newshub NZ was purchased by Discovery Channel (an American company). Five months later, in May 2021, Discovery merged with Warner to create a mega mega-media company. Who owns this new behemoth? A company called AT and T own 71%, and Discovery owns 29%. So who are the top shareholders in AT and T? Vanguard and Blackrock. Who are the top shareholders in Vanguard? Blackrock Who are the top shareholders in Blackrock? Vanguard. Who are the top shareholders of Pfizer.....Blackrock and Vanguard⁸⁰.

The Pfizer Trial

18. Vaccine development is usually a slow and laborious process that takes between 5 to 10 years. Vaccine Safety requires proper animal trials and peer-reviewed data.
19. Dr Bridle and Dr Palmer⁸¹ state that there were few animal studies for the vaccine. They found one study which Pfizer had submitted to the Japanese health authorities, which pertained to the distribution and elimination of a model vaccine. Dr Bridle and Dr Palmer summarised that:
“Pfizer’s animal data clearly presaged the following risks and dangers:
 - *blood clotting shortly after vaccination, potentially leading to heart attacks, stroke, and venous thrombosis*
 - *grave harm to female fertility*
 - *grave harm to breastfed infants*
 - *cumulative toxicity after multiple injections.”*
20. The CCCA⁸² reviewed Pfizer’s trial design and its first and second reports. The CCCA’s findings are alarming.
21. The CCCA states in the hierarchy of evidence, a randomised control trial is the gold standard. 43,548 people participated in Pfizer’s Phase III randomised control trial, half received the vaccine, and the placebo group received saline for a period of 2 months. The blind trial was meant to run until 2 May 2023. However, Pfizer gave the vaccine to the majority of the placebo group in early 2021. The trial is no longer a randomised control trial as the control group is gone. As a result, the long-term safety data that was supposed to be assessed in 2023 is no longer possible. Deviating from well-established protocols is alarming.
22. Pfizer’s original trial report was published on 31 December 2020 and claimed that the vaccines were safe and showed 95% efficacy seven days after the 2nd dose. But that 95% was the Relative Risk Reduction (“RRR”) ⁸³. The Absolute Risk Reduction (“AAR”) was only 0.84%. The RRR considers participants who could benefit from the vaccine, whereas the ARR (i.e. the difference between cases with and without a vaccine) considers the whole population. The author of a paper in The Lancet states that the omission of the ARR leads to reporting bias which affects the interpretation of vaccine efficacy and public health. In addition, the analysis

⁷⁸ <https://www.canadiancovidcarealliance.org/>

⁷⁹ <https://nzdsos.com/>

⁸⁰

https://money.cnn.com/quote/shareholders/shareholders.html?symb=PFE&subView=institutional&fbclid=IwAR3IoEQJkacZcj0cxvfJel5_KGjIAbr5HeKx7PiuzkyqNOcDySBY1Y2jzU

⁸¹ <https://doctors4covidethics.org/wp-content/uploads/2021/07/Pfizer-pharmacokinetics-and-toxicity.pdf>

⁸² www.canadiancovidcarealliance.org

⁸³ COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room, Piero Olliaro; Els Torrelee; Michel Vaillant (Published April 20, 2021) The Lancet Journals

[https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247\(21\)00069-0/fulltext](https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00069-0/fulltext)

of full datasets along with independent scrutiny is difficult to perform due to issues with the available data.

23. The CDC⁸⁴ reports that 95% of people who have died with COVID-19 disease have had at least one comorbidity listed as the cause of death. The average is four comorbidities. However, Pfizer chose participants from younger demographics. Only 4% of the trial participants were over the age of 75 years, and only 21% of the trial participants had a co-existing condition⁸⁵, and many health conditions were excluded. These included pregnant or breastfeeding women, people with allergies, psychiatric conditions, immunocompromised people, bleeding disorders, a previous positive test for SARS-CoV-2 (the virus, not the disease), and those who had been prescribed steroids, etc. No Pfizer Trial data exists to make safety claims about administering the vaccine to these groups. Yet these people are subject to mandates and vaccine passports, including my husband.
24. Information obtained under the Official Information Act (“OIA”) shows that the Government knew that the above health conditions had been excluded from the trial. Regardless, the Government actively encourages these individuals to take the vaccine. In addition, the Government encourages organisations that support these communities to push the vaccine in exchange for continued Government funding.
25. In November 2021, the FDA released the first batch of documents under a Freedom of Information court order. The FDA did not want to release the documents and asked the Court to grant them 50 plus years to release the documents. The Court settled for the FDA to select which documents it releases over time.
26. Researcher Craig Paardekooper⁸⁶, Kingston University, London, claims that the U.S. Vaccine Adverse Event Reporting System (“VAERS”) data shows vaccine batches are sequentially marked by varying toxicity and that there have been 33 confirmed lots of the vaccine. He also claims that manufacturing processes at different sites do not comply with ‘Good Manufacturing Practices’, and as such, the production of the product is not consistent. Dr Michael Yeadon, former Vice President Respiratory & Chief Scientific Advisor of Pfizer, has also demonstrated how different batches are used to have an experiment within an experiment⁸⁷ and that 5-10% of the batches account for around 80% of the adverse reactions. New Zealand groups were tracking different lot numbers to identify the risky batches. Subsequently, the Government removed the lot numbers from the vaccine cards blocking transparency.
27. A study out of the Penn Medicine Center for Evidence-based Practice published a meta-analysis of phase 1 and 2 clinical trials of several of the vaccines and found that *“[s]evere systemic adverse events were reported by 5 to 10 percent of trial subjects.”*⁸⁸ . Such a percentage is relatively high for severe adverse events, orders of magnitude higher than the chances of dying from severe COVID-19 infection. The risks clearly outweigh the benefits of a mass-vaccination roll-out.
28. Recently the British Medical Journal⁸⁹ reported on an investigation into Ventavia, one of the research companies Pfizer hired to conduct the trials. A whistle-blower, the Regional Director, reported her company to the FDA for falsifying data, unblinding participants, not following up

⁸⁴ <https://www.cdc.gov/nchs/covid19/frands.htm>

⁸⁵ <https://www.nejm.org/doi/pdf/10.1056/NEJMoa2034577?articleTools=true>

⁸⁶ <https://www.bitchute.com/video/WMUvLcmP1Wtk/>

⁸⁷ <https://dailyexpose.uk/2022/01/06/death-by-covid-injection-is-premeditated-and-co-ordinated-experts-conclude/>

⁸⁸ [mRNA vaccine review final.pdf \(upenn.edu\)](https://www.bmj.com/content/375/bmj.n2635)

⁸⁹ <https://www.bmj.com/content/375/bmj.n2635>

and testing participants who reported symptoms and mislabelling specimens. Several other employees backed up her account. Despite all this, neither Pfizer nor the FDA ever audited or investigated the research company, and Pfizer never disclosed the problems in its Emergency Use Application. Ventavia will continue to run four more COVID-19 clinical trials.

29. One example of Pfizer’s “bias” in reporting adverse reactions concerns a 12-year-old girl who was classified as suffering from stomach issues in Pfizer’s documents, yet she is now paralysed in a wheelchair, tube fed, suffers memory loss, and Pfizer will not return her parents telephone calls⁹⁰.
30. The CCCA produced a conflict of interest diagram for the authors of the Pfizer report and found that 84% had a conflict, including two founders of BioNTech whose stock value allegedly increased by \$9 billion.


Reducing Transmission

31. High vaccination rates using traditional vaccines have been effective in reducing diseases such as measles, polio and smallpox. Accordingly, high vaccination rates were expected to reduce the transmission of SARS-CoV-2 (i.e. the virus) and thereby reduce the burden of the Covid-19 disease. However, this experimental mRNA vaccine has not been effective in reducing transmission or infection.

32. In early 2021 the CDC Director, Rochelle Walensky, said that:

“... our data from the CDC today suggests, you know, that vaccinated people do not carry the virus, don’t get sick, and that it’s not just in the clinical trials but it’s also in real world data⁹¹”

33. Our Government told us that the vaccine was 95% effective and sent us the following information:



34. In August 2021, Rochelle Walensky said fully vaccinated people who get COVID-19:

"breakthrough" infection can spread the virus to others even if they are not symptomatic⁹².

35. In September 2021, the Ministry of Health (“MOH”) confirmed in writing that the vaccine was not designed to reduce transmission of Covid-19 (a copy of the letter is set out at **Schedule 1**).

⁹⁰ <https://youtu.be/t4X6VMdTK8Y>

⁹¹ <https://thehill.com/changing-america/well-being/546234-cdc-reverses-statement-by-director-that-vaccinated-people-are-no>

⁹² https://www.realclearpolitics.com/video/2021/08/06/cdc_director_vaccines_no_longer_prevent_you_from_spreading_covid.html

36. Rochelle Walensky recently stated:

"...what they [the vaccine] can't do anymore is prevent transmission⁹³".

37. Regardless, our Government mandates vaccine passports despite there being no evidence that segregation prevents transmission hence Dr Baker and Dr Bloomfield's comments as set out above. The science which emerged over 2021 shows that the vaccinated have a similar viral load and spread the virus (refer to **Schedule 2**).

38. Our Government now proclaims that vaccines and boosters are necessary to prevent the hospitals from becoming overwhelmed and delaying those with cancer from receiving treatment. Ironically, my husband, who was on chemotherapy at the time, had to wait five days to get urgent tests over the August lockdown. One of his blood results which should have been under 60, was at 911, and he had been in ICU a few months earlier. However, he could not get an urgent ultrasound due to "Covid paperwork" even though there were only a handful of cases in Tauranga, and I am not aware that Tauranga hospital was overwhelmed with COVID-19.

39. The vaccine mandates are hypocritical, given other harmful lifestyle choices are permitted and allowed to have a hospital bed. For example, smoking and the dangers of second-hand smoke on others, obesity, unprotected sex and the potential impact on others, along with drugs and alcohol. There is a correlation between obesity and hospitalisation and mortality rates from COVID-19⁹⁴.

40. If the Government is concerned about the availability of medical treatment, why has it mandated health workers, which has resulted in large numbers of staff leaving hospitals and medical centres? I note that infected vaccinated staff are being recalled to work in overseas hospitals in breach of the protocols due to staff shortages⁹⁵.

41. The mainstream media is now reporting that the vaccinated are the ones in the hospitals. Two examples are set out below. However, I am happy to provide you with further examples.

- The NSW government's COVID-19 Critical Intelligence Unit has revealed that as of Jan. 9, 68.9 percent of COVID-19 patients aged 12 and over in hospitals had two doses of the vaccine, with 28.8 percent unvaccinated (source: <https://aci.health.nsw.gov.au/covid-19/critical-intelligence-unit/monitor>); and
- Covid Scotland: Case rates lowest in unvaccinated as double-jabbed elderly drive rise in hospital admissions (source: <https://www.heraldscotland.com/news/19843315.covid-scotland-case-rates-lowest-unvaccinated-double-jabbed-elderly-drive-rise-hospital-admissions/>)

42. The constant scapegoating of the unvaccinated does not stand up to scrutiny or evidence and is entirely unwarranted. The term "unvaccinated" should not be conflated with "infectious". If the

⁹³ <https://www.msn.com/en-us/health/medical/cdc-director-covid-vaccines-cant-prevent-transmission-anymore/ar-AASDndg>

⁹⁴ [COVID-19-and-Obesity-The-2021-Atlas.pdf \(worldobesityday.org\)](https://www.worldobesityday.org/); <https://www.forbes.com/sites/jemimamcevov/2021/03/04/obesity-and-covid-death-rate-closely-linked-in-new-study/?sh=40333a1a643e>;

<https://onlinelibrary.wiley.com/doi/full/10.1111/obr.13128><https://care.diabetesjournals.org/content/43/7/1392.abstract>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385759/>

⁹⁵ <https://www.theguardian.com/australia-news/2022/jan/03/covid-positive-nurses-are-working-in-nsw-hospitals-due-to-severe-staffing-shortages>

vaccine worked, there would be no need for the vaccinated to shun the unvaccinated as they would have immunity (i.e. no transmission or infection).

43. Will the Government encourage Kiwis to collude, shun and hate their neighbours and loved ones for the sake of the vaccine which was developed for the alpha variant and has subsequently not stopped transmission of beta, delta, omicron and IHU variants to both the vaccinated and the unvaccinated? What is the next variant or pandemic? Marburg (refer to **Schedule 4**)?

Reducing Serious Outcomes

44. The majority will agree that there is no benefit to a reduction in cases if it comes at the cost of increased illness and death. We know that the vaccine does not stop transmission and infection. Accordingly, the Government asserts that the vaccine will reduce hospitalisation for COVID-19.
45. The recent U.K. Health Security Agency report⁹⁶ shows that despite the booster campaign being well underway, the majority of Covid-19 hospitalisations were among the fully vaccinated population (refer page 39).

Table 11. COVID-19 cases presenting to emergency care (within 28 days of a positive specimen) resulting in an overnight inpatient admission by vaccination status between week 49 and week 52 2021

Please note that corresponding rates by vaccination status can be found in [Table 13](#).

Cases presenting to emergency care (within 28 days of a positive test) resulting in overnight inpatient admission, by specimen date between week 49 and week 52 2021	Total	Unlinked*	Not vaccinated	Received one dose (1 to 20 days before specimen date)	Received one dose, ≥21 days before specimen date	Second dose ≥14 days before specimen date ¹
	[These data should be interpreted with caution. See information below in footnote about the correct interpretation of these figures]					
Under 18	899	47	796	8	38	10
18 to 29	899	23	405	10	88	373
30 to 39	1,063	12	541	7	66	437
40 to 49	1,165	12	558	10	47	538
50 to 59	1,406	17	594	5	55	735
60 to 69	1,326	17	491	11	52	755
70 to 79	1,379	5	349	4	50	971
80 or over	1,844	1	322	5	52	1,464

46. Regardless, disease-specific primary endpoints are no longer used in many fields of medicine owing to the fact that they can conceal data that indicates the toxic effects of the vaccines. If a person dies from the treatment or is severely injured by it, even if the treatment helped block the progression of the disease they are being treated for, the end result is still a negative one. For this reason, the appropriate endpoint that should be used is all-cause mortality and morbidity.
47. Illness and death from all causes should be studied to ensure that the vaccines are not causing harm. We were not told that the all-cause mortality in the initial phase of the Pfizer trial was 30 % higher in the vaccinated group versus the matched control group. Pfizer’s second report also showed an increase in illness and deaths. A recent article in Trends in Internal Medicine⁹⁷

⁹⁶

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045329/Vaccine_surveillance_report_week_1_2022.pdf

⁹⁷ US COVID-19 Vaccines Proven to Cause More Harm than Good Based on Pivotal Clinical Trial Data Analyzed Using the Proper Scientific Endpoint, “All Cause Severe Morbidity”, J Bart Classen, MD (Received 24 July 2021, Accepted 25 August 2021) Trends in Internal Medicine,

concluded none of the vaccines provides a health benefit, and all pivotal trials show a statistically significant increase in *"all cause severe morbidity"* in the vaccinated group compared to the placebo group.

48. Dr Peter Schirmacher, Pro-Vaccine Director of the Pathological Institute and Chief Pathologist at the University of Heidelberg, recently announced that the Covid-19 vaccine caused the death of 30 to 40% of those who died shortly after vaccination⁹⁸.
49. Interestingly, the death rate in the U.S. for those aged 18-64 has risen an astonishing 40% over pre-pandemic levels. According to the CEO of Indianapolis-based insurance company OneAmerica *"We are seeing, right now, the highest death rates we have seen in the history of this business – not just at OneAmerica"*⁹⁹. OneAmerica is a \$100 billion insurance company that's been in operation since 1877 and has approximately 2,400 employees.

Lack of Transparency of the Risks

50. Under medical ethics, any medical intervention must be proven safe before its roll out to the public. Once a new medical intervention is rolled out the accurate reporting and investigation of adverse events is essential. Unfortunately, our Government and others do not require mandatory reporting of adverse events for the vaccine. Reporting is voluntary.
51. The consequences of voluntary reporting systems have been studied in the U.S. and N.Z.:
 - (a) A 2010 study performed by Harvard consultants found that *"fewer than 1% of adverse events"*¹⁰⁰ were reported to VAERS. Medical professionals claim that VAERS reports are time-consuming and a complex process.
 - (b) The Centre to Adverse Reactions Monitoring System ("**CARMS**") is the early warning system in New Zealand. CARMS is contracted by Medsafe to collect voluntary reports of adverse reactions. Medsafe estimates that only 5% of all reactions are reported¹⁰¹.
52. The low level of reporting is of great concern given U.S. Senator Ron Johnson's recent tweet that America had passed two milestones on their reporting system, 1 million adverse events and 21,000 deaths, of which 30% occurred within three days of the vaccine. What would be the real number of adverse events and deaths from the vaccine if reporting had been mandatory?
53. Regardless of voluntary reporting in New Zealand, safety signals have been found, and others are emerging for the vaccine.
54. It would seem that the Government is not being transparent about the adverse events. The Minutes of the Covid 19 Vaccine Technical Advisory Group¹⁰² ("**TAG**") dated 11 May 2021 record the following at item 5:

Classen Immunotherapies, Inc <https://newsrescue.com/wp-content/uploads/2021/08/us-covid19-vaccines-proven-to-cause-more-harm-than-good-based-on-pivotal-clinical-trial-data-analyzed-using-the-proper-scientific-1811.pdf>

⁹⁸ <https://www.augsburger-allgemeine.de/panorama/Corona-Chef-Pathologe-der-Uni-Heidelberg-draengt-auf-mehr-Obduktionen-von-Geimpften-id60235361.html>

⁹⁹ [Life Insurance CEO Says Deaths Up 40% Among Those Aged 18-64 | ZeroHedge](https://lifeinsurance.com/news/2021/05/18/life-insurance-ceo-says-deaths-up-40-among-those-aged-18-64/)

¹⁰⁰ <https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf>

¹⁰¹ <https://www.medsafe.govt.nz/Profs/PUarticles/ADRreport.htm>

¹⁰² <https://fyi.org.nz/request/16691/response/65106/attach/5/H202112324%20documents%20redacted.pdf>

- The level of work is unprecedented; usually CARM receives about 5,000 reports a year but have already received around 2,600 reports since the beginning of the COVID-19 vaccine rollout.

55. The Minutes also show that TAG was investigating four signals, including thrombosis with thrombocytopenia syndrome, appendicitis, herpes zoster and myocarditis, in May 2021 while the unprecedented marketing campaign continued to state that the vaccine was safe and effective. The Summary of Medsafe’s Investigations into possible safety signals is set out below:

Safety signal	Outcome
Blood clots	Continue to monitor. See also the Monitoring communication
Appendicitis	Continue to monitor
Myocarditis/pericarditis	Information has been added to Comirnaty data sheet . See also the Alert communication . Medsafe will continue to monitor this closely.
Herpes zoster	Continue to monitor
Bell’s palsy/facial paralysis	Continue to monitor
Menstrual disorder	Continue to monitor. See also the monitoring communication .
Stroke	Continue to monitor
Tinnitus	Continue to monitor
AEFIs in the elderly	Continue to monitor and updated data sheet
Pancreatitis	Continue to monitor
Glomerular diseases	Continue to monitor
Guillain-Barré Syndrome	Continue to monitor
Thrombocytopenia	Continue to monitor
AEFIs in children	Continue to monitor
Erythema multiforme	Continue to monitor
Pregnancy	Continue to monitor. See also the monitoring communication .

Myocarditis – What did the Government Know?

56. The Health and Disabilities Act and its Code require all health and disability services to comply with certain minimum standards of patient care, including the provision of adequate information so patients can make informed decisions. The principle of “*informed consent*” is fundamental. This requires information about risks, benefits and uncertainties as well as alternatives, and also that decisions are freely made, without duress.
57. The Government has known about the risk of myocarditis from at least May 2021. However, the Government should have known about the risk since October 2020 following the FDA ACIP Meeting.
58. The **FDA ACIP Meeting**¹⁰³ on 30 October 2020 set out a working list of possible adverse event outcomes:

¹⁰³ <https://www.fda.gov/media/143557/download>

FDA Safety Surveillance of COVID-19 Vaccines :
DRAFT Working list of possible adverse event outcomes
*****Subject to change*****

▪ Guillain-Barré syndrome	▪ Deaths
▪ Acute disseminated encephalomyelitis	▪ Pregnancy and birth outcomes
▪ Transverse myelitis	▪ Other acute demyelinating diseases
▪ Encephalitis/myelitis/encephalomyelitis/ meningoencephalitis/meningitis/ encephalopathy	▪ Non-anaphylactic allergic reactions
▪ Convulsions/seizures	▪ Thrombocytopenia
▪ Stroke	▪ Disseminated intravascular coagulation
▪ Narcolepsy and cataplexy	▪ Venous thromboembolism
▪ Anaphylaxis	▪ Arthritis and arthralgia/joint pain
▪ Acute myocardial infarction	▪ Kawasaki disease
▪ Myocarditis/pericarditis	▪ Multisystem Inflammatory Syndrome in Children
▪ Autoimmune disease	▪ Vaccine enhanced disease

59. Our Government’s Clinical Evaluation¹⁰⁴ dated January 2020 (obtained under the OIA) does not seem to include the FDA’s list of adverse reactions. Unless myocarditis is listed on one of the three redacted pages, which would raise a number of serious questions.

IX. SELECTED INITIAL ADVISORY GROUP COMMENTS

Responses to an early request (with very limited information) for advice from the Medsafe COVID-19 Vaccine Advisory Committee have included the following.

Covid-19 vaccines can be expected not to provide long term protection – the need for booster doses can be expected. (For viral vectored vaccines, heterologous boosting may be needed).

Significant delayed adverse consequences of vaccination, generally, are very uncommon. For example, a recent article highlighted vaccines that had been withdrawn for safety concerns. All of the events, resulting in withdrawal, occurred within 2 months of vaccine receipt (Reid S Vaccine Safety NZMJ 21 February 2020 Vol 133 No 1510. www.nzma.org.nz/journal-articles/vaccine-safety). Possible delayed AEs could include:

- VAERD in specific age groups (eg geriatric, pediatric) or in individuals with uncommon comorbidities (eg autoimmunity / immune deficiency)
- Guillain Barre Syndrome
- narcolepsy.

s 9(2)(b)(ii)

Pages 75- 77 withheld under section 9(2)(b)(ii) of the Act.

60. The Covid-19 Vaccine Technical Advisory Group (“TAG”) raised numerous concerns in regard to myocarditis^{105 106} as set out below:

Date of Minutes	Concerns
11 May 2021	<ul style="list-style-type: none"> • Four signals are currently being investigated: thrombosis with thrombocytopenia syndrome (TTS), appendicitis, herpes zoster, and myocarditis.
25 May 2021	<ul style="list-style-type: none"> • Events of myocarditis post-vaccination are being evaluated by regulators, including the EMA and FDA. Preliminary evidence suggests that rates are low in the US, UK and the EU (~1 per million) and Israel (~6 per million).

¹⁰⁴ <https://static1.squarespace.com/static/612c674b10fbd22a00202ceb/t/614d72f6a8c6667866a71081/1632465696127/H202106950-+Response+Documents+%28redacted%29+%28003%29+%281%29.pdf>

¹⁰⁵ [H202112324 documents redacted.pdf \(fyi.org.nz\)](https://static1.squarespace.com/static/612c674b10fbd22a00202ceb/t/614d72f6a8c6667866a71081/1632465696127/H202112324+documents+redacted.pdf)

¹⁰⁶ [H202115494 Response.pdf \(fyi.org.nz\)](https://static1.squarespace.com/static/612c674b10fbd22a00202ceb/t/614d72f6a8c6667866a71081/1632465696127/H202115494+Response.pdf)

8 June 2021	<ul style="list-style-type: none"> Israel Health Ministry has concluded that the cases of myocarditis, predominantly in younger males, following the Pfizer vaccine are probably linked to the vaccine. The US and EU regulators have stated that a causal link is yet to be established.
22 June 2021	<p>The decision to use Pfizer for 12 to 15 years</p> <ul style="list-style-type: none"> It would be advisable to delay until more safety data is available, especially with regards potential safety signals such as myocarditis, which have been reported in some overseas rollouts eg, Israel
29 June 2021	<p>Myocarditis after Pfizer Vaccination</p> <ul style="list-style-type: none"> Advice on the Decision to Use Pfizer for 12-15-year-olds was issued to Cabinet, however a decision has been deferred pending advice from CV TAG on myocarditis. The FDA have added a warning for myocarditis and pericarditis to the Pfizer and Moderna vaccine data sheets, after observing a series of cases following vaccination. It is seen most predominantly in adolescent and young adults, particularly males aged <30 years, and after the second dose. CV TAG discussed the current evidence and risks. <p>Key points of discussion:</p> <ul style="list-style-type: none"> The University of Auckland is leading a project estimating background rates of adverse events in New Zealand, including myocarditis, and is expected to report findings within the next 7-10 days. Data on the ethnic breakdown of cases was requested to be included. CV TAG noted concern about the potential risk of myocarditis has grown and a sense of urgency to develop options, e.g., for alternative vaccine schedules, and advice.
	<ul style="list-style-type: none"> While evidence is still emerging, IMAC clinicians are already fielding requests on myocarditis. It was noted that because the issue is relatively rare, the true risk may not be known for some time until the vaccine rollout internationally has progressed further. There is a need to communicate safety information to inform the public and present a balanced assessment of the risk and benefits. Science communicators who can appeal to a range of different ethnicities will be important. Further information is needed on vaccine hesitancy among young adults and men <30 and how this may be impacted by a potential safety signal, to inform how the commentary would be managed. Possible options raised by CV TAG included: <ul style="list-style-type: none"> Considering using only a single dose among people who are at higher risk (e.g. young males <30, people with a history of myocarditis) until further evidence is available. It was noted that Israel is actively considering this option Heterologous vaccine schedules (e.g., offering Janssen or another vaccine – when available - as a second dose). Considering the ongoing use of Pfizer in young males <30 until further evidence emerges. It was noted that many within this population would have been captured under groups 1-3. Data on the numbers in each of these groups, as well as when they are expected to be vaccinated, is needed from CVIP. <p>It was agreed that a subgroup would be convened to draft advice which will be presented to the CV TAG next week (06 July) to inform recommendations around using the Pfizer vaccine in younger people.</p>

<p>6 July 2021</p>	<p>Myocarditis after Pfizer Vaccination</p> <p>CV TAG discussed advice provided by the STA and a subgroup of CV TAG, on the current evidence on events of myocarditis/pericarditis post vaccination, and related questions.</p> <p>Key points:</p> <ul style="list-style-type: none"> • Previous studies of US military personnel, that evaluated the risk of myocarditis following the smallpox vaccine, indicated that myocarditis was a potential safety issue, with cases usually occurring within a few days of vaccination. • Events of myocarditis tend to be associated with the second dose of mRNA COVID-19 vaccines, although some cases occur after the first dose. The rate of myocarditis tends to be higher in males and younger age groups, particularly in males aged 16-30. • There is limited information, to date, on the long-term outcomes and severity of myocarditis following vaccination. Of the 29 cases in the Vaccine Safety Datalink (VSD) reported in the US, 24 (83%) were hospitalised with a median stay of 1 day (range 0-13 days), including two who were admitted to the ICU. All cases were discharged, and nearly all cases had resolution of symptoms at follow up. • Overall, emerging evidence suggests that myocarditis is a largely self-limiting and rare event following mRNA vaccination, with the rate for Pfizer in the US being approximately 0.8 per 100,000 in 12-39 year-olds within 21 days following the second dose. • CV TAG discussed possibility of alternative vaccination schedules that might mitigate the risk in younger age groups. However, any change in dosing schedule will require Medsafe approval. • CV TAG discussed potential recommendations, including advice for those with rheumatic heart disease, those with a previous history of myocarditis, or those who develop myocarditis following the first dose. <p>A subgroup of the CVTAG will meet 08 July to draft recommendations. The recommendations will be finalised by the end of week and discussed at the next CV TAG full meeting.</p>
<p>13 July 2021</p>	<p>Myocarditis Recommendations</p> <ul style="list-style-type: none"> • Draft recommendations on the risk of myocarditis after mRNA vaccination were presented to CV TAG. • It was noted that, this is a developing issue, and there are still several uncertainties in the data. • Based on preliminary US data, the risk of myocarditis after Pfizer vaccination is approximately 1 in 25,000 for males 12-29 years, and 1 in 240,000 for females 12-29 years. For individuals 30 and over, the corresponding risks decrease to approximately 1 in 400,000 for males, and 1 in a million for females. While the risk for females is lower than for males, it is still greater for younger people, and therefore any recommendation should be applied to all people aged under 30.
	<ul style="list-style-type: none"> • CV TAG progressed to summarise an initial draft of the approach: <ul style="list-style-type: none"> ○ The second dose of Pfizer vaccination could be deferred in individuals aged 29 years and under until further information is available about the risk, long-term outcomes of myocarditis and/or pericarditis, and protection offered by one dose for this age group. ○ People 29 years of age and younger who require regular clinical review by a cardiologist are advised to discuss the risks and benefits of the first dose of COVID-19 vaccine for their specific situation with their healthcare team ○ People aged 30 years and over should still receive two doses of the vaccine, 21 days apart as the risk of myocarditis and/or pericarditis post vaccination is less than 1 in 400,000 and risks of severe disease and sequelae due to COVID-19, including myocarditis, are substantially higher in this age group compared to people aged 29 years and under. ○ Anyone who develops confirmed myocarditis and/or pericarditis after the first dose should not receive a second dose of the Pfizer COVID-19 vaccine. CV TAG will consider alternative options for a second dose of COVID-19 vaccination in this group at a future date as evidence emerges from overseas safety monitoring. ○ CV TAG will continue to monitor all relevant effectiveness and safety data closely and advise on the need and options for the second dose for individuals aged 29 years and under at a future date. Options for the second dose may include: 1) proceeding with the second dose of the Pfizer COVID-19 vaccine after a longer interval between doses; 2) not administering a second dose; 3) administering a second dose of an alternative COVID-19 vaccine.

20 July 2021	<ul style="list-style-type: none"> • A Medsafe alert on myocarditis will be published later this week. The draft communication was shared with CV TAG, and feedback will be collated by the Secretariat to share back to Medsafe. • CV TAG discussed the background rates of myocarditis, and rates post-Pfizer vaccination, internationally and in Aotearoa New Zealand. <ul style="list-style-type: none"> ○ It was agreed that the US rates provided the best available baseline for comparisons with Aotearoa New Zealand. ○ The US data is broken down further by gender, age group and follow-up time, and notes a risk of 1 in 25,000 for males aged 12-29 within 7 days of the second dose, and 1 in 238,000 for females aged 12-29 within 7 days of the second dose, for mRNA vaccines. ○ Severity measures should also be incorporated into the presentation of the data, for example hospitalisation and/or ICU admission rates, if data are available. • Draft recommendations on the risk of myocarditis after Pfizer vaccination were discussed. <ul style="list-style-type: none"> ○ CV TAG noted that there is some evidence that young people aged 16 to 29 years have a strong immune response after one dose, however that two doses provide the best protection. A delayed schedule for the second dose was discussed. Whether this potentially reduces the risk of myocarditis, in addition to the severity of other adverse events, is unknown.
27 July 2021	<p>Myocarditis Recommendations Update</p> <p>The final memo on Myocarditis after Pfizer mRNA vaccination was shared with CV TAG and discussed.</p> <ul style="list-style-type: none"> • The final memo included input and advice from Medsafe. • The Director-General has received the recommendations, and an implementation plan is currently being prepared within the Ministry, once the recommendations have been agreed by Ministers • CV TAG discussed the data supporting longer dosing intervals for Pfizer; Data showed higher immunogenicity was associated with an extended dosing interval (median 10 weeks) compared to the usual 3-4 weeks. • CV TAG discussed the recommended dosing interval for people under 30 years. CV TAG discussed the while an 8-week interval is recommended for this age group, administering the second dose between 6 and 12 weeks is acceptable, and that the exact timing is a programming decision. • It was agreed that all changes must communicated in a way to provide clarity.
3 August 2021	<p>Myocarditis Recommendations Update</p> <p>The Chair updated CV TAG on progress with the final recommendations on myocarditis.</p> <ul style="list-style-type: none"> • The Director-General has accepted the recommendations. An announcement and implementation plan for extending the dosing interval is forthcoming. • It will result in significant programmatic changes and has important equity considerations, however the emphasis on distributing first doses to priority groups has been noted and accepted.
31 August 2021	<p>Myocarditis after Pfizer Vaccination</p> <p>The recent death of a woman with myocarditis post-vaccination was discussed with CV TAG:</p> <ul style="list-style-type: none"> • ISMB determined that vaccination was one of the causal factors. • It was noted that this myocarditis following vaccination is extremely rare. • The case is under review by a coroner and the case report will be published providing greater detail.
I have been unable to locate information from August through October 2021	

<p>19 October 2021</p>	<p>Myocarditis Update</p> <ul style="list-style-type: none"> • An update was provided from STA on the risk of myocarditis according to international evidence. Data presented at the latest US ACIP meeting on 30 August 2021 and data from Israel indicate that myocarditis reporting rates following mRNA COVID-19 vaccination continue to be rare overall, but highest risk tends to occur after the second dose, particularly in younger males. • Medsafe also shared the latest data on cases. The safety profile differs to the US in that New Zealand is seeing more cases after dose 1 than dose 2, however this could reflect the vaccine rollout with more young people being vaccinated later. Onset tends to be reported in the first few days for both dose. Data on dosing intervals has not been analysed, however it has been noted that cases have still occurred at an interval of 6-8 weeks. Overall, the rate is approximately 7 per million doses after dose 1, and 10 per million doses after dose 2. People aged 30-39 are the most affected age group in New Zealand overall, and after dose 1, and people aged 20-29 are most affected after dose 2. Long-term follow-up data is expected by end of November. • ISMB shared that levels of reporting seem to correlate with the numbers of reports being received, looking at the number of hospitalisations in vaccinated individuals. Every case reported to CARM is reviewed by a medical assessor, and when there is insufficient data, further information is requested. If there is a risk of death, biopsies and post-mortems of myocardium are requested. No long-term outcome data is currently available. • Information on symptoms to watch out for have been provided to all vaccinators, however it is possible that some centres are still using older booklets from before the advice was given. • Milder cases may benefit from further clinical investigation, and greater standardisation in management of care may be needed with ECGs and provision of troponins. Accessibility of the guidance for general practice and primary care will be reviewed. • As previously noted, people who have myocarditis after their first dose should not be offered a second dose of an mRNA vaccine, and an alternative vaccine or no further doses should be considered for those people. • No further evidence had emerged that decreasing the dose interval had impacted myocarditis. • A clinical research project is one option to consider looking at myocarditis in greater detail.
<p>2 November 2021</p>	<ul style="list-style-type: none"> • There was discussion about the risks of mandating vaccinations for people at elevated risk of adverse events e.g., younger people aged 12-17 and the increased risk of myocarditis after the second dose, and a single dose may be sufficient
	<p>Research Studies: Myocarditis research</p> <p>A request to support research myocarditis following COVID-19 vaccination was also considered.</p> <ul style="list-style-type: none"> • An ongoing long-term follow-up study was discussed regarding cases with a clinical diagnosis of myocarditis and/or pericarditis following vaccination, as reported to CARM. • CV TAG members were requested to volunteer to form a subgroup to develop plans and present a proposal for additional research questions to the Post-Event team.
	<p>Decision to Use for 5-11-year-olds</p> <ul style="list-style-type: none"> • An initial discussion occurred on the Pfizer vaccine for 5–11-year-olds. • The recent clinical trial occurred among a relatively small sample of ~2000 children. Rare adverse events cannot be evaluated in a clinical trial of that size. New Zealand would be able to wait for the real-world data of the vaccine rollout internationally to evaluate safety and effectiveness. • The benefit:risk ratio was not as obvious for this group as for older populations, as COVID-19 presents as a mild disease in this age group and there appears to be an increased risk of myocarditis after vaccination in younger age groups. • Concern was also expressed on including 5–11-year-olds under vaccine certificates and mandates, with potential effects on education and wellbeing. • However, different risks for Māori and 5-11-year-olds vulnerable to severe COVID-19 or immunocompromise should be considered • A subgroup of CV TAG will be meeting to draft recommendations in the coming days.

61. On 8 November 2021, the **American Heart Foundation**¹⁰⁷ published the following:
“We conclude that the mRNA vacs dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination”.
62. A preprint study has now been released showing that the risk of myocarditis for young people in the United States is greater than the risk of hospitalisation due to Covid-19, even in regions heavily affected by Covid-19¹⁰⁸. This is also highlighted in Israeli studies,¹⁰⁹ which have exclusively used the Pfizer Comirnaty vaccine. One such study shows a 13.6-fold (1,260% increase) in new cases of myocarditis after the second vaccine in 16 to 19-year-old males, compared to background rates of the disease between 2017 to 2019.
63. Finally, on 15 December 2021, the MOH issued an update for myocarditis/pericarditis. Unfortunately, this warning came too late for many New Zealanders. As of 31 December 2021, Medsafe’s website shows that 133 deaths were reported (which is under-reported). This included Rory Narin and my friend’s sister.
64. Dr Noelyn Hung states the risk of myocarditis from the vaccine is less than the risk of myocarditis from Covid-19. Dr Hung¹¹⁰ is one of the key personnel for Zenith Technology, a contract research organisation that provides clinical trial and analytical laboratory services for the international pharmaceutical industry and teaches at the department of pathology at Otago University. I could not locate any myocarditis or Covid-19 publications in her name.
65. Dr Peter McCullough¹¹¹ is a top cardiologist and the most highly cited physician on the early treatment of Covid-19 and has more than 600 citations in the National Library of Medicine. Dr McCullough disagrees with Dr Hung’s suggestion and has warned that myocarditis due to the vaccine is far more serious than myocarditis contracted from the virus itself. Dr McCullough states that the difference is that the ailment produced by the natural infection tends to elevate troponin levels, which is a protein found in cardiac and skeletal muscle. *“[T]he myocarditis in COVID-19 is mild, it’s inconsequential, and it’s largely a component of election [of troponin].”* In contrast, Dr McCullough contends that contracting the ailment through the vaccine may cause lipid nanoparticles to go directly to the heart. *“The heart expresses the spike protein, the body attacks the heart. There are dramatic EKG changes. I don’t want anybody to think that the myocarditis of a natural infection is anything like what we’re seeing with the vaccines,”* the top cardiologist warned.
66. Dr McCullough claims that the heart injuries due to the vaccine are around 10-100 times higher than the troponin seen in natural infections. Worsening matters; the doctor states that when kids develop myocarditis after the vaccine, 90% require immediate hospitalisation to prevent heart failure. Dr McCullough states that *“Vaccine-induced myocarditis is a big deal, and in children, it’s way more serious and more prominent than a post-COVID myocarditis.”*

¹⁰⁷ Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning, Steven R Gundry (Originally published 8 November 2021) AHA Journals
https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712

¹⁰⁸ SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis, Tracy Beth Høeg; Allison Krug, Josh Stevenson; John Mandrola (8 September 2021) MedRxiv, The Preprint Server for Health Sciences
<https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1>

¹⁰⁹ SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis, Tracy Beth Høeg; Allison Krug, Josh Stevenson; John Mandrola (8 September 2021) MedRxiv, The Preprint Server for Health Sciences
<https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1>

¹¹⁰ <http://www.zenithtechnology.co.nz/key-personnel/index.cfm>

¹¹¹ https://www.youtube.com/watch?time_continue=17&v=lxfcP8wvt58&feature=emb_logo

67. I find it hard to believe that heart inflammation from the vaccine is rare, given I am prepared to swear under oath as to the following:

(a) I know a young lady in her 20s that was previously fit and healthy prior to the vaccine. She emailed me two days after her first vaccination and stated the following:

"I have had bad heart pains this weekend so went to the Dr and she did an ECG and blood tests and they think I just have severe inflammation around the heart which is a big relief over being heart issues. She said she has had multiple girls my age with the same symptom after their first vaccine. So hopefully the medication they have given me will ease the pain and discomfort."

(b) The young lady also reported heart pain and required an ECG and bloods following her second vaccine.

(c) A staff member of the Tauranga Council sent me an email reporting that his young fit daughter suffered from myocarditis following the vaccine.

68. I have friends that have relatives and friends with heart issues (and other adverse reactions). One person I know reported that North Shore Hospital sees an average of 4 cases a day. Another contact said that there were over 30 heart attacks deaths in one month in Tauranga Hospital, which is well above the average.

[The number of Cases and Deaths are not accurate](#)

69. Public health policy should be based on accurate and independently verifiable data to identify infectious people and ensure sick people get medical attention. When in medical history has a public health authority needed to "test, test, test" healthy people with no symptoms to define a medical "case".

70. The results of the RT-qPCR ("PCR tests") have driven the fear and extension of the pandemic, with cases (most of which are mild) being announced daily in a hypnotic fashion.

71. Dr Anthony Fauci¹¹², director of the U.S. National Institute of Allergy and Infectious Diseases, stated that when a cycle threshold of 35 or more is used for the PCR Test, the chances of it being replication confident is minuscule. There are false-positive results when the PCR Test is set to a cycle threshold of 40. The WHO¹¹³ has confirmed that the PCR test has false positives.

72. The MOH confirmed in their letter in response to an OIA request (#H202007723¹¹⁴) that:

"Polymerase Chain Reaction (PCR) tests utilised in our accredited laboratories typically run for 40 cycles."

73. Why does the Government require the PCR test to be run at such a high threshold resulting in false positives? As of September 2021, the Government had spent approximately \$617,306,580¹¹⁵ to undertake 3,248,982 tests, which resulted in 3,242,989 negative tests and

¹¹² <https://www.bitchute.com/video/X0Z3Whf2SopB/>

¹¹³ <https://web.archive.org/web/20210120083427/https://www.who.int/news/item/14-12-2020-who-information-notice-for-ivd-users>

¹¹⁴ <https://fyi.org.nz/request/16779-effect-of-pfizer-vaccine-on-reducing-transmission> I note that some OIA are not as easy to find as they were previously

¹¹⁵ <https://fyi.org.nz/request/15879-cycle-thresholds-of-positive-sars-cov-2-tests-in-new-zealand#incoming-59660>

5133 positive tests (some individuals produced more than one positive test due to weekly testing etc.).

74. The PCR Test has already been ruled inadmissible in at least two European courts. The Portuguese Court of Appeal¹¹⁶ cited a study conducted by *"some of the leading European and world specialists"* which show that a cycle threshold of 35 or higher, the chances of that person being infected is less than 3%, and that *"the probability of... receiving a false positive is 97% or higher."*
75. People may die with a positive PCR test and not from Covid-19 but still, be counted as a Covid-19 death. One particularly fitting illustration of this is the 40-year-old Auckland man who died on 5th November 2021 of a gunshot wound and whose death was reported as a Covid-19 death¹¹⁷.
76. Examples of the "revision" of number by other countries are set out below:
 - (a) In June 2020, The CDC revised the number of deaths attributable to Covid-19 and stated that *"For 6% of the deaths, COVID-19 was the only cause mentioned. For deaths with conditions or causes in addition to COVID-19, on average, there were 2.9 additional conditions or causes per death"*¹¹⁸.
 - (b) In 2021, the Italian Higher Institute of Health¹¹⁹ showed only 2.9% of the 130,468 deaths registered by official statistics since the end of February 2020 would be due to Covid 19.
 - (c) A Lisbon court ruled only 0.9% of 'verified cases' died of COVID, numbering 152, not 17,000 claimed.
 - (d) In August 2021, the CDC adjusted the number down for Florida after State officials fought back. The CDC initially claimed 28,317 new cases, while the Florida DOH puts that number at 15,319. The CDC adjusted its number down to 19,584.
 - (e) Recently, the U.K. Office for National Statistics¹²⁰ has confirmed in response to a Freedom of Information request that as of the end of quarter 3 in 2021, 17,371 people had actually died of Covid-19 with no underlying causes. The media reports that 150,000 have died from Covid-19 but neglects to explain that people can die with the disease and not from the disease. On average, 30,000 people lose their lives during a single bad flu year in the U.K.

¹¹⁶ <https://off-guardian.org/2020/11/20/portuguese-court-rules-pcr-tests-unreliable-quarantines-unlawful/>

¹¹⁷ <https://www.washingtonexaminer.com/policy/healthcare/new-zealand-man-who-died-of-gunshot-wound-to-be-recorded-as-covid-19-death-report>

¹¹⁸ Conditions contributing to deaths involving COVID-19, by age group, United States, Week ending 2/1/2020 to 12/5/2020, National Center for Health Statistics. National Vital Statistics System (12 June 2020) Centers for disease control and prevention

https://www.cdc.gov/nchs/data/health_policy/covid19-comorbidity-expanded-12092020-508.pdf

¹¹⁹ Big mess in the death report. For the ISS, most of the deaths were not caused by Covid, Franco Bechis (21 October 2021) Il Tempo https://www.iltempo.it.translate.google/attualita/2021/10/21/news/rapporto-iss-morti-covid-malattie-patologie-come-influenza-pandemia-disastro-mortalita-bechis-29134543/?_x_tr_sl=it&_x_tr_tl=en&_x_tr_hl=it&_x_tr_pto=nui and Fake Mortality Data Corrected: Italian Institute of Health Reduces Official Covid Death Toll from 130,000 to 4,000, Paul Craig Roberts and guest contributions (9 November 2021) Paul Robert Institute for political economy <https://www.paulcraigroberts.org/2021/11/09/fake-mortality-data-corrected-italian-institute-of-health-reduces-official-covid-death-toll-from-130000-to-4000/>

¹²⁰

<https://www.ons.gov.uk/aboutus/transparencyandgovernance/freedomofinformationfoi/deathsfromcovid19withnootherunderlyingcauses>

77. The New Zealand Government highlights all COVID-19 deaths even where an elderly person with underlying comorbidities was close to passing. In 2020, Dr Bloomfield stated:

“Right from the start of the pandemic we’ve been very inclusive in our approach to categorising deaths as Covid related deaths ...The latest case we had was someone who had a confirmed C19 infection. Whilst they had a significant serious existing pre-existing condition, we have categorised the deaths as Covid related. You’ll see most countries doing this.”

78. The mainstream media may or may not report the age of the deceased and state that no further details will be provided due to privacy reasons, as per the screenshot below. A source has alleged that the deceased in this case was elderly with terminal cancer. Why are these details be withheld from COVID-19 deaths but published for deaths from other causes? Why the doublespeak?

Covid-19 patient dies in Tauranga; 74 new community cases

A patient with Covid-19 in Tauranga Hospital has died.

The Ministry of Health said that no further details will be released at this stage for privacy reasons. “Our thoughts are with the patient’s whānau and friends at this deeply sad time,” said a spokesperson.

79. The doublespeak was highlighted by the RSV outbreak in 2021 (which did overrun the hospitals). The media¹²¹ reported that an "older adult" died in Tauranga after catching RSV. The cause of the adult's death was attributed to numerous underlying medical conditions, the Bay of Plenty District Health Board said.
80. Sadly, a vaccine death of an elderly person with underlying comorbidities is viewed as an unfortunate event as they were going to die anyway. Examples of the doublespeak are set out in Minutes of the TAG meeting dated 29 June 2021 and Clinical Evaluation dated January 2020, which was obtained under the OIA.

- CV TAG were informed that there have been two recent incidences of frail elderly individuals passing away shortly following administration of the Pfizer vaccination. Each was showing serious progressive decline prior to vaccination, and there was a concern from the family and general practitioner that the vaccination may have played a role in their death.

¹²¹ <https://www.nzherald.co.nz/bay-of-plenty-times/news/rsv-in-tauranga-older-adult-dies-hospital-sees-hundreds-with-virus/X73EEAT5QNCH2TMN7BOVEKCXWU/>

V.8 Post marketing experience/Norway deaths

There are reports of deaths of 23 **frail elderly patients** shortly after receiving the Pfizer BioNTec vaccine. The Norwegian Medicines Agency (NOMA) has commented that there is no certain connection between these deaths and the vaccine.

The agency has investigated 13 of the deaths so far and concluded that common adverse reactions of mRNA vaccines, such as fever, nausea, and diarrhoea, may have contributed to fatal outcomes in some of the frail patients. "There is a possibility that these common adverse reactions, that are not dangerous in fitter, younger patients and are not unusual with vaccines, may aggravate underlying disease in the elderly".

Norwegian Authorities have prioritized the immunization of residents in Nursing Homes, most of whom are very elderly with underlying medical conditions and some which are terminally ill. NOMA confirms the number of incidents so far is not alarming, and in line with expectations.

All reported deaths will be thoroughly evaluated by NOMA to determine if these incidents are related to the vaccine. The Norwegian government will also consider adjusting their vaccination instructions to take the patients' health into more consideration.

<https://www.bmj.com/content/372/bmj.n149>

News. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination

BMJ 2021; 372 doi: <https://doi.org/10.1136/bmj.n149> (Published 15 January 2021) Cite this as: BMJ 2021;372:n149

Ingredients

81. Medsafe¹²² lists the ingredients of the vaccine as BNT162b2 [mRNA] 0.5 mg/mL equivalent to 30 µg/0.3mL dose, 1,2-Distearoyl-sn-glycero-3-phosphocholine, ALC-0159, ALC-0315, Cholesterol, Dibasic sodium phosphate dihydrate, Monobasic potassium phosphate, Potassium chloride, Sodium chloride, Sucrose and Water.
82. The Consumer Medicine Information Summary on Medsafe's website states the vaccine should not be given to a person if they are allergic to BNT162b2. However, there is no test to ascertain if a person is allergic to BNT162b2 or not. Instead, an individual needs to play Russian roulette.
83. The Cayman Chemicals Safety Data Sheet for 1,2-Distearoyl-sn-glycero-3-phosphocholine states at 1.2 "Relevant identified uses: For research use only, not for human or veterinary use"¹²³. Point 2.3 states under the heading 'Adverse Human Health' "Material may be irritating to the mucous membranes and upper respiratory tract". Then under the 'Effects and Symptoms' heading "May be harmful by inhalation, ingestion or my skin absorption ... the toxicological properties have not been thoroughly investigated". Do you think it may be a good idea to do such an investigation before pushing four monthly boosters?
84. ALC-0159 and ALC-0315 are two patented ingredients that are manufactured by a Chinese pharmaceutical and medical company. Medsafe has responded to an OIA email request on 11 November 2021 and confirmed in writing that "[w]e do not hold the MDSS [Material Safety Data Sheet] for these [ALC-0159 and ALC-0315]".
85. The substances are manufactured by a company in China called Sinopeg. Sinopeg's website does not have any MDSS information either. However, the information does say that these substances are for "research use only"^{124 125}.
86. Pfizer's Safety Data Sheet is set out at **Schedule 3**. Why is the Government forcing people to be injected with a substance when the Safety Data Sheet states the following:

¹²² Medsafe Product Detail, Medsafe (Revised 21 May 2019) New Zealand Medicines and Medical Devices Safety Authority

<https://medsafe.govt.nz/regulatory/ProductDetail.asp?ID=21938>

¹²³ <https://www.caymanchem.com/product/15100>

¹²⁴ https://www.sinopeg.com/2-polyethylene-glycol-2000-n-n-ditetradecylacetamide-alc-0159-cas-1849616-42-7_p477.html

¹²⁵ https://www.sinopeg.com/4-hydroxybutyl-azanediy-bis-hexane-6-1-diy-bis-2-hexyldecanoate-alc-0315-cas-2036272-55-4_p476.html

- (a) 2.2 Hazard Statements: “Not classified in accordance with international standards for workplace safety”.
- (b) 3.2 Mixtures: “no data available”.
- (c) 4.1 Most important symptoms and effects: “no data available”.
- (d) 5.3 Advice for Firefighters: “Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment”.
- (e) 11 Toxicological Information: “Toxicological properties have not been thoroughly investigated”.
- (f) 11.2.2 Environmental Overview: “Environmental properties have not been investigated. Release to the environment should be avoided”.
- (g) 13.1 Waste Treatment Methods: “Consider the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release”.

87. How can employers require employees to inject a substance into their bodies without holding the MDSS or information about the medium and long term data? Is this not a breach of the Health and Safety at Work Act 2015 under which directors and boards of trustees are personally liable. Would such directions by the Government and an employers be in breach of the International Covenant of Civil and Political Rights, which was adopted by the United Nations, and which New Zealand has ratified, states in Article 7:

*“No one shall be subjected to torture or to cruel, inhuman or degrading treatment or punishment. In particular, no one shall be subjected without his free consent to **medical or scientific experimentation.**”*

Ingredients for the Children

88. The TGA’s minutes dated 2 November 2021 state that section 12 the following¹²⁶:

<p>Decision to Use 5–11-Year-Olds</p> <ul style="list-style-type: none"> • Medsafe are expecting an application from Pfizer in mid-November. The US FDA are reviewing data for 5-11-year-olds at the end of October. • Little information has been provided on the paediatric formulation which Pfizer are currently trialling, however it may be of importance. • STA will convene a subgroup of CV TAG to discuss priority groups and equity considerations for recommendations and a Decision to Use. • Whether the 5–11-year-olds and 12–15-year-olds who are of lower weight may need a lower dose was discussed. Medsafe are reviewing whether any dose ranging studies were included in Pfizer’s initial application. 	
--	--

89. Why have the ingredients for the vaccine for children been changed from that of the adult dose? Page 14 of the Pfizer [paperwork](#) filed with the FDA states that tromethamine buffer instead of the phosphate buffered saline will be used for the vaccine administered to 5- to 11-year-olds. Why is a tromethamine buffer being used? Some say that this ingredient has been added due to storage issues of the vaccine. Does that mean that there have been issues with the storage that have emerged? Whistleblower Karen Kingston says tromethamine is used for two reasons, by surgeons to dissolve blood clots in the heart and in the lab to permeate the walls of cells to introduce new genetic material. Please could you provide me with the answer in a sworn affidavit? If you are not prepared to swear an affidavit, please explain why?

¹²⁶ <https://fyi.org.nz/request/16691/response/66492/attach/3/H202115494%20Response.pdf>

90. Please note that a brand of tromethamine was recalled in 2020¹²⁷ and then again in September 2021¹²⁸.

Definition

91. Merriam-Webster Dictionary changed the definition of vaccine early this year as mRNA products did not meet the definition of a vaccine.

Previous Definition	The definition changed as of 26 January 2021
<p>vaccine <small>noun</small></p> <p>vac·cine \ˈvɑk-ˈsēn ˈvɑk-ˈsēn \</p> <p>Definition of vaccine</p> <p>: a preparation of killed microorganisms, living attenuated organisms, or living fully virulent organisms that is administered to produce or artificially increase immunity to a particular disease</p>	<p>vaccine <small>noun</small></p> <p>Save Word</p> <p>vac·cine \ˈvɑk-ˈsēn ˈvɑk-ˈsēn \</p> <p>Definition of vaccine</p> <p>: a preparation that is administered (as by injection) to stimulate the body's <i>immune response</i> against a specific infectious disease:</p> <p>a : an antigenic preparation of a typically inactivated or attenuated (see <i>ATTENUATED sense 2</i>) pathogenic agent (such as a bacterium or virus) or one of its components or products (such as a protein or toxin)</p> <p>b : a preparation of genetic material (such as a strand of synthesized <i>messenger RNA</i>) that is used by the cells of the body to produce an antigenic substance (such as a fragment of virus <i>spike protein</i>)</p>

92. The definition was further changed again on 23 October 2021 and can be viewed at www.merriam-webster.com/dictionary/vaccine. How would you feel about mandating the vaccine if they were called something different—experimental gene therapy, for example?

Boosters

93. The vaccine was developed for the alpha variant and has not subsequently stopped the transmission of beta, delta, omicron and IHU variants to both the vaccinated and unvaccinated. The data shows that the vaccine wanes quickly for the variants.
94. The Lancet¹²⁹ reported that people that have had two doses of the vaccine have 5-6-fold lower amounts of neutralising antibodies, which suggested that further boosters will be necessary.
95. The Government promoted the “double jab” as effective even though its Clinical Evaluation from January 2021 stated that the need for boosters was expected. The Clinical Evaluation states that the Government did not know if the vaccine would provide protection beyond two months. Many people thought they were doing the “right thing” by taking the “two shots”, not realising they were signing up for four monthly boosters.

<p>IX. SELECTED INITIAL ADVISORY GROUP COMMENTS</p> <p>Responses to an early request (with very limited information) for advice from the Medsafe COVID-19 Vaccine Advisory Committee have included the following.</p> <p>Covid-19 vaccines can be expected not to provide long term protection – the need for booster doses can be expected. (For viral vectored vaccines, heterologous boosting may be needed).</p>

¹²⁷ <https://www.fresenius-kabi.com/us/documents/Fresenius-Kabi-USA-Ketorolac-Tromethamine-Injection-USP-Nonc.pdf>

¹²⁸ https://www.fresenius-kabi.com/us/documents/Fresenius-Kabi-USA-Ketorolac-Tromethamine-2nd-Noti-6SMxj0aVBvUT4G_PDajYuucW5ZYXVXDn-yYoUisCY.pdf

¹²⁹ *Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination*, Emma C Wall; Mary Wu; Ruth Harvey; Gavin Kelly; Scott Warchal; Chelsea Sawyer (Published June 03 2021) The Lancet Journals [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)01290-3/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01290-3/fulltext)

Uncertainties

Pivotal trial design and sample size means that study results are not expected to address all of the following uncertainties.

- It is not clear that the method of administration of the Comirnaty vaccine, as described in the datasheet's 'Special precautions for disposal and other handling' section, is similar to the method of administration in the pivotal study.
- The duration of vaccine protection has not been established beyond two months.
- At this stage, there is limited evidence of protection against severe disease.

Document 10

- There is no long-term safety follow-up information.
- Vaccine prevention of asymptomatic infection and disease transmission has not been established.

At this stage there is no information regarding vaccine effectiveness regarding:

- new variant virus lineages that may become important epidemiologically (including the possibility of change because of vaccine-selection pressures)
- immunocompromised people, and for pregnant women
- Pacific and Asian populations
- subjects with evidence of prior COVID-19 infection at baseline.

Summary

The benefit risk balance of Comirnaty (COVID-19 mRNA Vaccine) for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, in individuals 16 years of age and older, is not clear. At this stage, there is evidence only for short-term protection, and longer-term safety data are lacking. However, experience with the vaccine is accumulating rapidly.

Notwithstanding uncertainties, in the light of high clinical need and the expectation of further data (including regarding duration of protection) around April 2021, a provisional consent under section 23 of the Medicines Act 1981 may be appropriate.

96. An article in the New England Journal of Medicine¹³⁰ showed that immunity against the Delta variant of SARS-CoV-2 waned in all age groups a few months after receipt of the second dose of vaccine. Many more studies confirmed waning immunity¹³¹.

97. The Nature Public Health Emergency Collection¹³² raised the question of the vaccine and the various variants.

"More importantly, the variants have shown more than 10 amino acid mutations in the SARS-CoV-2 spike (S) protein, which has been an area of concern for the effectiveness of the BNT162b2 vaccine against these variants."

¹³⁰ *Waning Immunity after the BNT162b2 Vaccine in Israel*, Yair Goldberg, Ph.D.; Micha Mandel, Ph.D.; Yinon M. Bar-On, M.Sc.; Omri Bodenheimer, M.Sc.; Laurence Freedman, Ph.D.; Eric J. Haas, M.D.; Ron Milo, Ph.D.; Sharon Alroy-Preis, M.D.; Nachman Ash, M.D.; and Amit Huppert, Ph.D. (October 27 2021) The New England Journal of Medicine <https://www.nejm.org/doi/10.1056/NEJMoa2114228>

¹³¹ Canaday, D. H. (2021). Significant reduction in humoral immunity among healthcare workers and nursing home residents 6 months after COVID-19 BNT162b2 mRNA vaccination. MedRxiv. Israel, A. (2021). Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. MedRxiv. <https://www.medrxiv.org/content/10.1101/2021.08.19.21262111v1>
Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Katz, R., Herzl, E., Kuint, J., Chodick, G., Gazit, S., 9 Patalon, T., & Kishony, R. (2021). Viral loads of delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nature Medicine. Published. <https://doi.org/10.1038/s41591-021-01575-4>

Nordstrom, P. (2021). Effectiveness of covid-19 vaccination against risk of symptomatic infection, hospitalization, and death up to 9 months: A Swedish Total-Population cohort study. SSRN. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3949410
Saade, C., Gonzalez, C., Bal, A., Valette, M., Saker, K., Lina, B., Josset, L., Trabaud, M. A., Thiery, G., Botelho-Nevers, E., & On Behalf Of COVID-SER Study Group. (2021). Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.v1 and 20H/501Y.v2 isolates of SARS-CoV-2. Emerging Microbes & Infections, 10(1), 1499–1502. <https://doi.org/10.1080/22221751.2021.1945423>

Suthar, M. S. (2021). Durability of immune responses to the BNT162b2 mRNA vaccine. BioRxiv. <https://www.biorxiv.org/content/10.1101/2021.09.30.462488v1>

¹³² *Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization*, Nimrat Khehra; Inderbir Padda; Urooj Jaferi; Harshan Atwal; Shreya Narain; Mayur S. Parmar (June 7 2021) National Library of Medicine, National Center for Biotechnology Information <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184133/>

98. Dr Robert Malone reports on a recent study in medRxiv, which highlighted that vaccine effectiveness against Omicron was 37% (95%CI, 19-50%) \geq seven days after receiving an mRNA vaccine for the third dose¹³³.
99. As I am sure you are aware, Israel is now up to their 4th vaccination and Turkey up to their 5th vaccination but still reaching record high infections. How many boosters will the Government require for the vaccinated to maintain their freedoms under the vaccine passport? How will the Government monitor cumulative toxicity with more and more boosters required?
100. Why is natural immunity being ignored? It is highly likely that many New Zealanders travelling in late 2019 and early 2020 contracted SARS-CoV-2 but did not develop COVID-19. Emerging data show that natural immunity confers longer-lasting and stronger protection against infection, symptomatic disease and hospitalisation, compared to the two-dose vaccine-induced immunity.
101. The U.K. Health Secretary Sajid Javid recently visited King College Hospital in London and asked the staff about the mandates. Steve James, a consultant anaesthetist who has been treating coronavirus patients since the start of the pandemic replied:
- "I'm not happy about that," he said. "I had COVID at some point, I've got antibodies, and I've been working on COVID ICU since the beginning .."I have not had a vaccination, I do not want to have a vaccination. The vaccines are reducing transmission only for about eight weeks for Delta, with Omicron it's probably less ...And for that, I would be dismissed if I don't have a vaccine? The science isn't strong enough¹³⁴."*

Vaccine Selection Pressure

102. The Government dismisses concerns about vaccine selection pressure to increase the dominance of immune-escape variants and safety concerns from highly credible and independent international doctors, scientists and vaccine developers.
103. The 'Covid-19 Vaccine Surveillance Report – 2022 – Week 1'¹³⁵ was published by the U.K. Health Security Agency (formerly Public Health England) on 6 January 2022, and it shows that the vast majority of Covid-19 cases between 6th Dec 21 and 2nd Jan 22 were among the fully vaccinated population (refer page 38).

Table 10. COVID-19 cases by vaccination status between week 49 and week 52 2021
Please note that corresponding rates by vaccination status can be found in [Table 13](#).

Cases reported by specimen date between week 49 and week 52 2021	Total	Unlinked*	Not vaccinated	Received one dose (1 to 20 days before specimen date)	Received one dose, \geq 21 days before specimen date	Second dose \geq 14 days before specimen date ¹
	[These data should be interpreted with caution. See information below in footnote about the correct interpretation of these figures]					
Under 18	429,155	32,145	308,183	7,104	72,620	9,103
18 to 29	628,127	52,666	102,948	5,532	36,594	430,387
30 to 39	529,948	38,026	75,057	2,973	20,676	393,216
40 to 49	408,892	24,189	35,758	1,206	9,075	338,664
50 to 59	308,585	17,250	17,385	568	4,430	268,952
60 to 69	148,836	8,902	6,419	313	1,659	131,543
70 to 79	70,723	4,297	2,098	116	515	63,697
80 or over	32,314	2,589	1,214	50	395	28,066

¹³³ <https://doi.org/10.1101/2021.12.30.21268565>

¹³⁴ <https://news.sky.com/story/covid-19-sajid-javid-directly-challenged-on-mandatory-coronavirus-jabs-by-unvaccinated-nhs-doctor-12511224>

¹³⁵ [COVID-19 vaccine surveillance report - week 1 \(publishing.service.gov.uk\)](https://www.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/105444/covid-19-vaccine-surveillance-report-week-1-2022.pdf)

104. On 21 January 2021, Stuff reported that more than a third of Covid-19 cases caught at New Zealand's border over the space of one week were unvaccinated or ineligible due to their age, a snapshot of data shows¹³⁶. Meaning over 60% of the cases were vaccinated.
105. A landmark 2004 paper outlining a “phylodynamic” framework to describe the evolution of RNA viruses under epidemic conditions theorises that viral adaptation occurs at the highest rate under intense immune-selection pressure and high infectious pressure¹³⁷.
106. Dr Geert Vanden Bossche is an independent vaccine expert and a former academic at universities in Belgium and Germany, who has since served in various R&D and senior program roles at GSK Biologicals, Novartis Vaccines, Solvay Biologicals, Bill & Melinda Gates Foundation and GAVI, has been an outspoken critic of the mass vaccination campaign.
107. Dr Vanden Bossche is warning humanity of the devastating impact of mass vaccination with non-sterilising vaccines on a background of high infectious pressure. On 6 March 2021, Dr Vanden Bossche published an open letter on his website to appeal to the WHO¹³⁸ to immediately open the channels for scientific debate and declare a public health emergency of international concern, given the paradigm of mass vaccination ever pressurising the spike protein towards full immune escape. Dr Vanden Bossche has not wavered from his thesis on the folly of the current strategy. Regrettably, his thesis is increasingly being vindicated through the research of molecular and genomic epidemiologists and the number of “breakthrough” cases.
108. Data from California already suggests that fully vaccinated individuals are significantly more likely than unvaccinated (77.6% vs. 47.7%) to be infected with antibody-resistant SARS-CoV-2 variants¹³⁹.
109. Dr Chris Martenson interviewed ¹⁴⁰ Dr Geert Vanden Bossche in June 2021. In September 2021, Dr Phillip McMillan (U.K.) hosted a meeting between two of the world's prominent voices Geert Vanden Bossche, expert vaccine developer (Belgium) and Robert Malone MD, the inventor of mRNA (USA). Please watch these interviews.
110. Vanden Bossche takes the current Israeli data and shows how the widespread vaccination rate is creating pressure on the virus to mutate into variants with higher levels of contagion. The unvaccinated group has been keeping the pressure down by defeating the virus and carrying natural immunity. However, as the unvaccinated population is increasingly made smaller, the pressure on the virus to mutate increases. Subsequently, these mutations stay at higher or more effective levels of infection. The meeting can be watched at: [Meeting of the COVID-19 Giants with Geert Vanden Bossche and Robert Malone MD - YouTube](#)
111. Virologist Prof Luc Montagnier, the co-discoverer of HIV and 2008 Nobel Prize Winner in Medicine, stated in a video interview translated and published by the RAIR Foundation U.S.:

¹³⁶ [Covid-19: One third of border cases over one week were unvaccinated | Stuff.co.nz](#)

¹³⁷ <https://collaborate.princeton.edu/en/publications/unifying-the-epidemiological-and-evolutionary-dynamics-of-pathoge>

¹³⁸ [Open Letter to the WHO: Immediately Halt All Covid-19 Mass Vaccinations-Geert Vanden Bossche, DMV, PhD – Freedom Of Speech \(fos-sa.org\)](#)

¹³⁹ Area FB, Servellita CV, Morris M-K, et al. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. medRxiv: the preprint server for health sciences. Published online August 25, 2021. doi:10.1101/2021.08.19.21262139

¹⁴⁰ <https://www.youtube.com/watch?v=cjMZvpmuaKY>

"It's an enormous mistake, isn't it? A scientific error as well as a medical error. It is an unacceptable mistake... The history books will show that because it is the vaccination that is creating the variants...It is clear that the new variants are created by antibody-mediated selection due to the vaccination... "Many epidemiologists know it and are 'silent' about the problem known as 'antibody-dependent enhancement."¹⁴¹"

Vaccine-associated enhanced disease

112. Vaccine-associated enhanced disease (VAED, also known as AED), including vaccine-associated enhanced respiratory disease (VAERD), is a known risk. With ADE, the vaccines suppress the innate immune response so that the immune system fails to neutralise the viruses as they enter the body instead of allowing them to replicate in the body. The infection is amplified rather than killed off. Moreover, the vaccine primes the immune system for a potentially deadly overreaction known as a "hyperinflammatory response" to subsequent infections. This paradoxical reaction has repeatedly been seen in other vaccines and animal development trials, especially coronavirus vaccine trials¹⁴² (as noted above).
113. According to a recent peer-reviewed article,¹⁴³ a study was undertaken to determine if sufficient literature exists to require clinicians to disclose the specific risk that COVID-19 vaccines could worsen disease upon exposure to challenge or circulating virus. The study found:

"COVID-19 vaccines designed to elicit neutralising antibodies may sensitise vaccine recipients to more severe disease than if they were not vaccinated. Vaccines for SARS, MERS and RSV have never been approved, and the data generated in the development and testing of these vaccines suggest a serious mechanistic concern: that vaccines designed empirically using the traditional approach (consisting of the unmodified or minimally modified coronavirus viral spike to elicit neutralising antibodies), be they composed of protein, viral vector, DNA or RNA and irrespective of delivery method, may worsen COVID-19 disease via antibody-dependent enhancement (ADE). This risk is sufficiently obscured in clinical trial protocols and consent forms for ongoing COVID-19 vaccine trials that adequate patient comprehension of this risk is unlikely to occur, obviating truly informed consent by subjects in these trials.

114. In 2020, the New Zealand Ministry of Health Committee noted that:

"...low prevalence of COVID infection in New Zealand means that vaccine-associated enhanced disease (VAED) may be less of a risk compared with other countries"¹⁴⁴"

¹⁴¹ Mass vaccination during pandemic a historic blunder: Nobel laureate Luc Montagnier. Zee News. Published May 25, 2021. Accessed September 5, 2021. <https://www.msn.com/en-in/news/world/mass-vaccination-during-pandemic-a-historic-blunder-nobel-laureate-luc-montagnier/ar-AAKmnJ>

¹⁴² COVID-19 Vaccines: Should We Fear ADE?, Scott B Halstead; Leah Katzelnick (12 August 2020) The Journal of Infectious Diseases <https://academic.oup.com/jid/article/222/12/1946/5891764>

¹⁴³ Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease, Timothy Cardozo; and Ronald Veazey, Department of Biochemistry and Molecular Pharmacology (n.d) https://www.researchgate.net/publication/346464618_Informed_consent_disclosure_to_vaccine_trial_subjects_of_risk_of_COVID-19_vaccines_worsening_clinical_disease/fulltext/5fc3873e458515b79784d097/Informed-consent-disclosure-to-vaccine-trial-subjects-of-risk-of-COVID-19-vaccines-worsening-clinical-disease.pdf?origin=publication_detail

¹⁴⁴ Minutes Of The Out Of Session Medicines Adverse Reactions Committee Meeting, Medsafe (20 January 2020) New Zealand Medicines and Medical devices Safety Authority <https://www.medsafe.govt.nz/profs/adverse/minutesOoS-20-jan-2021.htm?fbclid=IwAR1iiZ86hJ1doeAZlkfdsirpevhDwlAK0yt0r91Yf2igrXiwnax7qh4FBsk>

115. How does this statement hold up now that we are being told that we will have high numbers of cases in New Zealand? BUT ADE does not solely apply to Covid-19 infections. The phenomenon equally applies to any virus that enters the body. It is more than fortuitous that the “worst cold ever” has been reported as sweeping through the U.K.

Alternative Treatments

116. In June 2020, John Ioannidis, a professor of epidemiology and population health at Stanford University, published a paper ¹⁴⁵ stating that the “*seroprevalence studies*”, which measure infection rates using the presence of antibodies in blood samples, “*typically show a much lower fatality than initially speculated in the earlier days of the pandemic.*” The professor concluded that the infection fatality rate (as opposed to the case fatality rate, which is different) for COVID-19 is now estimated to be 0.15% (similar to that of the flu). For people under 70, the IFR is 0.05% and is likely lower in people without serious comorbidities.
117. For most people, the risk of developing COVID-19 and being hospitalised or dying is low. So why is the Government determined to vaccinate and boost a predominantly healthy population rather than use well established early treatment protocols? Why is the Government and the Medical Board sanctioning doctors that use or prescribe these early treatment protocols? Does the Big Pharma contract prevent the promotion of these early treatment protocols in favour of its sales targets?
118. There are numerous alternative safe and effective treatments for COVID-19. These alternative treatments are supported by hundreds of studies, including randomised controlled studies. Treatments such as Ivermectin, Budesonide, Dexamethasone, convalescent plasma and monoclonal antibodies, Vitamin D, Zinc, Azithromycin, Hydroxychloroquine, Colchicine and Remdesivir are being used effectively¹⁴⁶.
119. The Government’s Clinical Evaluation¹⁴⁷ (refer V.1) states:
Treatment of acute Covid-19 disease has improved, and several medicines are recognised to have a role in treatment.
120. Dr Peter McCullough stated in an interview with Dr Reiner Fuellmich that 85 percent of the more than 600,000 U.S. deaths could have been prevented with a multi-drug treatment given in the early to mid-point of the disease ¹⁴⁸. Dr Peter McCullough’s ¹⁴⁹ testimony (19 minutes) to the senate looked at the veracity of early treatment protocols can be viewed by copying and pasting the link in the footnotes below. On 19 November 2020, Dr Peter McCullough testified to the senate (2:20:27):

“I’m in close communication for this worldwide disaster with many countries, and I can tell you I did a program with Eamonn Mathieson at the Covid Medical Network in Australia to show you how off-kilter the world is. [Webinars: <https://www.covidmedicalnetwork.com/webinars/prof-peter-mccullough.aspx> EARLY COVID TREATMENTS: Guest Speaker - Prof Peter McCullough MD, Presented by Dr Eamonn Mathieson, Anesthetist, Covid Medical Network, Convenor. 14 Nov 2020 (32:46)] In Queensland, Australia a doctor will be put in jail for prescribing hydroxychloroquine. If you go over to India they’re going to give it to you right away. In Greece they’re going to give it to you right—it’s in their guidelines.”

¹⁴⁵ <https://www.who.int/bulletin/volumes/99/1/20-265892.pdf>

¹⁴⁶ Numerous studies can be reviewed here: <https://c19early.com>

¹⁴⁷ Clinical Evaluation ([response documents at www.covid19openletter.co.nz](https://www.covid19openletter.co.nz))

¹⁴⁸ Dr. Peter McCullough on with Reiner Fuellmich June 11, 2021 ([bitchute.com](https://www.bitchute.com))

¹⁴⁹ <https://www.youtube.com/watch?v=QAHi3IX3oGM>

121. The Association of American Physicians & Surgeons have published a Physician List & Guide to Home-Based Covid Treatment¹⁵⁰.
122. On 17 June 2021, the American Journal of Therapeutics¹⁵¹ published a peer-reviewed meta-analysis of 15 trials that found that ivermectin reduced the risk of death compared with no ivermectin. The study found that ivermectin probably reduced deaths by 62% and possible transmission by 86%.
123. Dr Lawrie (one of the authors of the meta-analysis) has also sent numerous letters with evidence to Matt Hancock and the U.K. Government regarding ivermectin and COVID 19¹⁵². She and others have started a non-for-profit organisation with the 1st International Ivermectin for Covid Conference.
124. In addition, a recent peer-reviewed study by Dr Pierre Kory and colleagues on ivermectin has been published in the American Journal of Therapeutics¹⁵³. The study summarises the evidence base for the use of ivermectin and concludes that:

"Meta-analyses based on 18 randomised controlled treatment trials of ivermectin in COVID have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID has been identified."
125. Uttar Pradesh, India, announced that the state is COVID-19 free after using early treatment protocols.¹⁵⁴ This state will have an estimated population of 241 million people in 2021 and has the highest population in India. This population is almost two-thirds of the United States population in 2021, yet it is now a COVID-19 free nation.
126. The Gauteng High Court¹⁵⁵, Pretoria, has recently issued an order allowing for medicine that contained ivermectin as an active ingredient to be used to treat Covid-19 if prescribed by a doctor.
127. The Indian Bar Association is officially suing the WHO's chief scientist for spreading misinformation about ivermectin¹⁵⁶.
128. Hydroxychloroquine became a political controversy last year when former President Donald Trump touted it to cure COVID. However, experts are reporting that politics have cost and is costing lives. A study published by Dr Peter McCullough in January 2021 in the American Journal of Medicine found that early treatment of coronavirus patients with hydroxychloroquine lowered the mortality rate for the disease. Refer above for the link to his paper.

¹⁵⁰ Physician List & Guide to Home-Based COVID Treatment - AAPS | Association of American Physicians and Surgeons (aapsonline.org)

¹⁵¹ https://journals.lww.com/americantherapeutics/Abstract/9000/ivermectin_for_Prevention_and_Treatment_of.98040.aspx

¹⁵² http://medisolve.org/yellowcard_urgentprelimreport.pdf

¹⁵³ https://journals.lww.com/americantherapeutics/Fulltext/2021/00000/Review_of_the_Emerging_Evidence_Demonstrating_the.4.aspx

¹⁵⁴ [HUGE: Uttar Pradesh, India Announces State Is COVID-19 Free Proving the Effectiveness of "Deworming Drug" IVERMECTIN \(thegatewaypundit.com\)](https://www.thegatewaypundit.com/2021/06/14/huge-uttar-pradesh-india-announces-state-is-covid-19-free-proving-the-effectiveness-of-deworming-drug-ivermectin/)

¹⁵⁵ [Doctors can now prescribe ivermectin as treatment for Covid-19 \(iol.co.za\)](https://www.iol.co.za/news/south-africa/14-june-2021/doctors-can-now-prescribe-ivermectin-as-treatment-for-covid-19-20210614)

¹⁵⁶ [Legal-Notice-to-Dr.-Soumya-Swaminathan_Chief-Scientist-WHO-1.pdf](#) and [Sync.com - Legal-Notice-to-Dr.-Soumya-Swaminathan_Chief-Scientist-WHO-1.pdf](#) and [WHO Celebrates As Indian Health Regulator Removes Ivermectin From its COVID Protocol | ZeroHedge and VERMECTIN - The COVID Blog](#)

129. Dr Emanuel Garcia¹⁵⁷ has stated:

"Where is the emphasis on treating this? On finding a cure, on finding a mitigating agent [for covid]... There are some very effective treatments & preventative measures."

"I was astonished to find out what the Lancet did with Hydroxychloroquine. They published an article slamming it, talking about all the dangers & then they retracted it because it was complete propaganda. It could have saved a lot of lives."

130. Vitamin D is known to help people with COVID-19. The Journal of Clinical Endocrinology & Metabolism¹⁵⁸ reported on 17 June 2021 that vitamin D deficiency is associated with higher hospitalisation risk from COVID.

[The Narrative, Goal Posts and Rules](#)

131. The Government continues to change the narrative and move the goal posts.

132. In 2020 the Government narrative was structured on the following points:

(a) The death rate was going to be devastating in New Zealand. On 27 February 2020, Mr Bloomfield received a report from Mr Baker and his colleagues from the University of Otago Wellington COVID-19 Response Group (UOWCRG) in which they "estimate[d] likely deaths to be between 12,600 and 33,600, which Bloomfield "thought was likely an underestimation", despite 33,600 or 0.67% of the N.Z. population equating to over 52 million deaths worldwide¹⁵⁹";

(b) A national emergency was declared, and the "team of 5 million" needed to "go hard, go early" and "two weeks to flatten the curve";

(c) "There is no need to wear a mask" and "masks are useless" but "wash your hands";

(d) "be kind" and "we are all in this together";

(e) "vaccines will not be compulsory".

133. In 2021 the Government flipped the narrative, and face coverings (including cloth coverings) are mandated, vaccines are mandated, vaccine passports are mandated, and Ms Ardern gleefully admits on camera that she is creating a segregated society.

134. Almost two years on from the modelling, which terrified a nation, there have been 52 deaths in New Zealand and approximately 5,500,000 deaths around the world. The numbers of deaths are questionable (as set out later in this letter), but the economic and social destruction is undeniable.

135. Should vaccine be mandatory when you still need a booster to maintain your fully vaccinated status and freedoms? When you still need to be tested despite being fully vaccinated. When do

¹⁵⁷ [Dr Emanuel Garcia On The Abrogation Of Human Liberties & A Delusional Belief In Vaccines As Saviour \(odysee.com\)](#)

¹⁵⁸ [Vitamin D deficiency is associated with higher hospitalisation risk from COVID-19: a retrospective case-control study | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic \(oup.com\)](#)

¹⁵⁹ Lucy Barnard, Nick Wilson, Amanda Kvalsvig, Michael Baker, "Modelled Estimates for the Spread and Health Impact of Covid-19 in New Zealand: Revised Preliminary Report for the NZ Ministry of Health", University of Otago Wellington (27 February 2020), 1, 5, 11, 12: <https://www.health.govt.nz/publication/covid-19-modelling-reports>; Bloomfield, Affidavit (13 Jul 20), 101.4.

you still need to wear a mask after being fully vaccinated? We you still transmit, get infected and may end up in hospital despite being fully vaccinated?

136. Why are there rules for some but not for others?
137. As you are aware, the vaccinated British DJ brought Omicron into New Zealand as he did not follow the protocols. It is beyond belief that the vaccinated British DJ did not face charges. Yet New Zealanders that attended freedom protests (especially during level 2) causing no harm to our communities are arrested and face jail time.
138. A quick scan of the Gazette Notices for November and December 2021 shows the following exemptions granted:
- (a) Class Exemption for New Zealand Based Aircrew on Jetconnect Limited Flights Traveling From Auckland to Los Angeles From Requirements of the COVID-19 Public Health Response (Air Border) Order (No 2) 2020¹⁶⁰;
 - (b) Exemption of Bangladesh Men's Cricket Team From Requirements of the COVID-19 Public Health Response (Isolation and Quarantine) Order 2020¹⁶¹;
 - (c) Exemption of New Zealand Black Caps Cricket Team From Requirements of the COVID-19 Public Health Response (Isolation and Quarantine) Order 2020¹⁶²;
 - (d) Exemption for the crew on board the United States Coast Guard Cutter (USCGC) Polar Star¹⁶³.
139. Interestingly, I note that the Police have recently been exempted from Health and Safety in the Workplace for Gases under Pressure¹⁶⁴. Please could you explain what the intention of this exemption is? Perhaps tear gas for protests as Ms Ardern's pushes her segregated society?

[The World Economic Forum and Agenda 2030](#)

140. The World Economic Forum ("WEF") has been involved in the strategic management of the coronavirus pandemic, with a major emphasis on using the pandemic as a catalyst for digital transformation and the global introduction of digital identity systems.
141. Klaus Schwab, the founder and executive chairman of the WEF, is the champion of the Fourth Industrial Revolution (also referred to as the Great Reset and Agenda 2030). Schwab states:
- "The Fourth Industrial Revolution, as I wrote in the book four years ago when I coined the expression, many of those technologies just look at facial recognition, just look at the technologies which you need for tracking people. What we are seeing now with some of the companies engaged into research for vaccines using completely new methods based on synthetic biology. A tremendous challenge we have in creating this Great Reset".*
142. Ms Ardern is committed to creating the Great Reset. She told the audience at an event arranged by Goalkeepers in 2019, an organisation set up by the Gates Foundation, that:

¹⁶⁰ <https://gazette.govt.nz/notice/id/2021-go5362>

¹⁶¹ <https://gazette.govt.nz/notice/id/2021-go5164>

¹⁶² <https://gazette.govt.nz/notice/id/2021-go5165>

¹⁶³ <https://gazette.govt.nz/notice/id/2021-go5480>

¹⁶⁴ <https://gazette.govt.nz/notice/id/2021-au5511>

“...my Government is doing something not many other countries have tried. We have incorporated the principles of the 2030 Agenda into our domestic policy-making in a way that we hope will drive system-level actions... I believe that the change in approach that we have adopted in New Zealand is needed at a global scale...”¹⁶⁵”

143. Ms Ardern, the former President of the International Union of Socialist Youth and a frequent user of the word “comrade”¹⁶⁶, has been connected with Klaus Schwab and the WEF for many years. It would seem that Ms Ardern also has some other interesting connections, as discussed in this OIA request [Final-Open-Letter-to-Jacinda-Ardern-PDF-1.pdf\(Shared\)- Adobe Document Cloud](#). Please could you provide me with the response to this OIA request?
144. In 1992, Klaus Schwab established a parallel institution to the WEF, the Global Leaders for Tomorrow school, which was re-established as the Young Global Leaders in 2004. Members of the school’s very first class in 1992 already included many who went on to become important political figures, such as Angela Merkel, Nicolas Sarkozy, and Tony Blair (who Ms Ardern worked for in the U.K.¹⁶⁷). Ms Ardern is on the alumni list, and in 2014 she was picked as one of 200 Young Global Leaders by the WEF.
145. Not only political figures went through the programme but many that have risen to influence, such as Mark Zuckerberg¹⁶⁸, Jeffrey Zients (US White House Coronavirus Response Coordinator since 2021, selected in 2003), Jeremy Howard (founder of influential lobby group “masks for all”), Leana Wen (zero-covid CNN medical analyst), Eric Feigl-Ding (zero-covid Twitter personality), Gavin Newsom (Governor of California, selected in 2005), Devi Sridhar (British zero-covid professor) and numerous executives at Blackrock and Goldman Sachs, two of the world’s largest investment firms.
146. Ms Ardern is also a member of the WEF¹⁶⁹ and has attended meetings at Davos. On 23 November 2020, the Office for the Prime Minister received a copy of the book “Covid-19 – The Great Reset” from Klaus Schwab himself (he is also one of the authors), and on 3 February 2021, the Office of the Prime Minister received a copy of the book “Stakeholder Capitalism” also from Klaus Schwab¹⁷⁰.
147. Interestingly, in 2016 the WEF made the following predictions for 2030¹⁷¹ :
- (a) All products will become services. “You will own nothing. And you’ll be happy”. This includes everything from your home down to what you wear via digital passports¹⁷². Whatever you want, you’ll rent. And it’ll be delivered by drone.
 - (b) The U.S. won’t be the world’s leading superpower. A handful of countries will dominate.
 - (c) You won’t die waiting for an organ donor. Organs will be 3-D printed. Klaus Schwab made the following statements in “Shaping the Fourth Industrial Revolution.

Section 1 The Fourth Industrial Revolution – Chapter 2

¹⁶⁵ <https://youtu.be/1XsUV7pwSRg>

¹⁶⁶ <https://youtu.be/ZSMYa-JOwKg>

¹⁶⁷ <https://www.youtube.com/watch?v=3kcWHiTehF8>

¹⁶⁸ https://www.younggloballeaders.org/community?utf8=%E2%9C%93&q=zuckerberg&x=0&y=0&status=&class_year=§or=®ion=

¹⁶⁹ <https://www.weforum.org/people/jacinda-ardern>

¹⁷⁰ <https://fyi.org.nz/request/16378/response/62394/attach/3/03.09.2021%20Letter%20to%20Benseman%20PMO%202021%20180.pdf>

¹⁷¹ <https://www.bitchute.com/video/kTNQ31tG0VAp/>

¹⁷² <https://www.weforum.org/agenda/2021/05/tracking-fashion-clothes-sustainable/>

“Fourth Industrial Revolution technologies will not stop at becoming part of the physical world around us—they will become part of us. Indeed, some of us already feel that our smartphones have become an extension of ourselves. Today’s external devices—from wearable computers to virtual reality headsets—will almost certainly become implantable in our bodies and brains. Exoskeletons and prosthetics will increase our physical power, while advances in neurotechnology enhance our cognitive abilities. We will become better able to manipulate our own genes, and those of our children. These developments raise profound questions: Where do we draw “the line between human and machine? What does it mean to be human?”

Section 2.3 Altering the Human Being – Chapter 11

The future will challenge our understanding of what it means to be human, from both a biological and a social standpoint. Emerging biotechnology agendas promise to improve and augment human lifespans and to enhance physical and mental health. The opportunity for the integration of digital technologies with biological tissues is also growing, and what that portends for the next decades is inspiring a range of emotions, from hope to wonder to fear.”

These technologies will operate within our own biology and change how we interface with the world. They are capable of crossing the boundaries of body and mind, enhancing our physical abilities, and even having a lasting impact on life itself. They are more than mere tools and demand special “consideration for their ability to augment or intrude upon human beings, human behaviors and human rights.”

- (d) You will eat much less meat (but more of Bill Gate’s bugs¹⁷³).
 - (e) A billion people will be displaced by climate change.
 - (f) Polluters will have to pay to emit carbon dioxide.
 - (g) You could be preparing to go to Mars.
 - (h) Western values will have been tested to the breaking point.
148. Last year, the WEF¹⁷⁴ released its idea of a 15-minute city after the world experienced lockdowns. Digital vaccine passports have been introduced, and many have been programmed to accept track and trace. Zuckerberg has launched Meta to bring “3D spaces in the metaverse will let you socialise, learn, collaborate and play in ways that go beyond what we can imagine¹⁷⁵”.
149. Given Klaus Schwab’s comments in regards to the need to track people for the Great Reset and Ms Ardern’s commitment to Agenda 2030, it is easy to see how an extension of the vaccine passport in a few simple steps will see a totalitarian New Zealand. I note that the Government is also trying to bring in a digital currency and the Digital Identity Services Trust Framework Bill.
150. Microchips implanted in a human arm to scan for COVID-19 and provide your vaccine status are just a conspiracy theory, right(just as vaccine passports were a conspiracy theory not so long

¹⁷³ <https://www.weforum.org/agenda/2019/09/sustainable-food-alternative-proteins/>

¹⁷⁴ <https://www.weforum.org/agenda/2021/11/15minute-city-falls-short/>

¹⁷⁵ <https://about.facebook.com/meta/>

ago)? Well, not according to the Pentagon¹⁷⁶ and microchip technology start-up Epicentre¹⁷⁷. Klaus Schwab made the following statement in “Shaping the Fourth Industrial Revolution.

Chapter 5 – New Computing Technologies

“External wearable devices, such as smart watches, intelligent earbuds and augmented reality glasses, are giving way to active implantable microchips that break the skin barrier of our bodies, creating intriguing possibilities that range from integrated treatment systems to opportunities for human enhancement...Biological computing could soon allow us to replace specialised microchips with custom-designed organisms, a key aspect of a new cultural form of expression and consumption called “biohacking.”

151. Klaus Schwab has also stated:

“People assume that we are just going back to the good old world which we had and everything will be normal again. This is, let’s say, fiction. It will not happen. The cut which we have now is much too strong in order not to leave traces. We know that the world will look differently. There will be a lot of anger. We have to prepare for a more angry world. Social revolution. Anger on the streets. We are at a rapture point terminating of human kind”

152. As noted above, Ms Ardern wishes to create a segregated society where the unvaccinated will not enjoy freedoms and face financial hardship. Strangely, Ms Ardern’s fellow WEF members (she is a member) are also set on dividing society and creating an angry world. Justin Trudeau is also set to divide society by stating that unvaccinated persons who were hesitant about an experimental medical treatment were likely to be misogynists and racists, and Emmanuel Macron said unvaccinated people were irresponsible and as such were not citizens, and he wanted to make those citizens lives as unbearable as possible.

153. The WEF’s Great Reset website can be viewed at <https://www.weforum.org/great-reset>, which sets out how Covid-19 has presented an:

“unique window of opportunity to shape the recovery [from the Pandemic], this initiative will offer insights to help inform all those determining the future state of global relations, the direction of national economies, the priorities of societies, the nature of business models and the management of a global commons.”

154. Steve Levitsky once wrote:

“One of the great ironies of how democracies die is that the very defense of democracy is often used as a pretext for its subversion,” he wrote. “Would-be autocrats often use economic crises, natural disasters, and especially security threats—wars, armed insurgencies, or terrorist attacks—to justify antidemocratic measures.”

155. Why are we being forced to be repeatedly “jabbed” with an experimental vaccine in exchange for the reward of a vaccine passport? This is a digital I.D. Will vaccine passports be extended to control every aspect of our lives? Will cash be cancelled? The ability to enter a supermarket and buy food? To get on a bus or train? Moving further than a short distance from our homes? No passport, no access to our own lives?

¹⁷⁶ <https://www.thesun.co.uk/news/14623566/pentagon-microchip-skin-detects-covid-before-symptoms/>

¹⁷⁷ [Tech firm develops microchip that can be implanted in your arm to track Covid vaccine status with just a cell phone scan \(the-sun.com\)](https://www.thesun.co.uk/news/14623566/tech-firm-develops-microchip-that-can-be-implanted-in-your-arm-to-track-covid-vaccine-status-with-just-a-cell-phone-scan-the-sun-com/)

156. We seem to be standing on the knives edge of democracy. *Blackrock's CEO, Larry Fink, stated that "Markets like Totalitarian Governments"*¹⁷⁸. Will you support Big Pharma and the WEF? Both of which are de facto controlled by Vanguard (the largest shareholder in Blackrock) and Blackrock (the world's largest asset manager)¹⁷⁹¹⁸⁰, or will you serve "us the people"?

Yours sincerely

Hersten Musfitt

¹⁷⁸ <https://youtu.be/MFVecfbffUE>

¹⁷⁹ <https://www.weforum.org/organizations/blackrock-inc>

¹⁸⁰ <https://fintel.io/so/us/pfe/blackrock>

Schedule 1

MOH Letter re Transmission



133 Molesworth Street
PO Box 5013
Wellington 6140
New Zealand
T+64 4 496 2000

10 September 2021

Josephine Marsden

By email: josephinemarsden10@gmail.com
Ref: H202110912

Tēnā koe Josephine

Response to your request for official information

Thank you for your request under the Official Information Act 1982 (the Act) to the Ministry of Health (the Ministry) on 22 August 2021 for:

"copies of all Pfizer Vaccine studies and Pfizer Vaccine trials that relate to the demonstration of the efficacy of the vaccine in reducing the transmission of Covid-19 in the community."

Reducing transmission was not an outcome measured in trials of the Pfizer vaccine. Therefore, your request is refused under section 18(g)(i) as the information requested is not held by the Ministry of Health and there are no grounds for believing it is held by another agency subject to the Act.

Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any decisions made under this request. The Ombudsman may be contacted by email at: info@ombudsman.parliament.nz or by calling 0800 802 602.

Please note that this response, with your personal details removed, may be published on the Ministry website at: www.health.govt.nz/about-ministry/information-releases/responses-official-information-act-requests.

Nāku noa, nā

A handwritten signature in black ink, appearing to be 'Nick Allan'.

Nick Allan
Manager OIA Services
Office of the Director-General

Schedule 2

Recent Studies on Transmission and Viral Load

1. A summary of the recent studies on transmission is set out below.
2. **The Lancet Regional Health Europe**ⁱ published on 19 November 2021 the following statements:
"Recent data, however, indicate that the epidemiological relevance of COVID-19 vaccinated individuals is increasing. In the U.K. it was described that secondary attack rates among household contacts exposed to fully vaccinated index cases was similar to household contacts exposed to unvaccinated index cases (25% for vaccinated vs 23% for unvaccinated)."
3. A recent preprint studyⁱⁱ reviewed the viral load of SARS-CoV-2 in swab specimens from 36 counties in Wisconsin. There was effectively no difference between the symptomatic vaccinated and unvaccinated in terms of who was carrying and spreading the virus. The asymptomatic vaccinated individuals had a higher percentage with a high viral load.
4. A study published in **The Lancet**ⁱⁱⁱ found that:
"fully vaccinated individuals with breakthrough infections have peak viral load similar to unvaccinated cases and can efficiently transmit infection in household settings, including to fully vaccinated contacts".
5. The **CDC**^{iv} study of an outbreak in Barnstable County, Massachusetts, found that 74% of those infected were fully vaccinated for Covid-19 and that the vaccinated had on average more virus in their nose than the unvaccinated who were infected.
6. A **Tel-Aviv University**^v study of a SARS-CoV-2 outbreak among 42 patients in a hospital setting PPE, 39 were fully vaccinated. The authors wrote that this *"outbreak exemplifies the high transmissibility of the SARS-CoV-2 Delta variant among twice vaccinated and masked individuals."*
7. Data from **Public Health England**^{vi} collected between mid-September to mid-November for the vaccinated confirms that case rates for all age groups between 0-79 years have increased at a greater rate (31 to 42%) than unvaccinated rates (-7% to 25%).
8. Requiring the segregation of residents for protection is a paradox. There is no evidence that segregation prevents transmission. A vaccinated person is equally—if not more—likely to transmit the virus as a non-vaccinated person.
9. The vaccine is leaky and has resulted in significant numbers of *'breakthrough cases'*. The constant scapegoating of the unvaccinated does not stand up to scrutiny or evidence and is entirely unwarranted. The term "unvaccinated" should not be conflated with "infectious".
10. The **CDC** data shows that the vaccines are ineffective in treating or preventing SARS-CoV-2 or COVID-19. Deaths from COVID-19 in those who have received the recommended dosages of the vaccines increased from 160 as of April 30, 2021, to 535 as of June 1, 2021. Further, a total of 10,262 SARS-CoV-2 *"breakthrough infections"* of those who had already received the full recommended dosage of the vaccines.

11. The administration did not like this emerging trend. As of 1 May 2021, the CDC changed its policy and stopped reporting weekly COVID-19 “breakthrough infections” unless they resulted in hospitalisation or death.
12. I draw attention to one of the latest studies in **The Lancet**. The peer-reviewed prospective observational study of 1,072,313 patients, the U.K. group, was unable to tell the difference between vaccine effects and COVID-19^{vii}. In addition, it was reported by Reuters on 11 December 2021 that most of the U.S Omicron cases have hit the fully vaccinated^{viii}.

Refer to the endnotes for references.

Schedule 3

Safety Data Sheet



SAFETY DATA SHEET

Revision date 19-Mar-2021

Version 2

Page 1 / 12

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name	Pfizer-BioNTech COVID-19 Vaccine
Product Code(s)	PF00092
Form	nanoform
Synonyms	Comirnaty; PF-07302048 containing PF-07305885 (BNT162b2); CorVAC Containing PF-07305885 (BNT162b2) ; CoVVAC Containing PF-07305885 (BNT162b2); COVID Vaccine Containing PF-07305885 (BNT162b2); COVID-19 Vaccine Containing PF-07305885 (BNT162b2)
Trade Name:	Not applicable
Compound Number	PF-07302048
Item Code	H000022941; H000023057; H000024547; H000024742
Chemical Family:	Lipid Nanoparticles containing PF-07305885 (BNT162b2) and Lipids

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product

1.3. Details of the supplier of the safety data sheet

Pfizer Inc
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours); +1-703-527-3887
E-mail address pfizer-MSDS@pfizer.com

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Not classified as hazardous

2.2. Label elements

Signal word Not classified

Hazard statements

Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless

PF00092

SAFETY DATA SHEET

Product Name Pfizer-BioNTech COVID-19 Vaccine
Revision date 19-Mar-2021

Page 2 / 12
Version 2

of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Sucrose 57-50-1	< 10		200-334-9	No data available	Not Listed	No data available	No data available
SODIUM CHLORIDE 7647-14-5	< 10		231-598-3	No data available	Not Listed	No data available	No data available
Potassium phosphate 7778-77-0	< 1		231-913-4	No data available	Not Listed	No data available	No data available
POTASSIUM CHLORIDE 7447-40-7	< 1		231-211-8	No data available	Not Listed	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water 7732-18-5	*		231-791-2	No data available	Not Listed	No data available	No data available
ALC-0315 2036272-55-4	< 2		Not Listed	No data available	Not Listed	No data available	No data available
PF-07305885 -	< 1		Not Listed	No data available	Not Listed	No data available	No data available
PF-07302048 -	< 1		Not Listed	No data available	Not Listed	No data available	No data available
PEGA / ALC-0159 -	< 1		Not Listed	No data available	Not Listed	No data available	No data available
Disodium phosphate dihydrate 10028-24-7	< 1		Not Listed	No data available	Not Listed	No data available	No data available
Cholesterol 57-88-5	< 1		200-353-2	No data available	Not Listed	No data available	No data available
1,2-Distearoyl-sn-glycero-3-phosphocholine 816-94-4	< 1		212-440-2	No data available	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

PF00092

SAFETY DATA SHEET

Product Name Pfizer-BioNTech COVID-19 Vaccine
Revision date 19-Mar-2021

Page 3 / 12
Version 2

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Sucrose 57-50-1	29700	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3000	10000	No data available	No data available	No data available
Potassium phosphate 7778-77-0	3200	No data available	No data available	No data available	No data available
POTASSIUM CHLORIDE 7447-40-7	2600	No data available	No data available	No data available	No data available
Cholesterol 57-88-5	No data available	2000	No data available	No data available	No data available

Additional information

- Not Assigned
* Proprietary

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects No data available

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

SAFETY DATA SHEET

Product Name Pfizer-BioNTech COVID-19 Vaccine
Revision date 19-Mar-2021

Page 4 / 12
Version 2

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as mists) may fuel fires/explosions.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Restrict access to work area. No open handling permitted. Minimize generating airborne mists and vapors. If solvent based liquid, ground and bond all bulk transfer equipment. Use appropriate engineering controls to maintain exposures below the B-OEB taking all applicable routes of exposure into consideration. A change area to facilitate 'good laboratory/manufacturing' decontamination practices is recommended. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store at < -70 °C in properly labeled containers. Keep away from heat, sparks, and flames.

7.3. Specific end use(s)

Specific use(s) Vaccine.

SAFETY DATA SHEET

Product Name Pfizer-BioNTech COVID-19 Vaccine
Revision date 19-Mar-2021

Page 5 / 12
Version 2

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Sucrose

ACGIH TLV	10 mg/m ³
Bulgaria	10.0 mg/m ³
Estonia	10 mg/m ³
France	10 mg/m ³
Ireland	10 mg/m ³
	STEL: 20 mg/m ³
Latvia	5 mg/m ³
Spain	10 mg/m ³
OSHA PEL	15 mg/m ³
	5 mg/m ³
	(vacated) TWA: 15 mg/m ³ total dust
	(vacated) TWA: 5 mg/m ³ respirable fraction
United Kingdom	TWA: 10 mg/m ³
	STEL: 20 mg/m ³

SODIUM CHLORIDE

Latvia	5 mg/m ³
Russia	MAC: 5 mg/m ³

Potassium phosphate

Russia	MAC: 10 mg/m ³
--------	---------------------------

POTASSIUM CHLORIDE

Bulgaria	5.0 mg/m ³
Latvia	5 mg/m ³
Russia	MAC: 5 mg/m ³

Pfizer OEB Statement:

The Biotherapeutic Occupational Exposure Band (B-OEB) is an acceptable daily intake (ADI) range, based on available hazard data with appropriate safety factors applied. Engineering control measures should be utilized to bring exposures into the relevant B-OEB; supplementary administrative controls and personal protective equipment are to be used to achieve exposure control to the bottom of the band.

SODIUM CHLORIDE

Pfizer Occupational Exposure Band (OEB):	OEB 1 (control exposure to the range of 1000ug/m ³ to 3000ug/m ³)
--	--

ALC-0315

Pfizer Occupational Exposure Band (OEB):	OEB 3 - <u>Contact Hazards Unknown</u> (control exposure to the range of 10ug/m ³ to < 100ug/m ³)
--	--

POTASSIUM CHLORIDE

Pfizer Occupational Exposure Band (OEB):	OEB 1 (control exposure to the range of 1000ug/m ³ to 3000ug/m ³)
--	--

PF-07305885

Pfizer Occupational Exposure Band (OEB):	B-OEB Default (control exposure to the range of 10 µg/day to <100 µg/day)
--	---

PF-07302048

Pfizer Occupational Exposure Band (OEB):	B-OEB 5 (control exposure to <10 µg/day)
--	--

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, biosafety cabinet, or other engineering controls to maintain airborne levels within the B-OEB range. It is recommended that all large scale operations should be fully enclosed. Air recirculation is not recommended.

SAFETY DATA SHEET

Product Name Pfizer-BioNTech COVID-19 Vaccine
Revision date 19-Mar-2021

Page 6 / 12
Version 2

Environmental exposure controls No information available.

Personal protective equipment Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Eye/face protection Wear safety glasses as minimum protection (goggles recommended). (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection Wear impervious disposable gloves (e.g. Nitrile, etc.) as minimum protection (double recommended). (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection Wear impervious disposable protective clothing when handling this compound. Full body protection is recommended (scale dependent). Wear impervious protective clothing when handling this compound. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection Under normal conditions of use, if the applicable Biotherapeutic Occupational Exposure Band (B-OEB) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the B-OEB (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Liquid
Color	milky white
Odor	No information available.
Odor threshold	No information available
Molecular formula	Mixture
Molecular weight	Mixture
Property	Values
pH	7.4
Melting point / freezing point	No data available
Boiling point / boiling range	
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available

PF00092

SAFETY DATA SHEET

Product Name Pfizer-BioNTech COVID-19 Vaccine
Revision date 19-Mar-2021

Page 7 / 12
Version 2

Decomposition temperature
Kinematic viscosity
Dynamic viscosity
Particle characteristics
 Particle Size
 Particle Size Distribution
Explosive properties

No data available
No data available
No data available
No information available
No information available
No information available

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: * Toxicological properties have not been thoroughly investigated. The following information is available for the individual ingredients.

Known Clinical Effects: Based on clinical trials in humans, possible adverse effects following intravenous exposure to this compound may include: injection site pain, muscle pain, headache, fever, chills, tiredness, joint pain, abnormal redness of skin (erythema), and sleep disturbances. Serious allergic reactions, including anaphylaxis, have been reported.

Acute Toxicity: (Species, Route, End Point, Dose)

Sucrose

Rat Oral LD 50 29,700 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3 g/kg

SAFETY DATA SHEET

Product Name Pfizer-BioNTech COVID-19 Vaccine
Revision date 19-Mar-2021

Page 8 / 12
Version 2

Mouse Oral LD50 4 g/kg
Rabbit Dermal LD50 > 10 g/kg

POTASSIUM CHLORIDE

Rat Oral LD50 2600 mg/kg

Potassium phosphate

Rat Oral LD50 3200 mg/kg

Rabbit Dermal LC50 > 4640 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Sucrose	= 29700 mg/kg (Rat)	-	-
SODIUM CHLORIDE	= 3 g/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 g/m ³ (Rat) 1 h
Potassium phosphate	= 3200 mg/kg (Rat)	-	-
POTASSIUM CHLORIDE	= 2600 mg/kg (Rat)	-	-
Cholesterol		> 2000 mg/kg (Rat)	-

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin Irritation Rabbit Mild

Eye Irritation Rabbit Mild

POTASSIUM CHLORIDE

Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

PF-07302048

4 Week(s) Rat Intramuscular * 10 µg LOAEL Skin, Blood forming organs, Blood, Skeletal muscle, Lymphoid tissue, Spleen

Repeated Dose Toxicity Comments: PF-07302048: * Doses were administered once a week.

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

PF-07305885

Fertility & Embryonic Development - Females Rat Intramuscular 30 µg NOAEL No effects at maximum dose, Not teratogenic

Potassium phosphate

Reproductive & Fertility Rat No route specified 282 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus

Reproductive & Fertility Mouse No route specified 320 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Potassium phosphate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogenicity

See below

Cholesterol

IARC

Group 3 (Not Classifiable)

Data for the Drug Product

Reproduction & Development Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Fertility & Embryonic Development - Females Rat Intramuscular N/A Not specified No effects at maximum dose

11.2. Information on other hazards

SAFETY DATA SHEET

Product Name Pfizer-BioNTech COVID-19 Vaccine
Revision date 19-Mar-2021

Page 9 / 12
Version 2

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been investigated. Releases to the environment should be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

POTASSIUM CHLORIDE

Gambusia affinis (Mosquitofish) LC50 96 hours 920 mg/L
Lepomis macrochirus (Bluegill Sunfish) LC50 96 hours 2010 mg/L
Daphnia Magna (Water Flea) EC50 48 hours 825 mg/L
Scenedesmus subspicatus (Green Alga) EC50 72 hours 2500 mg/L

NO RESULTS

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does not apply
Potassium phosphate	The substance is not PBT / vPvB PBT assessment does not apply
POTASSIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does not apply
Cholesterol	The substance is not PBT / vPvB

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

PF00092

SAFETY DATA SHEET

Product Name Pfizer-BioNTech COVID-19 Vaccine
 Revision date 19-Mar-2021

Page 10 / 12
 Version 2

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

(CBI = CONFIDENTIAL BUSINESS INFORMATION)

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

SEE "LEGEND" PAGE 12

Water	
← CERCLA/SARA Section 313 de minimus %	Not Listed —
← California Proposition 65	Not Listed —
TSCA	Present PROPRIETARY (P)
EINECS	231-791-2
AICS	Present P CBI
Sucrose	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present P CBI
EINECS	200-334-9
AICS	Present P CBI
SODIUM CHLORIDE	
← CERCLA/SARA Section 313 de minimus %	Not Listed —
← California Proposition 65	Not Listed —
TSCA	Present P CBI
EINECS	231-598-3
AICS	Present P CBI
ALC-0315	
← CERCLA/SARA Section 313 de minimus %	Not Listed —
← California Proposition 65	Not Listed —
EINECS	Not Listed —
Potassium phosphate	
← CERCLA/SARA Section 313 de minimus %	Not Listed —
← California Proposition 65	Not Listed —
TSCA	Present P CBI
EINECS	231-913-4
AICS	Present P CBI
POTASSIUM CHLORIDE	
← CERCLA/SARA Section 313 de minimus %	Not Listed —
← California Proposition 65	Not Listed —
TSCA	Present P CBI

SAFETY DATA SHEET

Product Name Pfizer-BioNTech COVID-19 Vaccine
 Revision date 19-Mar-2021

Page 11 / 12
 Version 2

EINECS	231-211-8	
AICS	Present	<i>P CBI</i>
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4	
PF-07305885 <i>P CBI</i>		
CERCLA/SARA Section 313 de minimus %	Not Listed	---
California Proposition 65	Not Listed	---
EINECS	Not Listed	---
PF-07302048 <i>P CBI</i>		
CERCLA/SARA Section 313 de minimus %	Not Listed	---
California Proposition 65	Not Listed	---
EINECS	Not Listed	---
PEGA / ALC-0159 <i>P CBI</i>		
CERCLA/SARA Section 313 de minimus %	Not Listed	---
California Proposition 65	Not Listed	---
EINECS	Not Listed	---
Disodium phosphate dihydrate		
CERCLA/SARA Section 313 de minimus %	Not Listed	---
California Proposition 65	Not Listed	---
EINECS	Not Listed	---
AICS	Present	<i>P CBI</i>
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5	
Cholesterol		
CERCLA/SARA Section 313 de minimus %	Not Listed	---
California Proposition 65	Not Listed	---
TSCA	Present	<i>P CBI</i>
EINECS	200-353-2	
AICS	Present	<i>P CBI</i>
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4	
1,2-Distearoyl-sn-glycero-3-phosphocholine		
CERCLA/SARA Section 313 de minimus %	Not Listed	---
California Proposition 65	Not Listed	---
EINECS	212-440-2	

France
 Occupational illnesses (R-463-3, France)

Chemical name	French RG number	Title
SODIUM CHLORIDE 7647-14-5	RG 78	-
POTASSIUM CHLORIDE 7447-40-7	RG 67	-

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

SAFETY DATA SHEET

Product Name Pfizer-BioNTech COVID-19 Vaccine
Revision date 19-Mar-2021

Page 12 / 12
Version 2

Plant protection products directive (91/414/EEC)

Chemical name	Plant protection products directive (91/414/EEC)
Sucrose - 57-50-1	Plant protection agent
SODIUM CHLORIDE - 7647-14-5	Plant protection agent

* Legend: *

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 15 - Regulatory Information.

Revision date: 19-Mar-2021

Prepared By: Pfizer Global Environment, Health, and Safety

* Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

Schedule 4

Marburg

- Bill Gates [GAVI](#) published an article on 22-Apr-2021 titled “The next pandemic: Marburg?”. There have been numerous Mainstream Media articles highlighting an upcoming threat Marburg and referencing the WHO in recent months.
- [Marburg Virus](#) is a relatively rare haemorrhagic fever which was first described in 1967; there have only been a total of 376 related deaths and only 16 deaths since 2005.
- Primerdesign developed a one-step Real-Time PCR test [genesig®](#) in 2018 for Marburg haemorrhagic fever. Why would they develop a test in 2018 for an illness which has not had a major outbreak since 2005?
- Soligenix, are currently rushing to trial a ricin-rich vaccine [RiVax®](#) for Marburg haemorrhagic fever. RiVax has a Fast Track designation for the prevention of ricin intoxication by the US FDA. Approval of ricin toxin vaccine will utilise the FDA [Animal Rule](#) to eliminate the phase 1, 2 & 3 trials. Why such a rush now to trial a vaccine for which there has only been a total of 376 deaths since 1967 and only 16 deaths since 2005? The main component of the Rivax vaccine is Ricin is a lectin and a highly potent toxin produced in the seeds of the castor oil plant.
- Soligenix [shareholders](#) include Blackrock Fund Advisors, Goldman Sachs & Co. LLC, etc.
- [Ricin](#) is a lectin and a highly potent toxin produced in the seeds of the castor oil plant. Ricin is very toxic if inhaled, injected, or ingested. It acts as a toxin by inhibiting protein synthesis. It prevents cells from assembling various amino acids into proteins according to the messages it receives from messenger RNA in a process conducted by the cell’s ribosome (the protein-making machinery) – that is, the most basic level of cell metabolism, essential to all living cells and thus to life itself.
- A paper titled [Asymptomatic Infection of Marburg Virus](#) was published by the NIH in January 2021.

https://www.lewrockwell.com/2021/09/no_author/a-possible-marburg-rivax-final-solution/

WHO warns of Marburg

https://mobile.twitter.com/artvalley818_/status/1444162117746274305

Refer to Section 2 from the World Economic Forum website

<https://www.weforum.org/agenda/2021/08/covid-19-coronavirus-pandemic-20-august-2021/>

Notice the author

<https://www.weforum.org/agenda/2015/05/what-ebola-teaches-us-about-pandemics-and-inequality/>

-
- i The epidemiological relevance of the COVID-19-vaccinated population is increasing , Gunter Kampf (Published 19 November 2021) [https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762\(21\)00258-1/fulltext?s=08#%20](https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762(21)00258-1/fulltext?s=08#%20)
- ii Shedding of Infectious SARS-CoV-2 Despite Vaccination Kasen K. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, ; Peter J. Halfmann, et al (Published: August 2021) medRxiv <https://www.medrxiv.org/content/10.1101/2021.07.31.21261387v4.full.pdf>
- iii *Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.* Anika Singanayagam, PhD; Seran Hakki, PhD; Jake Dunning et al. (Published: October 29, 2021) The Lancet Journal [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(21\)00648-4/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00648-4/fulltext)
- iv *Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts.* Catherine M Brown; Johanna Vostok; Hillary Johnson; Meagan Burns; Radhika Gharpure; Samira Sami; Rebecca T Sabo; Noemi Hall; Anne Foreman; Petra L Schubert; Glen R Gallagher; Timelia Fink; Lawrence C Madoff; Stacey B Gabriel; Bronwyn MacInnis; Daniel J Park; Katherine J Siddle; Vaira Harik; Deirdre Arvidson; Taylor Brock-Fisher; Molly Dunn; Amanda Kearns; A Scott Laney (July 2021) National Library of Medicine, National Center for Biotechnology Information <https://pubmed.ncbi.nlm.nih.gov/34351882/>
- v *Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel.* Pnina Shitrit 1 2; Neta S Zuckerman 3; Orna Mor 3 4; Bat-Sheva Gottesman 2 5; Michal Chowers 2 5 (July 2021) National Library of Medicine, National Center for Biotechnology Information <https://pubmed.ncbi.nlm.nih.gov/34596015/>
- vi *COVID-19 vaccine surveillance report Week 46*, UK Health Security Agency (Published: 18 November 2021) https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1034383/Vaccine-surveillance-report-week-46.pdf
- vii [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(21\)00493-4/fulltext](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00493-4/fulltext)
- viii **Most reported U.S. Omicron cases have hit the fully vaccinated -CDC | Reuters**

Schedule B

The police's responses dated 12 April 2022 and 30 March 2022.



30 March 2022

Kirsten Murfitt and Sue Grey
Members of NZLSOS

By email to: NZLSOS@protonmail.com

Dear Kirsten Murfitt and Sue Gray

On 17 March 2022 you sent an email to the Commissioner of Police, attaching a letter that is said to represent the views of a newly formed lobby group. The letter is concerned with New Zealand's response to the Covid-19 pandemic, and the writers request a meeting with the Commissioner.

While the letter sets out a range of issues, attempting to highlight the writer's concerns with the response to the Covid-19 pandemic, Police is not able to comment on the matters that have been raised.

Similarly, I can advise that the Commissioner is unable to meet with you regarding the content of the letter.

Yours faithfully



Bill Peoples
Director, Legal Services

From  Management Assistants OOC <ManagementAssistantsOOC@police.govt.nz>
To NZLSOS@protonmail.com

☆   April 12th, 2022



Dear NZLSOS

Your letter dated 11 April 2022 has been received at the Office of the Police Commissioner.

Thank you for your further correspondence on this matter, Police have noted your concerns.

The Commissioner is unable to meet with you regarding this matter.

Kind regards

Management Assistant
Office of the Commissioner
Police National Headquarters



WARNING

The information contained in this email message is intended for the addressee only and may contain privileged information. It may also be subject to the provisions of section 50 of the Policing Act 2008, which creates an offence to have unlawful possession of Police property. If you are not the intended recipient of this message or have received this message in error, you must not peruse, use, distribute or copy this message or any of its contents. Also note, the views expressed in this message may not necessarily reflect those of the New Zealand Police. If you have received this message in error, please email or telephone the sender immediately.